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ABSTRACT 
 
This study investigates the efforts of stakeholders in a regional innovation system (RIS) to 
reconstruct the system to enable the development of the nascent biotechnology industry in the 
Western Cape province of South Africa. Various institutions and organisations played a crucial 
role in effecting these changes. One of the most important changes involved legislation that 
altered the role that universities play in bridging the gap between research outputs and reaping 
commercial benefits from such outputs. Following the logic of the regional innovation system, 
the study focused on the institutional changes, the mechanisms employed to bridge this gap 
(from creating spin-off firms, and licensing technologies based on university research, to 
designing programmes to support the development of bio-entrepreneurs). For a comparative 
perspective from another region that arrived on the biotechnology scene relatively late, the 
study includes a section on university spin-offs in biotechnology from Hong Kong universities. 
Since all the efforts to effect the changes to the RIS that would enhance the growth of this 
promising industry are relatively new, the study faced the usual problems associated with 
pioneering developments, such as small samples, a complete lack of databases, etc. For this 
reason, the questionnaire survey and case study methods were used throughout the study. 
Starting from the general to the specific, the thesis is divided into four complementary parts. 
Part I comprises the general literature survey and rationale for the study, while Part II narrows 
the focus to the organisations and mechanisms that connect knowledge creation and knowledge 
exploitation in the regional context in the Western Cape, South Africa and Hong Kong, China. 
Part III evaluates early efforts at building a bridge from science to business in the form of bio-
entrepreneurship programmes. Part IV takes a micro view, tracking the evolution of 
biotechnology spin-offs from Western Cape universities, and highlighting the role that 
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institutional changes played in the genesis, growth and, unfortunately, demise of some 
biotechnology spin-offs. The last section concludes. 
 
Throughout the study a familiar refrain repeated itself with respect to the challenges faced by 
new spin-offs, namely the perennial culprits of a lack of appropriate skills, and funding. From 
our study, bearing in mind the small scale and the danger of generalisations, it would seem as 
if the reconstruction of the RIS and related changes in the national innovation system (NIS1) 
did not generate the results that the strategy hoped for (at least in the Western Cape, the focus 
of our study). A beam of light is the relative success achieved with the development and 
implementation of a bio-entrepreneurship training programme, which laid the foundation to 
build a more sustainable bridge between the science of biotechnology and the commercial 
world where the wealth creation opportunities reside. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1 NIS and NSI, and RIS and RSI, respectively, are used interchangeably in the literature. 
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INTRODUCTION 
While knowledge is seen as the most important resource in the knowledge economy in general, 
biotechnology is distinguished as "one of the most knowledge-driven forms of activity", and 
referred to as a 'leading example' of an industry based on scientific knowledge (Coenen et al., 
2004: 1006). Modern biotechnology has the potential to transform large parts of the global 
economy and to have a major impact on the way we live. Its birth is usually traced back to the 
development of the recombinant DNA technique in 1973 and hybridoma technology in 1975. 
The rapid pace and widespread impact of developments in biotechnology since that time has 
often been referred to as the biotechnology revolution (Marsh, 2003). There is a large and 
growing international literature on economic aspects of biotechnology innovation which 
McKelvey (2001, cited in Marsh 2003: 103) has characterised as “an area of research which 
attempts to explain how and why the new techniques and knowledge of modern biotechnology 
can have economic impacts”.  
 
The emergence of biotechnology is expected to have a major impact on regional and national 
economies not only directly but also indirectly. Furthermore, the production of biotechnology 
products represents a relatively new and significant growth phenomenon on its own. Over the 
long run, the growth potential associated with the wider diffusion and the use of biotechnology 
products and processes, and their convergence with information technologies, 
nanotechnologies and other applied sciences, is probably even greater. In this sense, 
biotechnology appears to have the characteristics of a main technology, with the potential to 
underpin a new techno-economic paradigm (Gertler & Levitte, 2005). It should also be noted 
that biotechnology is not a singular industry but a set of specific activities and technologies 
such as biomaterials, DNA makers, genetic engineering, and recombinant DNA among others. 
These technologies produce not only new products, new processes for existing products, but 
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also new organisms for environmental cleaning and human consumption. Their applications 
cover different industries such as pharmaceuticals, food and beverages, and chemicals, among 
others (Niosi and Bas, 2003). 
 
The Regional Innovation System (RIS) concept provides a theoretical framework for analysing 
the emergence and growth of high-tech industries, i.e. biotechnology. The key thesis suggested 
here is that the development pattern of regional high-techs is strongly dependent on the 
structuring of the RIS (Trippl & Todtling, 2007). In the case of biotechnology, for example, 
strong RISs are located in California (in Los Angeles and San Francisco), Maryland and 
Washington DC, Massachusetts (Boston), New Jersey (Princeton), New York City, North 
Carolina (the Triangle Research Park), Pennsylvania and Texas (Niosi and Bas, 2001).  
Literature shows that concentration of biotech firms in these RISs typically arise around 
research universities and venture capital locations (Niosi and Banik, 2005).   
 
The biotechnology RIS consists of a basic set of organisations and institutions. According to 
Niosi and Bas (2003), biotechnology innovation systems have two key organizations; most 
noticeable among them are research universities, the fountains from which specialised 
biotechnology firms (SBFs) and their knowledge emerge.  Most major biotechnology firms are 
spin-offs from research universities or from public research organisations. The second key 
organisations are venture capital firms which provide the seed money, management 
competencies and credibility in the view of large pharmaceutical and chemical firms (Niosi 
and Bas, 2003). In the case of biotechnology, developments in the scientific base (which occur 
in universities, private firms and government laboratories) generally result in relatively quick 
changes in the stock of human capital, because such organisations have hiring policies that 
emphasize specific technical and research skills. Thus, biotechnology RIS evolve, because the 
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core scientific knowledge they exploit evolves, but also because firms are able to acquire this 
knowledge rapidly and effect changes in their organisational routines and technologies (Niosi 
and Banik, 2005). 
 
It is generally accepted that the regional innovative performance is improved when firms 
become better innovators by interacting with various supporting organisations and with firms 
within their region. In this sense, the institutional characteristics of the region, its knowledge 
infrastructures and knowledge transfer systems, as well as the strategies and performance of 
firms represent important basic conditions and stimuli for promoting innovation activities 
(Doloreux & Parto, 2005). 
 
Like other emerging economies, South Africa is also hoping to kick-start its biotechnology 
industry. To this end, the South African government formulated policies and enacted legislation 
to create the institutional framework that should help to stimulate this industry. In an attempt 
to modernise the approach towards the biotech industry to suit a new political and technical 
environment, South Africa adopted a NIS approach. Specifically, a key policy attempt to build 
a biotech hub was the Department of Science and Technology’s National Biotechnology 
Strategy (NBS) in 2001. One of the important results of this strategy was the creation of the 
Biotechnology Regional Innovation Centres (BRICs) (now a component of the Technology 
Innovation Agency- the TIA) which aimed to develop and commercialise the biotechnology 
industry. One of the BRICs was Cape Biotech in the Western Cape Province, with the mission 
"to develop and promote Biotechnology capacity in the Western Cape, which will create 
significant and sustainable economic and social value for South Africa". Cape Biotech was 
seen as one of the most important players of the RISs in Western Cape, representing the 
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interests of all stakeholders in the region, including industry, academia, government, finance, 
the public and all other role players in the field of biotechnology. 
 
1.1. Aim of the study 
The key interest of this study is to understand how the RIS in the Western Cape region was 
reconstructed, in order to allow for the evolution of the biotechnology sector in the region. 
Various institutions and organisations played a crucial role in effecting these changes. One of 
the most important changes involved legislation that altered the role that universities play in 
bridging the gap between research outputs and reaping commercial benefits from such outputs. 
Following the logic of the regional innovation system, the study focused on the institutional 
changes, the mechanisms employed to bridge this gap (from creating spin-off firms, and 
licensing technologies based on university research, to designing programmes to support the 
development of bio-entrepreneurs). 
 
1.2. Research Questions 
There are six interrelated question sets under study in this thesis. Two main and four sub-
questions. The first sub-set is concerned with analysing the phenomenon of scientists who 
created companies as spin-offs. The second sub-set considers scientists’ motivations on either 
creating companies or licensing their technologies. The third sub-set focuses on regional bio-
entrepreneurship training. The fourth sub-set is about the biotechnology companies’ growth or 
demise. The first and final main questions cover the questions for reconstructing the RIS. To 
an extent, these build upon each other. The first sub-set of questions is exploratory in nature 
and serves to prepare the ground for the second sub-set, which in turn has to be answered before 
we can say something about the third. Of course, the object of inquiry in the last set of questions 
already contains its own versions of answers to previous questions set.   
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The research questions which this thesis seeks to answer are as follows: 
 
QUESTION I: What should be the alternative ways of developing a favourable environment 
for regional biotechnology concentration to emerge and develop in the knowledge-based 
economy? 
QUESTION I.I. What were the key mechanisms used to bring the output of 
scientists to market, i.e. spinning off or licensing technologies? 
QUESTION I.II. What motivated academics to create spin-offs or license their 
technologies and what were the main obstacles they faced? 
QUESTION I.III. How effective was the first attempts at building a bridge 
between science and market through bio-entrepreneurship training in the 
region? 
QUESTION 1.IV. What happened to the biotechnology spin-offs and start-ups 
over time and what effect did changes in the institutional and policy 
environment have on their growth or demise?  
QUESTION II. What are the strong and weak points to promote a biotechnology regional 
innovation system in the Western Cape? 
 
The following section of this introductory section, which describes research methodology and 
the structure of the thesis and its delimitations, discusses in detail how the research questions 
are addressed in the different elements of the thesis. 
 
1.3. Research Methodology 
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In order to answer the research questions described above, this research specified a multi-
method research design which combines both theoretical grounding and empirical data 
collection (field work). 
 
Compared to developed countries, the South African biotechnology industry is very small and 
young. Because of the nature of the biotechnology industry in SA, and the lack of a database 
that allows for quantitative analysis, a qualitative research approach using case studies 
methodology is believed to be appropriate. This choice of methodology is supported by the 
relatively small number of the firms created in the region. In this research, the specific goals 
of the case studies on innovation systems are: 
 
i. to investigate characteristics of innovation systems for biotechnology industry, and 
ii. to develop recommendations that enhance the effectiveness of policies to encourage the 
economic performance of the innovation systems for biotechnology industry in Western 
Cape region. 
 
Furthermore, since the point of departure is garnering an understanding of a relatively young 
phenomenon, and the research is a first in several respects. Qualitative research methods allow 
the pursuit of such understanding even in the face of sparse data. Specifically, the case study 
permits understanding a phenomenon through its analysis, reconstruction and documenting of 
participants’ accounts. Moreover, it rests on a qualitative study having an exploratory aspect. 
Yin (2003: 40) defines a case study as a research design "that investigates a contemporary 
phenomenon within its real-life context, especially when the boundaries between phenomenon 
and context are not clearly evident". Yin also highlights the importance of having "multiple 
source[s] of evidence" to get a broad comprehension of the observed phenomenon. A case 
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study offers an opportunity to study a particular subject, e.g. one organization, an industry, in 
depth, or a group of people. This usually involves collecting and analysing information; 
information that may be both qualitative and quantitative. Thus, in this thesis, different 
methodological approaches were applied for the different phases of the project. At the 
beginning of the project and each section’s introduction a context analysis was done. This was 
achieved by means of secondary research (document and literature survey) focusing on 
innovation systems, university spin-offs, bio-entrepreneurship and biotechnology industry. 
 
Most of the empirical data was collected through case studies. In part two, section one, the case 
studies on university spin-offs in Western Cape draw from fieldwork conducted in the Western 
Cape. The data is collected through questionnaire and interview surveys with important public 
and private stakeholders. It was managed in two stages, the reason being that a database of 
spin-offs was not readily available for the Western Cape region and information on spin-offs 
had to be gathered in the first stage. Conversations were held with knowledgeable people, such 
as staff members of TTOs of universities. In the second stage a questionnaire was developed 
and emailed to the companies. Later, representatives of the companies who have responded 
were interviewed.  
 
In part two, section two, the case studies on biotechnology spin-offs in Hong Kong draw from 
fieldwork conducted in Hong Kong. An exploratory study by means of a questionnaire survey 
was conducted in order to understand the performance and innovative status of biotechnology 
spinoffs in Hong Kong. The survey was managed in two steps. During the first stage, research 
was carried out to identify how many universities have a TTO, and a five-page email 
questionnaire was sent to the TTOs. In the second stage, a nine-page questionnaire was 
developed specifically for the biotechnology spin-off companies. The questionnaire was 
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emailed to those companies identified through the TTO survey; thereafter companies were 
telephoned and visited to administer the survey. The questionnaire covered, amongst other 
things, the nature and activities of the company, motivations behind the creation of the 
company, and the identification of the major problems faced by the company during its life. 
 
In part two, section three, a questionnaire was developed to be completed by the principal 
researchers who created the technologies. Eleven researchers had responded to the survey of 
which only eight were willing to participate in our research. The participant number was 
therefore small, and the research makes no claims of generalisation. A TTO officer interviewed 
explained that this is not uncommon, since most researchers are reluctant to participate in 
questionnaire surveys. 
 
In part three, the study procedures included a literature survey, and conducting interviews with 
the bio-entrepreneurship programme graduates. A case study was undertaken in order to 
understand the bio-entrepreneurship education context and details in South Africa. Interviews 
were semi-structured and took 15–40 minutes. All interviews were recorded and transcribed. 
 
In part four, following the initial survey on university spin-offs held, research ventured into the 
field to establish whether biotechnology spin-offs identified in the survey were still in 
existence, and whether new ones have been created since. This exploration resulted in ten 
biotechnology firms being identified. For the purposes of these in-depth case studies, in this 
research the initial criteria were that the companies should have been created after 2000 (to be 
comparable), must be active in biotechnology, and particularly in manufacturing, product 
development or research. To garner the perspective of the supporting agencies in the regional 
innovation systems, interviews were conducted with senior staff at the company, at the 
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universities’ technology transfer offices and the TIA. The interviews yielded a considerable 
amount of information, which tell a tale of failure that holds important lessons for practitioners 
and policy makers. 
 
Limitations of the study 
The study is based on one province in South Africa, and the number of respondents was 
relatively small, the research cautions strongly that no generalizations to the rest of the country 
can be made. The research therefore regards this study as exploratory, but crucial as a source 
of insight for further research, for example of the biotechnology sector in the rest of the 
country’s regions.  
 
1.4.Structure of the Study 
Starting from the general to the specific, the present thesis consists of four complementary 
parts: five independent papers and a comprehensive introduction (parts 1-4). Whilst each of the 
respective papers researches one or several aspects of the aforementioned study object, the 
comprehensive introduction discusses basic concepts. The broad structure is as follows; 
 
i. Part I comprises the general literature survey and rationale for the study 
ii. Part II narrows the focus to the organisations and mechanisms that connect knowledge 
creation and knowledge exploitation in the regional context in the Western Cape, South 
Africa and Hong Kong, China which consists of three independent papers.2 
iii. Part III evaluates early efforts at building a bridge from science to business in the form 
of bio-entrepreneurship programmes which is presented as a research paper 
                                                 
2 For a comparative perspective from another region that arrived on the biotechnology scene relatively late, the 
study includes a section on university spin-offs in biotechnology from Hong Kong universities. 
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iv. Part IV takes a micro view, tracking the evolution of biotechnology spin-offs from 
Western Cape universities , and highlighting the role that institutional changes played 
in the genesis, growth and, unfortunately, demise of some biotechnology spin-offs 
which consists of an independent paper. The last section concludes. 
 
The format of the thesis has three consequences for the structure that are worth addressing here. 
Firstly, the links between the research questions, as presented above, and the results presented 
in each section, are less clear than in a traditional thesis. Secondly, since all the efforts to effect 
the changes to the RIS that would enhance the growth of a promising industry are relatively 
new, the study faced the usual problems associated with pioneering developments, such as 
small samples, a complete lack of databases, etc. For this reason, the questionnaire survey and 
case study methods were used throughout the study. A caveat is therefore sounded throughout, 
that because of the small samples, the results must be interpreted with care and generalisations 
cannot be made. Finally, some degree of overlap in content is unavoidable. However, none of 
the parts treat the same issue with the same depth. The study, furthermore, makes a significant 
contribution in the insights that it yields in a number of areas where the literature on spin-offs, 
biotechnology and bio-entrepreneurship training in developing countries is still sparse. The rest 
of this section, therefore, presents and explains the structure through which part-studies are 
linked. To begin with, Table 1.1 indicates which research questions each section covers. 
 
 
 
Table 1.1: Research questions covered and methodology used by each section 
Title Research Questions 
covered 
Methodology 
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Exploring Entrepreneurial Activity at Cape 
Town and Stellenbosch Universities, 
South Africa 
Q.I, Q.I.I literature survey, qualitative 
techniques; case studies, 
questionnaire and interviews 
Academic entrepreneurship in South East Asia: 
An Exploratory Study of Spin-offs in 
Biotechnology from Hong Kong Universities 
Q.I, Q.I.I, Q.II literature survey, qualitative 
techniques; case studies, 
questionnaire and interviews 
Spinning-Off or Licensing? The Case of 
Academic Technology Transfer at  Two South 
African Universities 
Q.I, Q.I.II literature survey, 
questionnaire and interviews 
Building a bridge between science and business 
in a regional cluster: Evaluating initial bio-
entrepreneurship training efforts in South Africa 
Q.I, Q.I.III, Q.II literature survey, 
questionnaire and interviews 
Where have all the university spin-offs gone? 
Turbulence in the biotechnology sub-sector of 
the Western Cape RIS 
Q.I, Q.I.IV, Q.II literature survey, qualitative 
techniques; case studies and 
interviews 
 
 
 
 
 
 
 
 
 
 
 
 
PART I: CONCEPTUALISING ARCHITECTURE  
 
1.1.Innovation 
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Innovations are new creations of economic significance and usually carried out by firms. They 
may be brand new, but are generally new combinations of existing elements. It is actually a 
matter of what is produced by firms and how is it produced (Edquist, 1997; Edquist, 2001). 
 
The category of innovation is complex and various. Traditionally, it includes process as well 
as product innovations as indicated below (Edquist, 2001; Kubeczko, Rametsteiner and Weiss, 
2006; Cozzens and Kaplinsky, 2009). 
 
Figure 1.1: The category of Innovations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Edquist (2001) 
 
 
Product innovation refers to radical changes in the output of an enterprise or organisation. 
Product innovation may be goods or services. It is a matter of what is being produced.  
 
Process innovation refers to either technological innovations or innovations in the organisation 
of an enterprise (Edquist, 1997; Edquist, 2001; Kubeczko, Rametsteiner and Weiss, 2006; 
Cozzens and Kaplinsky, 2009). It concerns how goods and services are produced. Some 
product innovations are transformed into process innovations in a ’second incarnation’ (or 
‘second appearance’). This concerns only ‘investment products’ – not products intended for 
 
Innovations 
Product Innovations Process Innovations 
Technological Organisational Goods Services 
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immediate consumption. For example, an industrial robot is a product when it is produced and 
a process when it is used in the production process.  
 
In this taxonomy, only goods and technological process innovations are considered as 
innovations of a ‘material’ kind. On the other hand, organisational process innovations and 
services are seen as ‘intangibles’. It is essential to take the “intangible innovations” into account 
as well, since their inputs are increasingly important for economic growth and employment. 
Although product innovations are crucial for changes in the production structure, this must not, 
however, be interpreted as reducing the importance of process innovations; the latter are 
necessary for the competitiveness of all firms in all countries, sectors and regions (Edquist, 
2001: 6). 
 
After this brief information on “innovation”, the next section explains the concept of innovation 
systems. 
 
1.2.Concepts of innovation systems 
In the last decade the concept of “innovation systems” has been used by academics and policy 
makers around the world (Edquist, 2001; Kubeczko, Rametsteiner and Weiss, 2006; Lundvall, 
2007; Bergek, 2007; Liu, 2009). It is worth mentioning here that the innovation systems 
approach is used here as a conceptual rather than a theoretical framework.  
 
Today it is possible to follow the diffusion of new concepts in time and space by using the 
internet. Giving ‘Google Scholar’ the text strings ‘innovation system(s)’, you may end up with 
a total of more than 71700 references (this search was done in April 2013). Going through the 
references scholars can find that most of them are recent researches and that many of them are 
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related to innovation policy efforts while others refer to new contributions in social science 
(Lundvall, 2007). 
 
Innovation systems comprise a set of different players and institutions that contribute to the 
development and diffusion of innovations. It is a set of interconnected players who form a 
system whose performance is determined both by the individual player’s performance and also 
by how they interact with each other as elements of a collective system (Kubeczko, 
Rametsteiner and Weiss, 2006). Edquist (1997: 14) defined an innovation system as “all 
important economic, social, political, organizational, and other factors that influence the 
development, diffusion, and use of innovations.” 
 
Lundvall (1992: 2) described an innovation system as “constituted by elements and 
relationships which interact in the production, diffusion and use of new knowledge.” In this 
definition, the knowledge can be interpreted as is exploited for practical, including commercial 
use (Cooke et al. 1997: 478). Consequently the knowledge created, diffused and used is not 
always in the form of commercial products or services but can also have practical and social 
effects. More specifically, knowledge may take the form of new ideas and concepts, new skills, 
or technological and organisational advances (Seppänen, 2008).  
 
An innovation system is a social and dynamic system (Lundvall 1992: 2). Seppänen (2008) 
asserts that the system is social because a central activity in the system is learning, which is a 
social activity. Innovation in the system involves positive feedback and reproduction which 
makes it a dynamic system. Thus, innovation is not a linear but a recursive process and the 
system is recursive by nature.  
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Innovation systems approach has been defined at different levels for different purposes of 
analysis. Over the last decade there have been several new concepts emphasizing the systemic 
characteristics of innovation. The most common approaches of innovation system refer to; 
 the national, as suggested by Freeman (1987), Lundvall (1992), and Nelson (1993) 
 the regional, as used by Cooke (1992) and other scholars; 
 the technological, as proposed by Carlsson and Stankiewicz (1991) 
 the sectoral, as proposed by Breschi and Malerba (1997) 
 
As suggested by their names, national and regional innovation systems (NIS and RIS) refer to 
innovative activities within national and regional boundaries, respectively. Cooke (1992) notes 
that the geographical boundaries of RISs are regions within countries or include parts of 
different countries. Bo Carlsson (Carlsson and Stankiewicz, 1991) with his colleagues 
introduced the concept ‘technological system’ already in the beginning of the nineties which is 
defined by a particular technology or set of technologies rather than by a geographic region or 
industry. To avoid confusion with the engineering concept of ‘technological system,’ the term 
‘technological innovation system’ is being used here. Franco Malerba and his colleagues 
(Breschi and Malerba 1997) developed the concept of ‘sectoral systems of innovation’ which 
focuses on various individual sectors or industries, technology fields or product areas (Edquist, 
2001; Carlsson, 2006; Lundvall, 2007; Bergek, 2007; Seppänen, 2008). 
 
The delineations about these approaches to innovation systems are different from different 
perspectives. Therefore, there is no right or wrong way to draw system boundaries and define 
them in the social and economic context. Most delineations about the national and regional 
innovation systems are largely determined by organizations and institutions essentially 
characterized by a certain territorial sphere of influence and interactions. In contrast, sectoral 
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innovation systems may be determined in terms of technology flow in the industries’ structure 
that usually cross geographic boundaries (Gao and van Lente, 2008). However, according to 
Carlsson and Stankiewicz (1991), actors, interactions and institutions are three basic elements 
in all innovation systems.  
 
The following section aims to shed light on the existing literature on types of innovation 
systems. It provides the reader with a theoretical understanding of the innovation concept and 
how it can be understood in a system perspective. 
 
1.3.Types of Innovation Systems 
The use of knowledge, together with innovation and its diffusion, has become key elements of 
economic growth in the modern world. Continuous innovation is a prerequisite for sustainable 
competitiveness of both nations and regions (Zhu and Tann, 2005). Innovation is now seen as 
a socially and territorially embedded process and the regional level has been recognised as 
being the best context for the development of innovation based learning economies. Regions 
can be viewed as evolving members of multi-level governance systems and play a key role in 
coordinating innovation processes (Muscio, 2006). 
 
The last 20 years have seen an increasing acknowledgement in economic and social sciences 
of the territorial dimension of industrial development and technological innovation. During this 
period, the literature on innovation has shifted from the national to the regional and local 
dimensions (Muscio, 2006).  
 
In the next section the innovation systems approach is elaborated from the historical 
perspective. 
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1.3.1.  National Innovation Systems 
Some of the basic ideas behind the concept ’national systems of innovation’ are rooted in 
Friedrich List’s concept ‘national systems of production’ (List 1841) (Carlsson, 2006; 
Lundvall, 2007; Lundvall et al., 2009; Pietrobelli and Rabellotti, 2009). His concept ’national 
systems of production’ took into consideration a wide set of national institutions including 
those engaged in education and training as well as infrastructures such as networks for 
transportation of people and commodities. He focused on the development of productive forces 
rather than on allocation issues.  
 
According to Lundvall (2007) and Lundvall et al. (2009), the first written contribution that used 
the concept ‘national system of innovation’ is an unpublished OECD paper by Christopher 
Freeman in 1982, which was on how countries could build knowledge and knowledge 
infrastructure at the national level with the aim to promote economic development and 
international competitiveness . The first time the handier ’innovation system’ appears in an 
Aalborg-publication is in Lundvall (1985) (although without the adjective ‘national’) 
(Carlsson, 2006; Lundvall, 2007). In this booklet on user-producer interaction and product 
innovation the concept was used to analyse innovation processes involving firms and 
knowledge institutions in interaction. A general assumption behind the analysis, that remains 
central in more recent work on innovation systems, was that innovation and learning are context 
dependent, interactive processes, rooted in the production structure (Lundvall, 2007). 
 
Again, it was Chris Freeman who brought the modern version of the full concept ‘national 
innovation system’ into the literature. He did so in 1987 in his seminal book on national 
innovation systems in Japan (Carlsson, 2006; Lundvall, 2007; Fagerberg and Srholec, 2009; 
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Liu, 2009; Niosi, 2011). Here the analysis was quite inclusive taking into account the intra- as 
well as inter-organizational characteristics of firms, corporate governance, the education 
system and not least the role of government. The following year, when Freeman collaborated 
with Nelson and Lundvall on technical change and economic theory the outcome was a book, 
edited by Dosi et al. (1988),  with a section with chapters on ’national systems of innovation’ 
(Carlsson, 2006; Lundvall, 2007; Soete, Verspagen and ter Weel, 2010; Niosi, 2011). 
 
The “national innovation system” concept has since been extensively discussed in both 
scholarly and policy-analytic work (Freeman 1987; Lundvall 1992 and Nelson 1993). 
Essentially, these studies describe categories of actors - government, universities, research 
institutes, and firms - and their interactions with institutions and policies. The National 
Innovation System concept places stress on the role of institutions in a system within a nation, 
through their interactions, in supporting the technological development process. It’s basically 
analyses of country-specific factors that influence companies’ innovative capabilities (Liu and 
White, 2001; Edquist, 2001; Carlsson et al., 2002; Sharif, 2006; Fagerberg, Mowery and 
Verspagen, 2008; Gao and van Lente, 2008; Lenger, 2008). 
 
The national innovation systems concept has been used in a broader sense, which encompasses 
learning, innovation and competence-building at different levels of aggregation and a narrow 
sense, which equals innovation to science and technology (Chung, 2002; Fagerberg, Mowery 
and Verspagen, 2008; Gao and van Lente, 2008; Lundvall et al., 2009). In the broader sense it 
extends to include all interrelated institutional actors (i.e. social institutions, macroeconomic 
regulation, financial systems, education, communication infrastructure, market conditions) that 
create, diffuse, and exploit innovations (Chung, 2002; Gao and van Lente, 2008; Lundvall et 
al., 2009). Lundvall (1992) defines NIS as;  
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‘A system of innovation ………constituted by elements and relationships which interact in the 
production, diffusion and use of new and economically useful knowledge… and are either 
located within or rooted inside the borders of a nation state’ (Lundvall 1992: 13).  
 
In the narrow sense, it is aimed at mapping indicators of national specialisation and 
performance which includes organizations and institutions directly related to searching and 
exploring technological innovations, such as R&D departments, universities, and public 
institutes (Chung, 2002; Gao and van Lente, 2008; Lundvall et al., 2009). The narrow definition 
can be quoted from Freeman (1987), which is  
 
‘…The network of institutions in the public and private sectors, whose activities and 
interactions imitate, import, modify and diffuse new technologies’ (Freeman 1987: 1).  
 
Moreover, Nelson and Rosenberg (1993) also give a definition from a narrow sense which they 
regard as; 
 
‘…The set of institutions whose interactions determine the innovation performance of national 
firms’ (Nelson and Rosenberg 1993: 4)  
 
There are many other definitions of NIS. For instance; a national system of innovation defined 
by Metcalfe (1995) as a “set of distinct institutions which jointly and individually contribute to 
the development and diffusion of new technologies and which provides the framework within 
which governments form and implement policies to influence the innovation process. As such 
it is a system of interconnected institutions to create, store and transfer the knowledge, skills 
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and artefacts, which define new technologies. The element of nationality follows not only from 
the domain of technology policy but also from elements of shared language and culture which 
bind the system together, and from the national focus of other policies, laws and regulations 
which condition the innovative environment (Metcalfe, 1995: 38).” 
 
Also, Chung (2002: 486) defines NIS as “a complex of innovation actors and institutions that 
are directly related to the generation, diffusion, and appropriation of technological innovation 
and also the interrelationship between innovation actors.” The major concern in this notion is 
how we can formulate an effective national setting of major innovation actors and how to 
animate information flows among them in order to generate and appropriate innovation 
effectively. The main idea of this approach is that a company’s capability for innovation 
depends on it being able to interact and coordinate with a variety of external sources of 
knowledge (competitors, suppliers, scientific organizations, etc.) as well as internally generate 
knowledge from interdependent sources (like production, marketing or R&D) (Todt et al., 
2004: 417). In short, national innovation system approach involves socio-institutional adaption, 
supplier-customer interactive learning, and firm competence and routines, all of which 
influence the diffusion of the innovation in the national area. (Gao and van Lente, 2008). 
 
The broader perspective is essential as economic growth benefits less from the creation of 
knowledge per se than from its application to the production of new and existing goods and 
services. An exclusive focus on the creation of new technologies that ignores their exploitation 
risks overlooking essential cross-national differences in the translation of new knowledge into 
economic gains (Fagerberg, Mowery and Verspagen, 2008). The effective exploitation of new 
knowledge or technology is especially important for developing countries such as South Africa, 
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whose contribution to the global pool of new knowledge necessarily is dwarfed by the potential 
contributions to South African’s economic growth from exploitation of this pool. 
 
1.3.2. Regional Innovation Systems  
The Regional Innovation System approach emerged at the beginning of the 1990s, focusing on 
analysing regional economies and economic geography. It has already gained much attention 
from academics, policy makers and researchers (Doloreux and Parto, 2004; Chung. 2002 and 
Gao and van Lente, 2008; D’Allura, Galvagno and Li Destri, 2012). Ohmae (1990, cited in 
Chung, 2002: 486) states that the region has become a focal point of economic activities 
replacing the nation in the modern economy. In support of this, he argues that regions are more 
dynamic and reflexive than states in R&D and economic activities. Florida (1998) argues that 
a region should become a learning region by appreciating the importance of knowledge and 
that public policy should not only target short-term economic competitiveness, but also the 
long-term sustainable advantage of regions (Chung, 2002: 487). Furthermore, Breschi and 
Malerba (1997) argue that the regional innovation activities can stimulate industrial clusters 
for the whole state, and it can improve the balance of state economic development. Therefore, 
studying phenomena at regional level is growing in importance as a mode for innovation 
system research. 
 
In addition, the reason why this concept should be narrowed down is well documented and 
discussed in Cooke et al. (1997) who argued that a systemic approach to technological change 
at a national level would be essentially inadequate since most of the interaction in fact takes 
place at sub-national levels i.e. regional levels. Additionally, Porter (1990, cited in Buesa et al. 
2006) argued that industries tend to concentrate in specific spaces. Therefore, the Regional 
Innovation System (RIS) appears as a more relevant, and appropriate approach to the problem. 
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The concept of RIS has been gaining much attention from policy makers and researchers in the 
wake of the academic studies on national system of innovation of Freeman (1987) and Lundvall 
(1992).  
 
The definitions of regional innovation system reduce the scope of innovation study into a 
region or local area within a nation. Thus, an RIS can be defined as “a complex of innovation 
actors and institutions in a region that are directly related with the generation, diffusion, and 
appropriation of technological innovation and an interrelationship between these innovation 
actors.” (Chung 2002: 487)  
 
Moreover, the concept of RIS has no commonly accepted definitions. Doloreux and Parto 
(2004: 3) state it as “a set of interacting private and public interests, formal institutions and 
other organizations that function according to organizational and institutional arrangements 
and relationships conducive to the generation, use and dissemination of knowledge in a 
region.” The basic argument is that this set of actors produce pervasive and systemic effects 
that encourage firms within the region to develop specific forms of capital that is derived from 
social relations, norms, values and interaction within the community in order to reinforce 
regional innovative capability and competitiveness. In other words, its research focuses on 
revealing the skills on the local supply in management and technology aspect, the ability of 
accumulating tacit knowledge, and the capacity of ‘knowledge spill-over’ in a limited 
geographical area. By studying RIS, the nations can prevent the problem of unfair geographical 
concentration of technological and economic capabilities, and develop the national economy 
as a whole (Chung 2002). 
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Niosi and Banik (2005) proposed that Regional Innovation Systems (RISs) are geographical 
concentrations of interacting organisations (firms, research universities, government 
laboratories and venture capitalists) designed at the development of a specific technology. 
Typically, the concentration of high-tech firms in RISs occurs around research universities and 
venture capital pools. Labour pools made up of graduates from research universities, 
knowledge spill-overs from academia to industry, complementary and input markets for 
university-created technologies, trust and reciprocity, together with reduced transaction costs 
within the network, has been put forward as explanations for the clustering of key organisations 
within a particular geographical region (Niosi and Banik, 2005).  
 
Asheim and Coenen (2005, cited in Lenger 2008) defined RIS as, “the institutional 
infrastructure supporting innovation within the production structure of a region”. The main 
focus of the system approach is the interaction within the network of public and private 
institutions which can be classified as firms, R&D institutes, universities, government agencies 
and venture capitalists.  
 
Like an NIS, an RIS is composed of three main innovation actor groups: universities, industrial 
enterprises, and public research organization. Additionally, regional government replaces the 
central government to effectively direct and coordinate innovation activities in each region. 
But the actual actors of innovation activities are universities, private enterprises, and public 
research organizations. These actors make a significant contribution to enhance regional and 
national technological competitiveness. 
 
In addition to this, the concept of RISs can also be a good tool to formulate SISs, as regions 
should concentrate specific industrial sectors for the effective development of their regional 
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economies. An RIS comprises of two key components: (1) firms in the regional core clusters 
and (2) institutions that create an institutional infrastructure. Lundvall in Zhu and Tann (2005: 
376) offer a definition that identifying five core elements of an RIS: (1) the internal 
organization of firms, (2) the inter-firm relationship, (3) the role of the public sector, (4) the 
institutional set-up of the financial sector, (5) R&D intensity and R&D organizations. All the 
core elements or key components of an RIS can also be applied to other types of systems that 
operate at sectoral and technological levels.  
 
According to Cooke (2002a) and Seppänen (2008) the two key subsystems in any functioning 
regional innovation system are (1) the knowledge application and exploitation and (2) the 
knowledge generation and diffusion. These subsystems are linked to global, national, and other 
RISs (Lenger, 2008). “The knowledge application and exploitation sub-system” is formulated 
by the firms that commercialize the knowledge and their contractors, competitors, collaborators 
and customers  whilst “the knowledge generation and diffusion subsystem” covers universities, 
research institutes, technology transfer agencies, regional and local governance bodies that 
support and regulate the innovation policies (Cooke, 2002b; Seppänen, 2008). However, 
private investors can be the most important players outside basic research in highly innovative 
regions and metropolitan areas. Also important actors in a regional innovation system include 
public and private funding organisations and non-firm organisations. Figure 1.2 is an attempt 
based on the work of Autio (1998, cited in Cooke, 2002a), to present the structure of a regional 
innovation system.  
 
The organisations of a regional innovation system are associative, meaning there is systemic, 
i.e. regular, two-way, interchange on matters of importance to innovation. The interactions 
within and between organisations and sub-systems generate the knowledge flows that drive the 
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evolution of regional innovation system. Linkages between key organisations can be specified 
in terms of flows of knowledge and information, flows of investment funding, flows of 
authority and even more informal arrangements such as networks, clubs, and partnerships 
(Seppänen, 2008). 
 
This research is aimed at the second subsystem in the RIS, namely the universities’ roles in the 
regional innovation systems, from the view of innovation systems which emphasized the 
importance of knowledge spill-overs from the research activities at universities in the regional 
knowledge spaces, towards the development of the third role for universities in stimulating 
regional economic and social development (Gunasekara, 2006). This makes the university an 
active agent of change, and implies that different competencies and approaches may be needed. 
Table 1.2 captures the roles of universities in regional innovation systems and summarize the 
key elements. 
 
In the context of the third role assigned to (and assumed by) universities, technology transfer 
is a cardinal focus of policy and research. Universities may seek to transfer technology from 
the public to the private sector, and therefore reap the benefits of commercialisation through a 
number of different mechanisms. The transfer of technologies developed in universities and 
public research organisations (PROs) to the private sector, i.e. “technology transfer” (TT), can 
be a significant vehicle in national/regional technological innovation and thus, economic 
growth can be improved (Garduno, 2004). This increased emphasis on TT from universities 
and research institutions to the industry and the need to develop more "rapid" linkages between 
science, technology and their utilisation has led to the emergence of a number of 
entrepreneurial initiatives within academic and research institutions (O’Shea et al., 2004).  
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Table 1.2: Analysing universities contribution to the development of RISs 
Key Element of RIS Generative role Developmental role 
Regional agglomeration 
or clustering of industry 
Knowledge capitalization and capital 
formation projects, centred on firm 
formation and co-location of new and 
existing firms near the university. 
Entrepreneurial activities, as well as 
regionally focused teaching and 
research, not necessarily linked to 
capital formation projects 
Human capital 
formation 
Integration of education and 
knowledge capitalization activities 
specifically, firm formation, through 
teaching incubators. 
Development of generic, advanced 
training programs to support firm 
formation and cross-institutional 
mobility by organizations and people 
Stronger regional focus on student 
recruitment and graduate retention. 
Education programs developed to 
meet regional skills needed 
Learning processes that are 
regionally informed 
Associative governance Driver of regional innovation strategy, 
centred on knowledge capitalization 
and capital formation projects; by 
analyzing strengths and weaknesses 
and bringing together the industry and 
government to build innovation 
strategy. 
Shaping regional networking and 
institutional capacity, through staff 
participation on external bodies; 
provision of information and 
analysis to support decision-making 
and brokering networking between 
national and international contacts 
and key regional actors 
Regional cultural norms Tradition of university industry 
linkages, involving knowledge 
capitalisation. 
Tradition of university industry 
linkages, involving knowledge 
capitalization and other research 
collaborations. 
Sources: Gunasekara, 2006 
 
 
 
Figure 1.2: Schematic Illustration of the structuring of Regional Innovation Systems 
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Source: Cooke (2002a) 
 
TT and other topics that relate to technology transfer, such as technology diffusion and 
dissemination, have become fundamental parts of prevailing research and the technology 
development policy. TT is a deliberate and planned process (e.g. through licensing, foreign 
investments, procurement) to disseminate or acquire knowledge, experience and related 
artefacts (Hameri,1996), and technology transfer offices (TTOs) to facilitate this technological 
diffusion through the licensing of inventions or intellectual property from university research 
results to the industry (Siegel et al., 2003; Phan and Siegel, 2006). Siegel et a.l (2007:641) 
viewed TTOs as ‘intermediaries’ between suppliers of innovations (university researchers) and 
those who can potentially assist to commercialise them, i.e. firms, entrepreneurs, and venture 
capitalists. A TTO represents an institutional mechanism created with the purpose of promoting 
universities’ interaction with the industry and the government. The idea of establishment of 
TTOs is not only the need to improve the effectiveness of university performance, but also 
boosts the university’s income through the transfer of research results to the industry and 
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licensing of technologies (Dos Santos and Rebolledo, 2008).  The mission of TTOs is thus to 
transfer university research results from laboratory to commercial application for society.  
 
1.3.3. Technological Innovation Systems (TIS) 
Innovation systems that are assigned to a specific technology or product have been referred to 
as technological innovation systems (TIS) in the literature. The components of a technological 
innovation system are the actors, networks and institutions contributing to the development, 
diffusion and application of a particular technology. Carlsson and Stankiewicz (1991) defined 
a technological system as; 
 
“A dynamic network of agents interacting in a specific economic/ industrial area under a 
particular institutional infrastructure and involved in the generation, diffusion and utilization 
of technology” (Carlsson and Stankiewicz, 1991, p. 93). 
 
TIS analyses a technological field by referring to systemic features, including actors, 
institutions, (sometimes) technologies and most importantly, all the interrelations between 
them. The TIS concept has been applied to develop an understanding of innovation processes 
as related to societal structures such as governments, universities, NGOs, intermediary 
organisations and the like (Suurs, 2009). A successful innovation system requires the 
interaction among the actors with different competences. Moreover, the nature of innovation 
and technology change contain scores of uncertainties and complexities, networks formed by 
the actors provide other alternatives for firms and other research organizations in governing 
innovations (Carlsson and Stankiewicz 1991). 
 
1.3.4. Sectoral Innovation Systems (SIS) 
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The sectoral innovation system approach provides an analytical framework to identify the 
performance of systems in terms of how well they support innovations in a specific sector. 
‘Sectoral innovation systems’ approach is represented by Breschi and Malerba (1997) “. . . 
different industries may have different competitive, interactive and organizational boundaries 
that are not necessarily national” (Niosi, 2011).  
 
Breschi and Malerba (1997: 131) define sectoral innovation system as ‘the specific clusters of 
the firms, technologies, and industries involved in the generation and diffusion of new 
technologies and in the knowledge flows that take place amongst them.’ Sectoral innovation 
systems are based on the idea that different sectors or industries operate under different 
technological regimes. These regimes may change over time, making the analysis inherently 
dynamic, focusing on the competitive relationships among firms by explicitly considering the 
role of the selection environment (Carlsson et al., 2002; Gao and van Lente, 2008). 
  
A SIS is, therefore, a system comprised mainly of players in one specific sector and interactions 
between these. Furthermore, the majority of functions of the innovation system are fulfilled by 
players in the sector. The SIS approach looks at firm and inter-firm level aspects as well as at 
institutional level aspects both of market and non-market relations and focuses on the 
differences between types of sectoral innovation systems. The key features of this approach are 
the differences in and the importance of the knowledge base and the learning process, the role 
of non-firm organisations and institutions, and the co-evolutionary process changing the sector. 
The agents within the SIS are individuals and organizations. These organizations may be 
enterprises and non-firm organizations (such as universities, government agencies. etc.), as 
well as other individuals or organizations such as consumers, research and development 
departments or industry associations. Agents are characterized by a specific learning process, 
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competence, structures and behaviour (Breschi and Malerba, 1997). In SIS, for instance, 
government, as a non-firm organization, may influence a specific technology flow from 
creation to diffusion through the formulation of technical standards. The technical standards 
can remove the barriers of interactions among the actors and enhance learning capacities and 
the technological negotiability (Gao and van Lente, 2008) 
 
The SIS approach of Breschi and Malerba (1997) distinguishes five major types: SIS in 
traditional sectors, the mechanical industries, the auto industry, the computer mainframe 
industry and the software industry. SISs in traditional, mature sectors typically often support 
more process innovations than product innovations. In particular, opportunities are pursued to 
introduce innovations related to reducing production cost (Kubeczko, Rametsteiner and Weiss, 
2006). 
 
Table 1.3 summarizes the different approaches to innovation systems and demonstrates and 
reveals the key features of the different approaches based on the three basic agents. 
 
Table 1.3: Different “systems of innovation” approaches’ summary 
 
 NIS RIS TIS/SIS 
Main Actors  Industry 
 Government 
 Education and 
Research 
organizations 
 Universities 
 Industrial 
enterprises 
 public research 
organization 
 Firms 
 Non-firm 
organizations 
 individuals 
Institution  National policies 
 Laws 
 National finance 
supports 
 Informal 
Institutions 
depending of trust 
and reliability 
among the actors 
 Standards 
 Regulations 
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Interaction   joint industry 
activities 
 R&D 
collaboration 
 technology 
diffusion 
 personnel mobility 
 Inter-firms 
interactions 
 External 
interactions for 
firms with research 
organizations 
 R&D collaboration 
 Inter-industry 
Interactions 
 Interactions 
among firms and 
non-firm 
organizations 
Source: Gao and van Lente, 2008 
 
Having considered an elaborate overview of the literature on innovation systems, two 
observations remain to be made: 
i) The innovation system approach locates this study within the framework of the 
economics of innovation, which draws on insights from other fields, such as 
business management and history. The value of this approach will become clear in 
the rest of the thesis; 
ii) For the purposes of this study, the regional system of innovation is more suited as 
a framework for analysis, rather than the sectoral system of innovation, given the 
fluidness of the boundaries of biotechnology in South Africa and the nascent nature 
of the sector.  
 
 
 
PART II: FROM KNOWLEDGE CREATION TO KNOWLEDGE EXPLOITATION  
 
This part of the thesis narrows the focus to the organisations and mechanisms that connect 
knowledge creation and knowledge exploitation in the regional context in the Western Cape, 
South Africa and Hong Kong, China. This part consists of three independent sections. 
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2.1.Exploring Entrepreneurial Activity at Cape Town and Stellenbosch Universities, 
South Africa3 
Addressing the first research focus area in part I4 (which is concerned with analysing the 
phenomenon of scientists who created companies as spin-offs), this section is devoted to the 
mechanism of spin-off formation as a means to bring the research output of academic scientists 
to the market, with the associated expectations of the benefits that such ventures may hold for 
the inventors, universities and the regional economy. Research starts with spin-offs generally 
and then narrows the focus to biotechnology spin-offs in subsequent sections. 
 
2.1.1. Introduction 
Entrepreneurial activity at universities, especially spin-off formation has emerged as an 
important mechanism to accelerate transfer of technology and knowledge to the market. 
Spinning off is a means of technology transfer from a parent organisation that presents a 
mechanism to create jobs and new wealth (Steffensen et al., 1999). A small but growing 
number of studies deals with the performance of university spin-offs around the world (O’Shea, 
2007) but in South Africa only a handful of studies focused on university spin-offs (Kruss, 
2008; Jafta and Uctu, 2009); mostly as part of a broad study on university-industry 
partnerships, technology transfer mechanisms or academic entrepreneurship (Garduno, 2004; 
Kruss, 2005; Reichelt, 2007; Grundling and Steynberg, 2008; Kruss et al., 2009). This is partly 
because of a lack of a comprehensive database of university spin-offs.  This study starts on a 
modest scale, focusing on the universities in the Western Cape region. A dearth of spin-offs at 
the University of the Western Cape limited the study to a questionnaire and interview survey 
of spin-offs at Cape Town and Stellenbosch universities. Although this study was conducted 
                                                 
3This section was published in a journal. Reference as follow; Jafta R. and R. Uctu, (2013), “Exploring University 
Spin-offs in the South African context: Entrepreneurial activity at Cape Town and Stellenbosch Universities, 
Industry and Higher Education, Vol. 27, No.2, April 2013, pp. 117-128  
4 It refers to Research Questions’ section, p. 4 
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on a relatively small scale, it is believed that the insights gained from this exploration into the 
field could prove useful for future research. 
 
This section strives to understand the spin-off phenomenon whereby a new firm is created and 
formed from parent universities.  Specifically, the objectives of this section are to gather 
information about the historical status of spin-offs and to identify the main characteristics of 
university spin-offs, which evolved from two South African universities. The research is 
further interested in the motivations behind the spin off, the relationships with the parent 
university post spin off, as well as the most important obstacles that the spin offs faced.  
 
In the following section the research elaborates on the definition and importance of university 
spin-off firms (USOs), where after the research present the methodology and the results of the 
study. The research then discusses the results and derives lessons and concludes in the final 
section. 
 
2.1.2. Definition and Importance of University Spin-Offs 
There is no single definition of university spin-offs (USOs) that are used consistently in the 
literature. Spin-offs can be categorised depending on the organisation they originate from, and 
on the source of the entrepreneur’s experience. Spin-offs may originate from different 
organisations, such as a government R&D organisation, a university or a private firm (Gubeli 
and Doloreux, 2005).  
 
First, the research assesses the existing definitions of spin-offs in the academic 
entrepreneurship literature to provide a contextual framework. According to Smilor et al. 
34 
 
(1990: 64) a spin-out firm5 is defined in two ways: (1) the founder was a faculty member, staff 
member, or student who left the university to start a firm or who started the firm while still 
affiliated with the university; and/or (2) a technology or technology-based idea developed 
within the university was used to start the firm. Pirnay et al.’s (2003: 356) definition is a “new 
firm created to exploit commercially some knowledge, technology or research results 
developed within a university”.  
 
Landry et al. (2005: 3) see a university spin-off as a new firm that is formed to transfer 
commercially available scientific and technological knowledge from a parent organisation to 
the market. According to the authors, two factors of this definition are to be taken into account; 
firstly, to understand the spin-off phenomenon one has to consider the nature of its parent 
organisation and, secondly, that the most important decisive factor to create university spin-
offs is the production of commercially useful knowledge by researchers. Rasmussen (2006) 
defines a USO as a new venture initiated in a university setting that is based on technology 
from a university, whilst Shane (2004) defines a university spin-off as a new firm founded to 
exploit a piece of intellectual property created in an academic institution (Rasmussen, 2006: 
3). 
 
After reviewing the definitions of spin-offs, the research can say that a spin-off involves: a core 
technology, knowledge or research results developed within a university and transferred into a 
new firm and the founder member(s) of the firm stay at or transfer from the parent university. 
 
Spin-off firms play a crucial role in the development and commercialisation of new 
technologies. For example, technology transfer activity performed through licensing of 
                                                 
5 In this research spin-off firms are also known as “start-up” and “spin-out” firms. 
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technologies to set up firms and creating spin-offs based on university-developed technologies 
plays an important role in the USA’s technology transfer system (Garduno, 2004). The figures 
are instructive. According to the Association of University Technology Managers (AUTM), 
3,376 spin-offs from American academic institutions were created in the U.S. between 1980 
and 2000 (Avnimelech and Feldman, 2011) and have contributed 280,000 jobs to the U.S. 
economy (O’Shea et al., 2005). In the last decade the university spin-off rate accelerated with 
an average of more than 500 new start-ups each year, for example, in 2010 alone, 651 
university-based start-up firms were started (AUTM, 2010). Another example can be given 
from Japan. Kondo (2004) explains that government in Japan launched a plan in 2001 to create 
1000 university spin-offs in the following three years and has taken various policy measures to 
promote spin-off creation since then. There are several reasons for the surge in interest in spin-
offs: 
1) Universities are very important sources of advanced technologies in both developing 
and developed countries. This is especially the case in the fields of Pasteur-type 
research, where basic research results can be applicable for commercial use (Kondo, 
2004). 
2) USOs seem like a relatively cheap way to promote the development of knowledge 
economies in different places. Policy-makers have been supported in this by research 
universities who have seen USOs as a means of generating revenue and thus reducing 
their exposure to external (governmental) interference (Benneworth and Charles, 
2004).  
3) Spin-offs from universities and government R&D labs are also seen as a bridge between 
the realm of academic research and industry. They facilitate the exploitation of 
academic research by allowing a specialised firm to move it into the industrial sector 
(Byrd, 2002). 
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4) Universities’ technological achievements need to be commercialised in a more rapid 
fashion to compete in the global market. Time (speed) to market is an important 
competitiveness factor. A university spin-off is one of the fastest ways to transfer 
technology to industry (Kondo, 2004). 
5) According to Byrd (2002), universities may use spin-off firms as a tool, not only to 
commercialise a development, but also to give them access to R&D investments. It may 
also be a more effective way to maximise the return on their investment while, at the 
same time, enhancing the university’s academic and research profile. 
6) The technology frontier is wide and key next generation technologies are not easily 
foreseen. Existing companies cannot investigate all the possibilities. In addition, they 
are downsizing corporate laboratories to shift their resources to more near-horizon 
projects (Kondo, 2004).  
7) Some USOs are ‘high-tech’ employers, paying good wages and promoting 
entrepreneurship, stimulate business support services and infrastructure, which benefit 
other start-ups (Benneworth and Charles, 2004). 
8) USOs build on global technological and client knowledge in developing new networks 
to access finance, sales and marketing (Benneworth and Charles, 2004). 
Given the powerful reasons for spin-off creation, South African universities have followed suit. 
Such commercialisation of knowledge, technology and research results is facilitated by a new 
policy framework. The South African government, with its Intellectual Property (IP) Act 2008, 
encourages commercialisations of IP created in public institutions through the creation of TTOs 
and other initiatives. The objective of the Intellectual Property from Publicly Financed 
Research and Development Act, 2008 (“the Act”) is to make provision that IP developed from 
publicly financed research is utilised and commercialised for the benefit of society 
(Government Gazette, 2008). The Act also aims to:  
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a. identify commercialisation opportunities 
b. encourage and reward human ingenuity and creativity; 
c. help grow and develop the private sector, in particular Small and Medium-sized 
Enterprises (SMEs) and Broad-Based Black Economic Empowered enterprises 
(BBBEEE)6; 
d. provide for protection of IP prior to publication of research findings; and 
e. provide for State “walk-in” rights - where necessary (the State may use the results of 
publicly financed research and development, in circumstances where IP is required for 
the country’s health, security and emergency interests).  
 
2.1.3. Methodology 
First, a literature survey which enabled an understanding of the general concept and importance 
of spin-offs was carried out. An exploratory study by means of a questionnaire and interview 
survey was then conducted in order to understand the performance and innovative status of 
spin-offs. The survey was managed in two steps. Since a database on spin-off firms in South 
Africa was not readily available7  for the Western Cape region, information on spin-offs was 
gathered in the first stage.  Conversations were held with knowledgeable people, e.g. staff at 
university technology transfer offices, to gain information about the existence of spin-offs and 
to gather advice on the questionnaire being developed. The search for spin-offs took place over 
the period from 2007-2010 and a total of 53 firms were identified. Based on our field work and 
interviews, four firms did not fall into the research area; one was sold by the professor who 
founded it, two were privatised and two are dormant firms. The remaining 44 firms were 
                                                 
6This stems from the legacy of inequitable access by the majority of the population to the economy under 
Apartheid, which has led to a provision for redress in almost all South African legislation. 
7This is not an unusual phenomenon. Not only in developing countries but in developed countries as well, not 
obtaining sufficient data in this relatively new branch of enquiry, led researchers to use more qualitative 
techniques, such as case studies (Rothaermel et al., 2007: 701). 
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considered suitable to include in our research. 
 
In the second stage, a questionnaire was developed aimed at spin-off founders and/or 
director(s) of the firms. First of all, the questionnaire was sent by email to the firm, after which 
the research interviewed, face to face, with the firms that responded to our questionnaire. The 
questionnaire contained several sections. The first part concerned the description of the firm, 
in terms of age, size, type of activity, and founders’ profiles. The second part of the 
questionnaire enquired about the motivations behind the spin-off formation, as well as the 
funding sources and target markets. The third dealt with the identification of the major 
problems faced by the firm during its life.  
 
Eighteen firms responded to the questionnaire8. Only eight firms, however, conceded face-to-
face interviews. Since the interviews used the same questionnaire as basis, the research 
combines the data supplied by the firms who completed it electronically, with the data obtained 
by putting the questions face to face. In order to protect the privacy of the case study firms, 
firms from the University of Cape Town are coded from Cape Town I to Cape Town VI and 
firms from Stellenbosch University are coded from Stellenbosch I to Stellenbosch XII. 
 
2.1.4. Limitations of the study 
Since the study is based on one province in South Africa. In addition, the number of 
respondents relatively small, therefore, the research cautions strongly that no generalisations 
to spin-offs in the rest of the country can be made. The research considers this an exploratory 
                                                 
8The research found that not all the firms were accessible for the following reasons: 1) researcher(s) did not 
consider their firms to be spin-offs; 2) researcher(s) were unwilling to participate in the study. A TTO officer 
interviewed explained that this is not uncommon, since most researcher(s) are reluctant to participate in 
questionnaire surveys. 
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study, as prelude to a larger scale study of the rest of the country’s regions. At this stage, 
comparisons to spin-offs at other South African regions are therefore not yet possible. 
 
2.1.5. The Results of the Study 
The research sought to answer certain key questions. In addition to the usual questions relating 
to profiles of the firms, the following key questions were posed. What motivated founder(s) to 
create a spin-off? Do the firms collaborate with other organisations, institutions, or firms? 
Where did university spin-offs receive assistance from at the time of start-up?  What obstacles 
did they face? In the following sections, the detailed answers are provided. 
 
2.1.5.1.The Profile of Western Cape USOs 
 
Definitions of a Spin-Off 
Before describing the profile of the USOs that responded, it is important to remark on the 
variation in the understanding of the concept of a USO. In our search for an appropriate 
definition of a USO for the South African context, we settled for the relatively simple definition 
employed by Smilor et al.9 In practice, it turned out that the definition could be more complex. 
Below, the research lists the more complex definitions of a university spin-off firm that 
emerged from our study. It was furthermore clear that, in some instances, where the firm 
definitely fitted the textbook definition of a spin-off, the founders did not consider themselves 
founders of a spin-off, but rather an independent start-up. This has implications for the 
measurement of the output of, amongst others, university transfer offices. 
 
                                                 
9Spin-out firms that provide consulting services were also included in the study. Smilor et al. excluded those types 
of companies in their research. 
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According to Smilor et al.’s simple definition there are two important key points; 1) the core 
technology of the spin-off firm was transferred from the parent university. 2) the founder and/or 
key employees of the spin-off was a faculty member, staff member, or student who left the 
university to start a firm or who started the firm while still affiliated with the university. In our 
case studies, a more complex definition of a university spin-off was identified: 
1. In three instances, the core technology originated from the parent university, but there 
was much variety with respect to the origin and employment status of founders. For 
example, for some firms, the founder(s) came from the parent university, and they 
continue to work for the parent university, while at others, the founders were employed 
by the parent university or were students there, but now no longer work or study there. 
In another case, the founders were not from the parent university. Another possibility 
is that the founders continue to work for the university and the spin-off simultaneously 
until retirement. 
2. In another example, the core technology did not originate from the parent university, 
but the founder(s) was/were an employee(s) or was/were student(s) of the parent 
university. 
3. In another case where the core technology did not originate from the parent university, 
nor were the founder(s) employed by the parent university, the spin- off firm used 
certain resources (such as laboratories) from the parent university. 
4. The spin-off firm was created by the parent university (wholly university-owned spin-
off firm).  
 
Age and Size 
Spin-off activity for these two universities is a relatively recent phenomenon. In the last few 
years of the previous century, only one spin-off was created before 1990. Following this, in 
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1990-1994, one company was set up whereas between 1995 and 1999, two companies were 
created. The number of new firm creation in the form of spin-offs picked up to 5 in the 2000-
2004 intervals and almost doubled (nine companies) in the 2005 to 2008 period. Most firms in 
the survey are therefore relatively young firms. 
 
The firms’ size is measured in terms of turnover, employment and R&D expenditure (Table 
2.1). As far as turnover is concerned, firm size is not too small (see, for example, Chiesa and 
Piccaluga, 2000 for comparison). All the firms have got employees, with the biggest 
concentration of firms falling in the six to ten employee categories. This is not strange for the 
university spin-off environment. Only four firms have got more than 31 employees. These 
firms have created more than 405 jobs since inception making some contribution to the 
reduction in unemployment, which remains a thorny challenge for the country. 
 
Since a core element of the spin-off activity usually involves a new technology or new scientific 
knowledge, it is helpful to consider how much the new firms spent on R &D. It reveals that all 
firms invest in R&D. Seven firms’ R&D budget is higher than one million Rand (about 
US$150,000). Only five of them are under the 50,000 Rand (about US$ 7000).  
 
Table 2.1: Firm size: turnover, employment, and R&D expenditure (2008) 
Turnover10 
(millions 
Rand) 
Number of 
companies 
Employees Number of 
companies 
R&D expenditure 
(Thousands of Rand) 
Number of 
companies 
0-10 
11-100 
 
13 
5 
 
1–5 
6–10 
11–20 
21–30 
31–50 
51–100 
4 
6 
2 
2 
1 
3 
<50 
50–150 
151–300 
301–500 
501–1000 
>1000 
5 
2 
1 
2 
1 
7 
                                                 
10 Some companies mentioned that they haven’t sold any products since they are still in development stage and 
do not have turnover yet.  
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 Total : 18 
companies 
 Total : 18 
companies 
 Total : 18 
companies 
 Source: Authors survey 2009-2010 
 
Table 2.2: Companies by Type of Activity 
Type of activity Number of Companies 
Manufacturing 
Services 
Consultancy 
Research 
Product-development 
Services+ Consultancy+ Research+ Product-development 
Manufacturing+ Services+ Consultancy+ Research+ Product-development 
10 
2 
2 
1 
1 
1 
1 
 Total : 18 companies 
 Source: Authors survey 2009-2010 
 
If the type of activity is taken into account (Table 2.2), the spread of R&D spending makes 
more sense. Most firms (10) in the sample were involved with manufacturing. Only one firm 
had a policy of selling research results, but it had not done so at the time of the survey, being 
newly established. Two firms were in service activities; and a further two had multiple 
activities – that is, they combined manufacturing, service, consultancy, research and product-
development. 
 
2.1.5.2.Who are the Founders and why did they spin off? 
 
Founders’ Profiles 
Founders mostly come from the academic environment (university).Two of the USOs were 
founded with the joint effort of people coming from the academic environment and industrial 
context (Table 2.3). Seven firms’ founders were individuals, while the rest involved teams.. 
Seven were created by two to three founders. Only one firm had between six and ten founders, 
while three had four to five founders. This most likely has to do with the nature of the firms’ 
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business activity, but is quite similar to the findings for spin-offs in other countries where small 
and medium-sized enterprises are ubiquitous (see, for example, McQeen and Wallmark, 1982; 
Smilor et al., 1990; Steffensen et al., 1999; Chiesa and Piccaluga, 2000; Erden and Yurtseven, 
2010). 
 
Table 2.3: Founders’ Profiles  
Founders original activity11  No of companies 
University 
Government research centre 
University and industry 
Industry 
University + Industry 
University + Government research centre + University and  industry + Industry 
9 
1 
2 
1 
3 
1 
 Total: 17 companies 
Source: Authors survey 2009-2010 
 
The research asked the respondents to rate their motivations behind the creation of a spin-off 
firm  on a five-point Likert scale where 5 was most important and 1 unimportant. Table 2.4 
reflects the outcome. For the majority of firms identifying market opportunities was the most 
important motivation. In other words, finding an opportunity to commercialize their products 
was the most important motivation behind the creation of the spin-off firm. Other very 
important motivations were applying knowledge into practical applications and utilizing the 
existing knowledge, followed by personal success and to be independent as important. Table 
2.5 shows the market at inception and currently. Most firms started with an eye on the 
international market.  
 
Table 2.4: Motivations behind the Formation of a Spin Off 
Motivations-Spin-offs Average 
Identification of market opportunities 
Apply knowledge into practical applications  
Fully utilise existing knowledge  
4.27 
3.88 
3.44 
                                                 
11 One company did not fill in the answer as they said “The two founders had finished their PhD’s at University 
and started the company independently i.e. with no University assistance. In my opinion this is not a clear case of 
a University “Spin off”. 
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Personal success 
To be independent12  
Complete the projects 
Aversion for bureaucracy and low risk orientation of the research environment 
Profit making 
Other factors13 
3.33 
3.29 
3.27 
3.22 
2.94 
2.88 
Likert scale: 5 = most important, 1= unimportant 
Source: Authors survey 2009-2010 
 
Table 2.5: Market at Foundation and at Present 
 Geographical market at start-up Present markets of the spin-off companies14 
Market Number of companies Number of companies 
Provincial 
National 
International 
5 
5 
8 
1 
5 
11 
Total 18 17 
Source: Authors survey 2009-2010 
 
Funding Sources 
Funding for the spin-offs in the sample came mainly from three types of sources, namely 
government (regional and national funding vehicles), venture capital (primarily from university 
venture capital funds) and other funds (such as project revenues, operational revenue streams, 
etc.). In three cases the University of Stellenbosch has provided the majority of the funds (100 
%, 90 % and 80% respectively). Only 10% of the funding was received from international 
foundations (Table 2.6).  
 
Table 2.6: Funding Sources  
Category Source Percentage of total capital at 
start-up 
Personal 
Resources 
(include friends 
and relatives) 
Stellenbosch I 
Stellenbosch II- Directors 
UCT I 
UCT V 
UCT VI 
10% 
20% 
20% 
40% 
70% 
Governments Stellenbosch III- Cape Biotech 
UCT II- Regional Innovation Centre 
100% 
100% 
                                                 
12 One company did not fill this motivation in. 
13 Nine companies did not fill this motivation in. 
14 One firm did not answer this question. 
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UCT III- DTI and Cape Biotech 
Stellenbosch IV- NRF IF 
Stellenbosch I 
UCT V- WRC, NRF 
- 
100% 
10% 
50% 
Bank Loans Stellenbosch II- Investec  20% 
Venture Capital Stellenbosch V- University  
Stellenbosch VI- University 
UCT III - Bioventure 
Stellenbosch VII - IDC 
Stellenbosch X- University (facility + interest) 
Stellenbosch I 
Stellenbosch VIII- JDH 
Stellenbosch II- JDH  
UCT I 
Stellenbosch XI- IDC through SPII 
UCT VI 
Approx 10% 
Approx 80% 
- 
95% 
100% 
60% 
100% 
60% 
80% 
- 
20% 
International 
research 
foundations 
Stellenbosch I 
 
10% 
Competitive 
grants 
Stellenbosch I 10% 
Other Stellenbosch VI - Operations in 1st year  
UCT III -Revenue (Sales) 
Stellenbosch IX- Client contract  
Stellenbosch V- Comes from projects 
UCT IV- Vodacom Found  
Stellenbosch XI- Consulting projects, Product 
sales 
UCT V- Competitions 
UCT VI- Competitions 
Stellenbosch XII- Research institute funds 
(University) 
Stellenbosch XII- Employees shares 
Approx 20% 
- 
100% 
Approx 90% 
- 
- 
10% 
10% 
 
90 % 
10% 
Not: UCT: University of Cape Town, Stellenbosch: Stellenbosch University, DTI: Department of Trade and 
Industry, NRF: National Research Foundation, NRF IF: National Research Foundation Innovation Fund, IDC: 
Industrial Development Corporation, JDH: John Daniel House Ltd, WRC: Water Research Commission 
Source: Authors survey 2009-2010 
 
2.1.5.3.Major Problems Encountered 
The most significant problems faced by spin-off firms in the Western Cape RIS, South Africa 
are funding problems and other factors such as getting skilled people, lack of facilities, 
marketing of the products they developed, and time available to do everything (Table 2.7). 
Other factors such as patenting, problems among the owners and family commitments do not 
create significant problems for the firms. 
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Table 2.7: Major Problems Faced by Spin-Offs 15 
Type of problem faced by spin-offs Average 
Funding 
Others factors (e.g. getting skilled people, lack of facilities, marketing of developed products, 
time available to do everything)16 
Technical problems in development and production 
Distribution 
Estimation of the market demand 
Commercialisation 
Regulatory Compliance 
Relationships with the parent university 
Problems related with the position played in the parent university 
Problems in the management of human resources 
Contractual problems 
Patenting 
Problems among owners 
Family commitments17 
4.00 
 
4.00 
3.35 
3.17 
3.11 
2.94 
2.64 
2.64 
2.64 
2.58 
2.58 
2.29 
2.17 
1.66 
Likert scale: 5 = most important, 1= unimportant 
Source: Authors survey 2009-2010 
 
2.1.5.4.Collaboration and Links to Other Organisations 
The results show that, in the case of the Western Cape RIS, it is evident that there is a strong 
link with the university and spin-off firms; government and spin-off firms. These links include 
funding, joint projects, sharing inputs and staff. All spin-off firms have collaboration with the 
universities (except two). Three firms collaborate with both national and international 
universities and hospitals. Twelve out of eighteen firms have collaboration with the 
government on different levels and one of the firms collaborates with a foreign government. 
There is no collaboration with the other spin-off firms except for two firms (Table 2.8). 
 
Table 2.8: Collaboration with Other Organisations 
Companies Government 
organizations 
Research groups/institutes at universities Other spin-off 
companies 
Stellenbosch I Yes Yes 
Stellenbosch University, South Africa 
University of Twente, Netherlands 
University of Grenoble, France 
Ecole Centrale de Nantes, France 
No 
                                                 
15 One company did not fill in this part of the survey. 
16 Nine companies did not fill this problem in. 
17 Eight companies did not fill this problem in. 
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Aachen University of Technology, Germany 
Kassel University, Germany  
Stellenbosch II Yes Yes 
St Louis Hospital, France 
Stemlife, Thailand 
UCT, South Africa 
No 
Stellenbosch III Yes Yes No 
Stellenbosch IV Yes Yes No 
Stellenbosch V Yes  
Danish government 
Yes 
Stellenbosch University, South Africa 
Copenhagen University, Denmark 
No 
Stellenbosch VI No Yes No 
Stellenbosch VII Yes Yes No 
Stellenbosch VIII Yes No No 
Stellenbosch IX Yes Yes No 
Stellenbosch X No Yes No 
Stellenbosch XI Yes Yes No 
Stellenbosch XII Yes Yes 
Stellenbosch University, South Africa 
University of Ford Hare, South Africa 
No 
UCT I No Yes 
MRC, South Africa 
UCT, South Africa 
No 
UCT II No Yes No 
UCT III Yes Yes No 
UCT IV Yes Yes Yes 
UCT V Yes 
WRC 
COFISA 
Yes 
UCT, South Africa 
Yes 
UCT VI No No No 
Source: Authors survey 2009-2010 
 
2.1.6. Discussion   
In this section, the research remark on the key issues in the study; concentrating on the 
founders’ motivations behind the creation of the firm, the collaboration among the spin-off 
firms, parent university and government and obstacles that firms faced. 
 
2.1.6.1.Motivations 
Much empirical work has focused on the factors that will foster the creation of university spin-
offs, including institutional support, local context features, and technology characteristics (Fini 
et al., 2009). On the contrary, the factors that motivate academics at university to venture into 
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spin-off activity have only more recently been the explicit focus of empirical studies. As 
illustrated in Figure 2.1, these factors are usually framed in terms of pull (demand-side) factors 
and push (supply-side or production) factors (see, for example, Smilor et al., 1990; 
Weatherston, 1995; Chiesa and Piccaluga, 2000; Bower, 2003; Meyer, 2006; Rasmussen, 2006; 
Kroll, 2009; Fini et al., 2009; Morales-Gualdrón et al., 2009; Erden and Yurtseven, 2010).  
 
Figure 2.1: Push and Pull Factors of University Spin-Off Activity 
 
Source: Author’ elaboration 
 
The literature also indicates that the motivations cited by academic entrepreneurs are as diverse 
as the definitions of university spin-offs and the nature of the activities carried out in such firms 
(Kroll, 2009: 98). If a spin-off is not related to a particular technology, therefore, the driving 
force may be to apply academic knowledge, for instance, in the supply of consultancy 
services18. The rationale for such decisions consequently requires a consideration of the 
environment in which they are made (Kroll, 2009). In order to understand spin-off decisions, 
we need to take account of interactions amongst individuals, organisations, policy measures, 
                                                 
18Indeed four of our respondents rate this as an important motivation, while five cited the need to exploit their 
experience as important. 
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and the overall environment the entrepreneurs face. 
 
In the case study this research considered, for the majority of firms identifying market 
opportunities was the most important motivation. This is an interesting finding, since other 
studies (such as Fini et al., 2009) found that supply-push factors, such as the existence of a 
potential invention, or the expertise or interest of the founders were most important. From the 
information supplied, however, the causality is not crystal-clear, i.e. was it possible to identify 
a market opportunity because some potential technology was already in the making, or did the 
existence of a market opportunity lead to the emergence of the technology? These are the kinds 
of questions that are being pursued in the follow-up studies.  
 
Given the importance founders assigned to market opportunities it is interesting to explore what 
their respective target markets (i.e. geographical market focus) were at the inception, and 
whether these have altered over time. This is revealed in Table 2.5. It is interesting to note that 
most firms (eight) have had an international market and five started in national and provincial 
respectively during their start-up phase. Most firms maintained this focus as currently; eleven 
firms have an international market, five national and one provincial market focus. 
 
Other very important motivations are: applying knowledge into practical applications and 
utilizing the existing knowledge, followed by personal success and to be independent as 
important. This personal success could be interpreted in various ways. From the literature it 
could mean enhancing one’s reputation, strengthening your position in a network of peers 
rather than success in money terms. Fini et al. (2009) for example, found from their survey of 
the founders of the 47 university spin-offs they studied in the Emilia Romagna region, that 
Italian academics did not seem to be driven by entrepreneurial attitude (such as personal 
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earnings, employment attainment), but by their expectations of enhancing their academic 
standing through new opportunities for basic research, accessing research grants, etc. Research 
based on the motivations behind early spin-offs from MIT (Roberts and Wainer, 1968) found 
that the primary driver was a desire for autonomy, while McQeen and Wallmark (1982) 
studying the motivations of entrepreneurs spinning off from Chalmers Institute of Technology 
found that it was the desire to fulfil their goal of commercialising their technologies rather than 
generating wealth that motivated the founders.  
 
2.1.6.2.Collaboration and Link to Other Organisations 
Even though over the last two decades collaboration has turned out to be of the utmost 
importance in the organisation of R&D in all knowledge-intensive industries (Valentin and 
Jensen, 2006), relations that develop between a spin-off and its environment during the various 
stages of its development is something that has only been investigated to a limited extent in the 
literature (Gubeli and Doloreux, 2005). The innovation systems approach suggests that 
collaboration is necessary to develop new scientific and technological knowledge for new 
products and processes (McKelvey, 2004).  Gubeli and Doloreux (2005) identified that firms 
may be interested in collaborative relationships with innovation and production centres, 
venture capitalists, business angels, banks and other financial organisations seeking high return 
on investment; and public institutions like government, development agencies, and science 
parks, innovation centres and incubators interested in starting a process of technological 
innovation in their regions. As a result of collaboration, firms are saved from isolation (Gubeli 
and Doloreux, 2005) and can access a pool of skills, equipments and some other opportunities 
(Byrd, 2002). Collaborative activities with other parties, including universities, research 
organisations, hospitals, and other spin-off companies, would increase the knowledge capital 
of researcher(s) in spin-offs. In other words, the knowledge inflow from the relationships 
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formed in such collaboration increases the intellectual capacity of spin-off firms and helps them 
realise the commercial value of their knowledge stock and research experience (Erden and 
Yurtseven, 2010). The importance of collaboration is shown in empirical studies, for example, 
Erden and Yurtseven (2010) found that all the firms (12 spin-off firms from universities in 
Turkey) in their sample report to have some collaborative relations with other parties. Most 
firms are motivated to collaborate with other parties to perform research and development 
activities, to develop new products and to share knowledge and skills. In the case of South 
Africa, it is evident that there is a strong link with the university and spin-off firms; government 
and spin-off firms.  
 
It may be argued that location of spin-offs on campus aids collaboration. Current study shows 
that most of the firms are still located on campus. Six firms19 are “in” campus, three firms have 
located in a techno-park and nine firms located nearby the university. Similarly, Erden and 
Yurtseven (2010) found that almost all the firms in the study opted to locate their business 
close to universities (eight of the firms reside in techno parks which have been established in 
university premises by law, three of the firms are hosted in incubation centres that are located 
within university and only one firm is operating elsewhere). Avnimelech and Feldman (2011) 
support this trend in their literature survey. For example, investigation of 72 spin-offs from 
MIT (between 1980 and 1996) revealed that 50% of the spin-offs are located within 20 km of 
MIT and over 70% are situated less than 100 km from MIT. Another example can be given 
from Germany, where it was found that 66% of academic spin-offs locate within 50 km from 
their university. Williams and Majewsky (2002:6), however, argue that while it may make 
sense for the spin-off to be located near the parent organisation for synergy purposes, it is not 
                                                 
19One company was created by the UCT and Cape Peninsula University of Technology (CPUT) staff together and 
are located on the CPUT Cape Town campus. The company works as a non-profit organisation with experience 
and understanding of the unique challenges facing the implementation of e-health systems working in the public 
sector in Africa. 
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advisable to remain on campus and to access university facilities and infrastructure for free. 
They argue that getting this access for free, does not allow the firm the opportunity to learn to 
carry overheads and incorporate it into a realistic cost structure (which it will have to do when 
it grows larger). Also, the academic atmosphere is often not conducive to the pace of work, 
flexibility and agility that a spin-off will have to face in a real competitive environment. In 
addition, housing staff of a spin-off with different conditions of employment together with the 
other academics may create destructive tensions. One of the biggest drawbacks of remaining 
on campus is the possibility of being locked-in to the university’s administrative processes that 
are designed for a purpose and work culture that is quite different from that of a business.  
 
Having discussed the motivations behind the firms’ creation and collaborations with other 
parties, the research now turn to the major obstacles which university spin-offs faced. 
 
2.1.6.3.Major Problems Encountered 
One strand of research in the academic entrepreneurship literature, has concentrated on 
identifying the factors that enhance and impede the formation and expansion of university spin-
offs (Rothaermel et al., 2007: 760). The impeding factors are grouped into those that have to 
do with information gaps, unrealistic expectations, lack of competencies in founding teams, 
scarcity of resources (i.e. funding and structural support), and cultural problems. Spilling 
(2004) also examined some of the barriers to commercialisation such as lack of management 
experience, networks to resources and role models of forming entrepreneurial teams, 
availability of services, access to financial resources (i.e. pre-seed, seed capital), conflict 
between shareholders regarding to the development of the venture. Indeed, in the current 
survey, the largest difficulty faced by spin-off firms in the Western Cape RIS is funding 
problems and other factors such as getting skilled people, lack of facilities, marketing of 
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developed products, and time available to do everything. This problem is not unique to South 
Africa but also prevails in developed countries. Funding for example, seems to be a universal 
problem: Canadian biotechnological spin-off firms reported difficulties in accessing capital for 
firm development (Byrd, 2002); Similarly, Japanese spin-off firms found difficulties in 
obtaining finance, recruiting staff and R&D funding (Kondo, 2004; Kondo and Hasegawa, 
2007); Italian spin-off firms experienced difficulties in funding and commercialisation of 
research (Chiesa and Piccaluga, 2000). Turkish spin-off firms’ most important obstacles were 
insufficient sources of financial capital (Erden and Yurtseven, 2010). The use of personal 
sources, loans, grants and other sources show that financing is a weak angle of the system in 
South Africa. The argument is usually when a well-developed venture capital market to provide 
the seed funding, is lacking, the university should create a venture fund to fill this gap. The 
empirical evidence so far indicates that universities have not had much success in filling this 
gap (Fini et al., 2009). 
 
Spilling (2004) found that it is important that academics must have an entrepreneurial 
orientation to identify potential opportunities for commercialisation and start the process. A 
lack of management experience may be perceived as a barrier to success. In a case study of 
Delft University, the Netherlands, (Van Geenhuizen and Soetanto, 2009) it was found that the 
primary obstacle for the university spin-off was market related (factors such as lack of 
marketing knowledge, sales skills and customer base).  Financial obstacles also played a 
significant role (cash flow, investment capital, R&D investment), along with management 
related issues (such as dealing with uncertainty).  The authors were not surprised by the market-
related problems owing to the fact that spin-off firms evolve from a non-commercial back 
ground.  In order to become profit-generating, different skills and knowledge are required.  
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2.1.7. Lessons and Conclusion 
An objective of this section was to endeavour to define spin-off firms and determine their 
nature, particularly in a South African context.  The focus of the research was spin-offs at the 
Universities of Stellenbosch and Cape Town, where a study was conducted on firms created 
by students and/or researchers who have or have had links with these institutions.  Some firms 
were created by post-graduate students, others still by faculty members or by the universities 
themselves.  The study was confined to knowledge and technology transfers from the university 
to the market irrespective of whether they received university support (from TTOs or 
otherwise) or not. Part of the results from the research was that some firms were created by 
individuals, who did not receive support from universities; hence, they did not view themselves 
as a “spin-off” firm. Therefore, some researchers came to the conclusion that firms supported 
by TTOs (universities) can be defined as a “spin-off” firm. It was furthermore clear that, in 
some instances, where the firm definitely fitted the textbook definition of a spin-off, the 
founders did not consider themselves founders of a spin-off, but rather an independent start-
up. This has implications for the measurement of the output of, amongst others, university 
transfer offices. 
 
As a result, this research can define the spin-off in South African framework as “A new firm 
created to exploit some knowledge, technology or research results conducted at the university 
by faculty members or students who receive (any kind) of support from the university (the TTO); 
a new firm created around a university license of intellectual property (founders may be or 
may not be from university); a firm created by the university itself (wholly university-owned)”. 
 
In summary, what the research have found can be put into two categories, that is, (i) what the 
field work experience taught and (ii) the insights the research derive from the information 
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garnered by means of questionnaires and personal interviews. Given that it was a small-scale 
study, the research cautions that the results should be handled with care. 
 
Two insights of a practical nature emerged from the field work: 
 Different interpretations of the definition of a spin-off firm exist in the minds of the 
founders themselves, as well as the people involved in the technology transfer process. 
This implies that researchers have to be very precise in how they define a spin-off and 
communicate this clearly to the respondents. 
 Universities keep records of spin-offs, but these records do not seem to be updated, i.e. 
the universities do not closely track the progress of their spin-offs (except in the cases 
where they have equity). After the field excursion, the research revealed that some of 
the spin-offs do not exist anymore, and others were discovered that do not appear on 
the lists. 
The research finds that spin-off formation is relatively new for these universities, with very 
little activity before 1990, accelerating at both universities after 2005, with the largest 
concentration in manufacturing. The founders originate primarily from universities, with some 
having held positions in both academia and industry, and a minority purely from industry. The 
most important reasons cited for spinning off are market opportunities, a desire to exploit 
knowledge and experience commercially. Like university spin-offs elsewhere, they consider 
funding to be the most significant problem facing them, followed by other factors (e.g. getting 
skilled people, lack of facilities, marketing of their products, time available to do everything).  
This exploratory study provides important lessons and insights that could inform similar 
research on a larger scale in future. 
 
The next section introduces biotechnology specifically and a comparative narrative of 
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biotechnology spin-off formation in another RIS which came to biotechnology ‘bandwagon’ 
relatively late. 
 
2.2.Academic entrepreneurship in South East Asia: An Exploratory Study of Spin-offs in 
Biotechnology from Hong Kong Universities20 
 
2.2.1. Introduction 
University research with associated spin-offs is at the heart of knowledge generation in the 
biotechnology industry. The role of universities all around the world has changed during the 
past two decades. In particular, universities now have a stronger mandate for promoting 
technology transfer to enhance a region’s economic development (Leung and Mathews, 2006). 
Universities contribute to the local economy through different channels, such as creating the 
pre-conditions for regional learning systems, generating technology-based spin-offs, 
collaborating in R&D with companies, and training scientists, engineers, researchers and other 
graduates. Adding to these channels, universities contribute through establishing science and 
technology parks and incubator centres, commercialising research activities and contracting 
research with companies (Longhi and Keeble, 2000). The advent of biotechnology and its 
potential benefits for nations sorely in need of economic development, has added urgency to 
the pursuit of the new role of active conduit between science and market. 
 
The channel on which this section focuses is the creation of a spin-off company that embodies 
a technology developed at a parent university. This is by no means a new phenomenon in 
developed countries, especially in the biotechnology industry (Zhang, 2009). There is an 
                                                 
20This section was published in a journal. Reference as follow; Uctu, R. and R. Jafta (2012), “Academic 
entrepreneurship in South East Asia: An Exploratory Study of Spin-offs in Biotechnology from Hong Kong 
Universities”, Asian Journal of Technology Innovation, Vol. 20, No. 1, June 2012, 141–154 
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increasing trend towards spin-off companies in Asia as well, although, only a small number of 
studies has so far dealt with biotechnology spin-offs from universities in Hong Kong as 
latecomer in biotechnology. The purpose of this research is to gather information about the 
history and innovative status of biotechnology spin-off companies from Hong Kong 
universities in order to understand the dynamics and influence of this phenomenon as 
knowledge transfer process in biotechnology in Hong Kong better. By using a case study 
method, the study analyses the local activity as an important step towards understanding the 
emerging biotechnology industry in latecomers. Although this study was conducted (out of 
necessity) on a relatively small scale, it is believed that the insights gained from this exploration 
into the field could prove useful for future research. Many of the issues involved have been 
analysed in the literature. These include university-industry technology transfer and technology 
transfer offices (TTO) (Poon and Chan, 2007; Sharif and Baark, 2008), research on the spin-
off process by higher education institutions conducted by Leung and Mathews (2006), 
biotechnology industry in Hong Kong discussed by Poon and Liyanage (2004) and Baark 
(2005) and biotechnology development in Hong Kong compared to Singapore by Tsui-Auch 
(2000). The merit of this section, however, lies in the fact that it combines all of these concepts, 
with a specific focus on university spin-offs in biotechnology. 
 
The rest of the sub-section consists of three parts: in the first, sub-section 2, the concept of 
spin-offs is defined, located in the context of academic entrepreneurship and then, sub-section 
3 discusses the findings of exploratory study on biotechnology spin-off companies in Hong 
Kong. The section concludes with some lessons learnt and pointers for further research on the 
growing worldwide spin-off phenomenon (sub-section 4). 
 
2.2.2. The Importance of Spin-Offs 
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Many universities have become increasingly interested in the creation of a spin-off company 
as an important tool for the commercialisation of research results (Rasmussen and Borch, 2010; 
Lee, 2010), but it transpires that there is no universally accepted definition of a spin off. Smilor, 
et al. (1990: 64) define a spin-off company in two ways: (1) the founder was a faculty member, 
staff member, or student who left the university to start a company or who started the company 
while still affiliated with the university; and/or (2) a technology or technology-based idea 
developed within the university was used to start the company. The effectiveness of this 
technology transfer method is typically visible in knowledge-intensive sectors such as 
biotechnology (Chiesa and Piccaluga, 2000; Nezu, 2005).  
 
Policymakers in developed countries are encouraging universities to increase the rate of spin-
off formation. The set-up of knowledge-based organisations with original ways of interacting 
and stimulating academic entrepreneurship is a main contributor to regional economic 
development (Smith and Bernardy, 2000). Policies to promote university spin-offs have a long 
history and the results in terms of numbers of new companies created are indicative of success. 
In the USA, for example, in 2010 alone, 651 university-based start-up companies were started; 
while a total of 3,657 companies were still operating in 2010 (AUTM, 2010a). Other countries 
have also followed American practice. In Canada, in 2010, the total number of operational 
start-ups increased in number from 591 (2009) to 632 (AUTM, 2010b). In UK, 273 new spin-
off companies were set up in 2009/10 to exploit intellectual property originating in UK higher 
education institutions (HEIs). Meanwhile, the total number of university spin-off companies 
that had been active for three years or more grew steadily, from 746 in 2005/6 to 969 in 2009/10 
(www.educationinvestor.co.uk). 
 
There is an increasing trend of spin-off companies in Asia as well (Ngan, 2006). For example, 
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Japan in 1995 created 15 university spin-offs but in 2004 leapt to 195 (Kondo and Hasegawa, 
2007). China is also visibly successful in creating high-tech start-ups from universities and 
research institutes. These start-ups are especially noticeable in Beijing (Kondo, 2003). The 
World Bank’s Report of 2001 on “China and the Knowledge Economy” cited by Nezu (2005) 
confirms that Beijing University and Tsinghua University created more than 60 spin-offs each 
in high tech areas. Hong Kong SAR of China has been in the creation of spin-offs for 19 years, 
starting in the early 1990’s. However, there is a limited amount of literature directly dealing 
with the topic of biotechnology spin-offs from universities in Hong Kong. 
 
2.2.3. Case Studies on Biotechnology University Spin-Offs 
 
2.2.3.1. Research Methodology 
A variety of secondary sources of information enabled an understanding of the general concept 
of biotechnology and spin-offs. An exploratory study by means of a questionnaire survey was 
conducted in order to understand the performance and innovative status of biotechnology 
spinoffs in Hong Kong. The survey was managed in two steps. During the first stage, research 
was carried out to identify how many universities have a TTO, and a five-page email 
questionnaire was sent to the TTOs at five universities in Hong Kong, namely University of 
Hong Kong (UHK), Chinese University of Hong Kong (CUHK), Hong Kong University of 
Science and Technology (HKUST), Hong Kong Polytechnic University (PolyU) and City 
University (CityU). All the universities responded to the questionnaire. TTOs were requested 
to specify the spin-offs at the university and indicate how many of them are in the 
biotechnology sector. This process yielded a total of 19 biotechnology companies which 
seemed to fit the definition of a spin-off. 
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In the second stage, a nine-page questionnaire was developed specifically for the biotechnology 
spin-off companies. The questionnaire was emailed to those companies identified through the 
TTO survey; thereafter companies were telephoned and visited to administer the survey. The 
questionnaire covered, amongst other things, the nature and activities of the company, 
motivations behind the creation of the company, and the identification of the major problems 
faced by the company during its life. During the second stage, field research revealed that two 
biotechnology companies are not active anymore and three companies are not biotechnology 
spin-offs. It was evident that one company was not in biotechnology after the completed 
questionnaires were received, and two others turned out not to be biotechnology companies 
after the follow-up telephone calls. Two companies had the same director and commercialized 
and accounted for their products under one company. A further company was identified as not 
being a biotechnology company after more investigation. In all, our research identified 12 
spinoffs related to biotechnology created by Hong Kong universities. Of these, 10 spin-offs 
were classified in the ‘biotechnology’ field and two in the ‘Chinese medicine’ field (Table 2.9). 
In the next section, the cases of five (41%) biotechnology spin-offs from the universities in 
Hong Kong are explored21. Due to the limited number of companies, no inferences to the other 
population of spin-offs can be drawn from the primary data and its analysis (Perez and Sanchez, 
2003). Companies presented in this section are coded as Company A, Company B, Company 
C, Company D and Company E. 
 
Table 2.9: Spin-offs from Hong Kong universities4 
Name of Institutions 
No of spin-off companies and joint 
ventures 
Biotechnology spin-off companies and joint 
ventures 
                                                 
21 This is not an unusual phenomenon. Even in developed countries obtaining insufficient data in this relatively 
new branch of enquiry, led researchers to use more qualitative techniques, such as case studies (Rothaermel, et al, 
2007: 701). 
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CityU 
PolyU 
HKUST 
UHK 
CUHK 
Total  
23 
18 
29 
6 
15 
91 
1 
1 
4 
3 
3 
12 
4 Biotechnology including Chinese medicine 
Source: Authors survey and university websites, 2009 
 
2.2.3.2.Results  
The study has highlighted the profiles of the companies; including the opportunities, obstacles 
and problems they faced. The survey posts a number of key questions, such as; what are the 
companies’ classifications by type of activity? What are the companies’ turnover and R&D 
budgets? Who is/are the founder(s) and where do they come from? What motivated them to 
create a spin-off? Do the companies have collaboration with other 
organisations/institutions/companies? Where did university biotechnology spin-offs receive 
assistance from at the time of start-up? The detailed answers are provided below. 
 
Definitions of a Spin-off in Hong Kong 
The research asked participants to define their companies, before analysing the companies’ 
profiles.  In this study the research settled for Smilor et al.’s (1990) simple definition22 
(discussed in Section 2). In the Hong Kong context, this research found that some companies 
clearly fitted this simple definition but some other companies were more complex and required 
an expanded definition: (1) The core technology and the founder(s) came from the parent 
university, and the founder(s) continue to work for the parent university, (2) The core 
technology of the company was created in the parent university, while the founder(s) were 
employed by or was/were research student(s) at the parent university, (3) The core technology 
                                                 
22 Smilor et al.’s (1990) two-dimensional definition. In the aforementioned study, the authors excluded the spin-
off firms that provided consulting services. However, those types of companies were included in our research. 
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of the company originated in the parent university, but the founder(s) was/were not from the 
parent university and (4) The company was created by the parent university. 
 
 The Age and Size 
The survey reveals that biotechnology university spin-off activities in Hong Kong have started 
mostly after 2000. Four companies (Company B, C, D and E) were created after 2000 while 
Company B, C and D were set up between 2000 and 2005. Company E was set up between 
2006 and 2009. Only one company (Company A) was set up before 1990, which was also the 
oldest biotechnology spin-off company that this survey discovered in Hong Kong. 
 
Table 2.10: Firm size: turnover, employment, and R&D expenditure 
 Turnover (Million HK$) Employees R&D budget (Thousand HK$) 
Company A 
Company B 
Company C 
Company D 
Company E 
11-50 
<3 
4-10 
<3 
<3 
31-50 
1-5 
1-5 
1-5 
1-5 
301-500 
<150 
- 
1000-5000 
<150 
Source: Authors survey 2009 
 
The firms’ size is measured in terms of turnover, employment and R&D spending. The 
company size is relatively small (Table 2.10). Turnover of three companies is under HK$ 3 
million, only company A has more than HK$ 11 million. Companies created after 2000 are still 
in the development stage, with turnover still relatively low. R&D expenditures are incurred in 
expectation of future growth in revenues. Companies in the biotechnology sector must spend 
capital resources on R&D in order to generate more revenues later on (Byrd, 2002). In the 
Hong Kong case studies, the R&D budget of the companies gives insight into the working of 
the companies as well. It reveals that only company D (i.e. product-development company) 
had more than one million HK dollar R&D budget in 2008. Two of them are under the 
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HK$ 150,000. The R&D budget of Company C was not provided. The companies’ size is also 
reflected in the number of employees. Biotechnology-related companies from universities are 
small in Hong Kong. Only one company has got more than 31 employees. Four of them have 
less than six employees. Despite that, our results show that all companies developed 
commercial products and services (Table 2.11). Two companies developed Chinese medicines, 
one focused on health care while another two developed biotechnology-related products. 
 
 
 
Table 2.11: Commercial products and services developed by the company 
 Commercial products and services developed by the company  
Company A 1.Five of Chinese Medicines 
2.DNA vaccine/in collaboration with others 
Company B 
 
1. Gel electrophoresis unit 
2. DNA fingerprinting reagent kit 
Company C 1. TCM-based products and health foods 
Company D 1.CardioDetect H-FABP rapid test 
2.CardioCare hs-CRP & infectCheck CRP ELISA kits 
3.INfectCheck NeoPT rapid test 
Company E  1. Skincare lines: MELI, GENE & SABIO 
2. Healthcare lines: GENECARE 
Source: Authors survey 2009 
 
Table 2.12: Companies classification by type of activity  
Type of activity Manufacturing-type Services-type Consultancy-
type 
Research-type Product-
development 
Company A O O O - O 
Company B - - - - O 
Company C - O - - - 
Company D - - - - O 
Company E - - - O - 
Source: Authors survey 2009 
 
When the companies’ activity is taken into account (Table 2.12), two companies (B &D) are 
of the product-development type. Only one company sells research results (Company E) and 
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one company (C) is in services. One company (A) has multiple activities, i.e. combines 
manufacturing, service, consultancy and product-development.  
 
Table 2.13: Companies collaborating with government organisation(s), research 
group(s)/institute(s) at universities and other spin-off companies 
Collaborations with Government organizations 
 
Research groups/institutes at 
universities 
Other spin-off companies 
Company A Yes Yes Yes 
Company B No No No 
Company C No Yes No 
Company D Yes Yes Yes 
Company E No No No 
Source: Authors survey 2009 
 
Collaboration has turned out to be of the utmost importance in the organisation of R&D in all 
knowledge-intensive industries (Valentin and Jensen, 2006), especially in biotechnology. As a 
result of collaboration, companies could access a pool of skills, lab equipment and some other 
opportunities. These companies do not normally possess all of the necessary elements to 
capitalize on new developments at the pace biotechnology demands. For example, a company 
may have sufficient funding but lack the ideas and expert knowledge another company has 
(Byrd, 2002). In the case of Hong Kong, it is evident that collaboration between spin-offs and 
institutions is not strong in all spin-off companies. Only Company A and D had collaboration 
with the government and other spin-off companies, Company A, C and D had collaboration 
with the research groups at universities and institutes. Company D is the only one that had 
collaboration with the research groups at universities and institutes located in Hong Kong, 
China and other parts of the world (Europe). Company B and E had no collaboration at all 
(Table 2.13).  
 
One of the most important science and technology indicators of biotechnology companies is 
the number of patents it creates in different categories. Patents are accepted to be evidence of 
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a country’s technological and inventive achievements (Pouris, 2005). Once patented, it is 
expected that the company will be able to develop the IP into a commercially viable product 
or use it to improve an existing one. Patents are also considered as a tangible asset, something 
the company may point to as proof that they are able to capitalize on their R&D (Byrd, 2002). 
On this note, Byrd (2002) analysed the profile of spin-off firms23 in the biotechnology sector 
included in the Biotechnology Use and Development Strategy Survey-1999. Of the 358 core 
biotech firms found in the manufacturing sector, 123 were core biotechnology spin-off firms 
(34%). The author also found that Canadian core biotechnology spin-offs hold a total of 1029 
existing patents. Rutherford and Fulop (2006) identified for five companies (as case studies) 
that IP was transferred to each company under licensing agreements, which gave the companies 
worldwide rights to their respective technologies. In Hong Kong, the companies’ intellectual 
property portfolios revealed of the five companies, three companies have patents (Company A, 
D and E). Two patents are worldwide and one is a China-based patent. 
 
Who Founded Biotechnology Spin-offs and Why? 
In this section the research want to paint a picture of the founders of spin-offs at Hong Kong 
universities in terms of their affiliation, number at inception, as well as the reasons leading to 
the creation of a spin-off.  The research begins with the founders’ affiliations (Table 2.14). It 
reveals the founders’ background. 
 
Table 2.14: Founder(s)’ original affiliation 
Founders original activity University University and industry Industry 
Company A O - - 
Company B O  - 
Company C - O - 
Company D O - O 
Company E O - - 
                                                 
23 In Byrd’s study, a spin-off is described as a new company created to transfer and commercialize inventions and 
technology developed in universities, firms or laboratories.  
66 
 
Source: Authors survey 2009 
 
The founders of the companies came mostly from the academic environment. One company 
(D) was established with the joint effort of people coming from the academic environment and 
industrial context, whilst another company (C) was established by people working in both 
academia and industry. The next table (Table 2.15) reveals the number of company founders 
at inception. All the companies were created with joint effort, i.e. have more than one founder. 
Three were created by two to three founders. One company had four to five founders, while 
another company had between six to ten founders. 
 
Table 2.15: Number of founder(s) 
No of founders 1 2-3 4-5 6-10 
Company A - O - - 
Company B - - - O 
Company C - - O - 
Company D - O - - 
Company E - O - - 
Source: Authors survey 2009 
 
A large selection of empirical work has focused on factors that can promote the creation of 
academic spin-offs, including institutional support, local context features, and technology 
characteristics (Fini, et al., 2009). However, the factors that motivate academics at university 
to venture into spin-off activity have only more recently been the explicit focus of empirical 
studies. These factors are usually framed in terms of pull (demand-side) determinants (like 
market opportunities, applying knowledge into practical applications) and push (supply-side or 
production) determinants (such as being independent or having a profit motive) (see for 
example Weatherston, 1995; Chiesa and Piccaluga, 2000; Rasmussen, 2006; Kroll, 2008; Fini, 
et al., 2009; Morales-Gualdrón, et al., 2009).  
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In addition, the literature also indicates that there is a large variety of motivations behind setting 
up an academic spin-off (Muller, 2010); and the motivations and aspirations cited by academic 
entrepreneurs for the foundation of a company are as diverse as the definitions of academic 
spin-offs and the nature of the activities carried out in such firms (Kroll, 2008; Muller, 2010). 
That is, if a spin-off is not strictly linked to a particular technology, it is possible that the driving 
force for the spin-off might be to apply academic knowledge in practice (as in providing 
consulting services). Understanding the set-up rationale also means taking into account the 
environment in which these decisions are made and implemented, i.e. ‘set-up decisions are 
decisions driven by human agency and taken by individuals that scan the environment for 
opportunities.’ (Kroll, 2008: 99). In the pre-seed phase, motivations such as opportunity 
recognition and organisational procedures may be accelerated. People who are mainly driven 
by the desire to work for themselves might have had the wish to become self-employed at the 
back of their mind long before. People such as these may therefore recognise the opportunity 
of exploiting the skills that they acquire, methods they develop or research they conduct 
(Muller, 2010). Hence, spin-off decisions are to be understood as part of interactions amongst 
individuals, organisations, policy measures, and the overall environment the entrepreneurs 
face. 
 
When an entrepreneur decides to set up a company there are various considerations: 
technological considerations will clearly be at the early stage, requiring proof of concept. On 
completion, a prototype will need to be developed effectively turning knowledge into a product. 
The university spin-off is then faced with the issue of market uncertainty, particularly the issue 
as to whether the product will find acceptability in the market.  Consequently, to overcome this 
problem, the company has to identify the right market application for the technology and to 
judge the market size (Shane, 2004).  
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Bearing in mind these insights from the literature, the research asked the founders in our survey 
what motivated them to create spin-off companies. Respondents were asked to rate their 
motivations on a Likert scale varying from 1 (not important) to 5 (most important). The results 
are shown in Table 2.16 and discussed below. 
 
The analysis of the motivations behind the foundation of a spin-off company shows that the 
major motivation is that the founder(s) wished to apply their knowledge to practical 
applications, followed by potential market opportunities and profit making. 
 
Table 2.16: Motivation behind the foundation of the spin-off company 
Motivations Average score 
Apply knowledge into practical applications  
Identification of market opportunities 
Profit making  
Complete the projects 
Fully utilize existing knowledge 
To be independent 
Aversion for bureaucracy and low risk orientation of the research environment 
Personal success 
Other factors5 
4,8 
4,6 
4,0 
3,4 
3,4 
3,2 
2,8 
2,6 
2,2 
Note: 1: Not important, 2: Slightly important, 3: Neutral, 4: Important, 5: Most Important  
5Two companies did not fill in this motivation in and none of the companies explained what the other factors are. 
Source: Authors survey 2009 
 
This is not a surprising result: other studies found similar results. Chiesa and Piccaluga (2000), 
for example, in their research on Italian spin-offs found that the majority of the firms’ 
motivations (nearly 60%) were pull factors such as identifying market opportunities and 
applying their knowledge into practical applications. Jafta and Uctu (2009) found similar 
rankings of motivations for the Western Cape university spin-off firms in South Africa. Kondo 
(2004) conducted a first survey on the university spin-off companies in Japan and found that 
the primary motive to found a company is to put inventions to practical use. Making a fortune 
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is mentioned by only a few founders as a primary motive. Kondo and Hasegawa (2007) 
conducted research on the characteristics of Japanese university spin-off companies by 
industry, region and founder-type. In their research respondents were asked to rate their 
motivations in six choices; commercialisation of developed technology, commercialisation of 
business ideas, asset making, social contribution, own capacity development and others. When 
faculty members started a spin-off their main motivation was commercialisation of 
technologies followed by social contribution and commercialisation of business ideas. This 
result is different in spin-offs created by the students. For them the major motivations were to 
commercialise business ideas, followed by social contribution and own capacity development. 
Researchers and technical staff, on the other hand, were motivated by social contributions, 
followed by commercialisation of business ideas and assets making with the same ratios. 
Unfortunately, our data for Hong Kong does not allow such a neat matching of founder-type 
to motivation rankings. 
 
Given the importance founders assigned to market opportunities it is interesting to explore what 
their respective target markets were at the firms’ establishment, and whether these have altered 
over time.  
 
Table 2.17: Market at foundation and at present 
 Geographical market at start-up Present markets of the spin-off companies 
 Hong Kong China S. E. Asia Others 
(Europe) 
Hong Kong China S. E. Asia Others 
(Europe) 
A O O - - O O - - 
B O - - - O - - - 
C O - - - O - - - 
D O O O O O O O O 
E O O - - O O - - 
Source: Authors survey 2009  
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Table 2.17 reveals the companies geographical target markets. Companies mainly targeted 
Hong Kong and Mainland China during their start-up phase and their current market still 
remains the same. Only Company D has focused on Hong Kong, China, other South East Asian 
countries and international market (especially Europe) since their start-up phase up until 2009. 
 
In all cases, the companies developed commercial products/services (discussed in Table 2.11). 
This illustrates that they applied their knowledge to practical effect. In terms of marketing their 
products, the companies had clear market objectives from their inception.  
 
Funding Sources 
It is generally accepted that it is important to measure the financial status of biotechnology 
spin-off companies in order to better estimate the future growth of the sector. For this research’s 
purposes, this funding source information is useful in relation to whether funding was an 
obstacle to spin-off formation and growth. Spin-off companies need to engage in technical and 
market development before selling their products or services and need finance to develop their 
companies. In many cases, companies cannot survive only with their own saving and must 
acquire finance from external sources like business angels, venture capitalists, and government 
agencies (Shane, 2004). In case studies in Hong Kong, funding came mostly from personal 
sources, venture capital and other sources (i.e. angel funds, personal loans) (Table 2.18). A 
small percentage of the funding was received from international foundations.  The use of 
personal sources, loans and grants show that financing is a weak angle of the system in Hong 
Kong. This is actually not only for spin-offs but in general for biotechnology companies as it 
is a relatively new sector and private venture capitalists in Hong Kong have not shown very 
much interest in biotechnology so far (Lindgren, 2008). This view was supported by one of the 
participants in this survey. In the interview, the participant opined that venture capitalists in 
71 
 
Hong Kong have not shown much interest in biotechnology because they expect investment 
return in a short period like investing in Information and Communication Technologies (ICT). 
Returns on investing in biotechnology are, on the other hand, a long term prospect. 
 
 
 
 
Table 2.18: Sources of funds for start-up 
Percentage of total capital at start-up (%) 
Category Companies 
A B C24 D E 
Personal sources (include friends and relatives) - - - 90 - 
Governments - - - 10 - 
Venture Capital (China-based) - - - - 100 
International research foundations 1 - - - - 
Competitive grants 40 - - - - 
Other(s) HK Jockey Club 50 - - - - 
University 10 - - - - 
Personal loan - 100 - - - 
Angel funds (investors) - - ~ 45 - - 
Source: Authors survey 2009 
 
 Obstacles to success 
The literature on biotechnology identifies three crucial elements, commonly called the “three 
pillars” essential to success for a biotechnology start-up company: (i) effective management, 
(ii) sufficient capital and (iii) access to new technology that leads to products. All 
biotechnology companies face difficult managerial challenges in R&D because it is both the 
most expensive and the most critical aspect of bringing a product to market which requires a 
complex repertoire of knowledge, skills and talents (including marketing, the basics of 
Intellectual Property Rights (IPR), early-stage technology finance, and knowledge of scientific, 
                                                 
24 Only given percentage 
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regulatory and ethical issues) (Schoemaker and Schoemaker, 1998; Meyers and Hurley, 2008; 
Malazgirt, 2011). The second pillar, sufficient capital presents a struggle for most 
biotechnology companies because the processes involved in developing a product is costly and 
time-consuming. (Schoemaker and Schoemaker, 1998; Malazgirt, 2011). Lastly, every 
biotechnology company, from its inception, must have a well-defined and well-articulated 
product focus. The company needs a clear vision to identify the avenues of its future revenue 
streams. For the biotechnology company it could be a single product to create the foundation 
for a profitable company. Once chosen, the company need to focus on the development of its 
chosen product and its underlying technology (Schoemaker and Schoemaker, 1998).  
 
In order to understand the relevance and extent of these major challenges for the companies in 
survey, the research asked respondents to rate the obstacles they faced on a 5-point Likert scale, 
where 1 was not important and 5 was most important. The results are illustrated in Table 2.19. 
 
Table 2.19: Major obstacles faced by spin-off companies 
Type of problem Average Score 
Estimation of the market demand 
Technical problems in development and production 
Funding 
Relationships with the parent university 
Regulatory Compliance 
Problems related with the position played in the parent university 
Commercialization 
roblems in the management of human resources 
Distribution 
Patenting 
Problems among owners 
Contractual problems 
Others6 
4,2 
4,2 
4,0 
4,0 
3,8 
3,6 
3,5 
3,4 
3,0 
2,6 
2,2 
2,2 
- 
Note: 1: Not important, 2: Slightly important, 3: Neutral, 4: Important, 5: Most Important 
6  None of the companies filled this obstacle in. 
Source: Authors’ survey 2009 
 
In the current survey, the biggest difficulties faced by biotechnology spin-off companies in 
Hong Kong are the estimation of market demand and technical problems in development and 
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production, closely followed by funding and relationships with the parent university, regulatory 
compliance and problems related to the role played in the parent university. Comparing the 
findings to other studies, it appears that this applies not only in developing countries but also 
in developed countries. Funding, commercialisation and managerial skills, for example, seem 
to be a universal problem. Van Geenhuizen and Soetanto (2009) explored a case study of Delft 
University of Technology in the Netherlands and found that the main difficulties faced by 
university spin-offs are market-related (marketing knowledge, sales skills, customer base), 
followed by financial (cash flow, investment capital, R&D investment) and management 
problems (dealing with uncertainty, management). According to Van Geenhuizen and Soetanto 
(2009), managerial skills (e.g. market-related problems) are not surprising obstacles since spin-
off firms must evolve from a non-commercial environment to become an established, profit-
generating firm which implies that a new and different type of knowledge and skill set are  
required to be successful. Rutherford and Fulop (2006) found similar lack of expertise in 
Australian biotechnology start-ups. The authors stated that business awareness of science is 
low and scientists lack entrepreneurial skills to commercialise their research. To overcome 
these problems, the authors suggested to train and equip scientists with the necessary 
commercialisation and managerial skills. Byrd (2002) found that the major problem faced by 
Canadian biotechnology spin-off companies is access to the capital to develop the company. 
Similarly, Kondo (2004) found that a major difficulty at start-up for Japanese companies was 
access to finance, followed by staff recruiting. Likewise, Kondo and Hasegawa (2007) found 
the major difficulty is recruiting R&D staff, followed by the lack of R&D funds. Chiesa and 
Piccaluga (2000) also found that some of the major problems Italian spin-off companies faced 
was funding and commercialisation of the research results. Perez and Sanchez (2003) studied 
ten companies spun-out from the University of Aragon in Spain and identified that the major 
obstacles spin-offs confronted are the small market size and lack of financial sources during 
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the first year of their activity. Although the rankings vary, it is evident that the top three to four 
obstacles elsewhere are similar to the ones listed in Table 2.19.  
 
Overall, although spin-off creation from Hong Kong universities in biotechnology is a 
relatively new phenomenon, it seems as if the motivations for creating them, and the obstacles 
they face, are not significantly different from the experiences of spin-off companies elsewhere. 
 
2.2.4. Conclusion 
This section surveyed university technology transfer offices and firms in order to gather 
information about the history and innovative status of biotechnology spin-off companies from 
universities to contribute to the understanding of this phenomenon as knowledge transfer 
process in Hong Kong. The research analysed the local activity as an important step towards 
understanding the emerging biotechnology industry in latecomers. Based on the case study, 
research could say that there is an increasing awareness of academic entrepreneurship in the 
form of creating university spin-offs in Hong Kong, but not yet for the biotechnology sector, 
where spin-offs are relatively few. This is actually not only for spin-offs but in general 
biotechnology is comparatively new and private venture capitalists have also not shown very 
much interest in biotechnology so far (Lindgren, 2008).  
 
One of the main results of this study is that the definition of biotechnology spin-offs for some 
companies clearly fitted the textbook definition but some others were more complex and 
required an expanded definition.  In one case, for instance, the founders were not from the 
university while in another case; the company was created by the university itself.  
 
75 
 
The study has also highlighted the profiles of the companies; opportunities, reasons for 
foundation, obstacles and major problems faced by biotechnology spin-offs. In summary, the 
results suggest that biotechnology university spin-off firms in Hong Kong; 
 are relatively small in size and young (less than ten years in existence), 
 operate more often in biotechnology product and process industries rather than services; 
 developed commercial products and services, 
 collaborate seldom with other organisations, with two exceptions, 
 are aware of IP protection, 
 are mostly formed by university staff, 
 are created with joint effort, i.e. have more than one founder, 
 are motivated to create spin-offs in order to apply knowledge to practical applications 
and utilise market opportunities, 
 experience problems with estimating the market demand, technical problems in 
development and production and difficulties with financing, as the most important 
inhibitors to success.  
 
Although this study was conducted on a relatively small scale, it is believed that the insights 
gained from this exploration into the field could prove useful for future research. This section 
contributed to the understanding of the rationale for and the nature of biotechnology spin-offs 
from Hong Kong universities. The research also generated a few interesting questions to pursue 
in further research, namely: 
i) it would be useful to track the survival strategies and / or growth paths of these firms 
over time; and (this idea is pursued in the pen-ultimate section for biotechnology spin-offs 
at Western Cape universities, South Africa). 
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ii) related to the first question, investigate the role that patents play in the success of these 
spin-offs, and finally 
iii) compare the motivations of academics who were in a position to spin-off, but did not, 
to better understand the pull and push factors in spin-off creation. (This idea is pursued 
for academic scientists at universities in the Western Cape RIS in the next section). 
 
2.3.Spinning-Off or Licensing? The Case of Academic Technology Transfer at Two South 
African Universities25 
 
When universities embark on technology transfer to the private sector in order to reap the 
benefits of commercialisation, they have a number of different mechanisms at their disposal.  
This section focuses on the option of Intellectual Property (IP) licensing of technologies from 
universities. In particular, the study asked why academics that are in a position to create a spin-
off, based on the commercial value of their invention, would rather opt for licensing. This 
question was pursued in the context of the universities’ rationale for technology transfer, the 
nature and performance of their technology transfer institutions, and the motivations behind 
the academics’ decisions. Although the research have previously introduced the concept of 
technology transfer and discussed it briefly, the research give a more extensive exposition here, 
as prelude to the description of TTO activities at the two universities. This case study focuses 
on two of South Africa’s oldest research-led universities, based in the Western Cape region.  
 
2.3.1. Introduction 
                                                 
25 This section was accepted to a journal for publication. Reference is as follow; Uctu, R. and Jafta, R. 
(forthcoming, 2014), “Spinning-Off or Licensing? The Case of Academic Technology Transfer at Two South 
African Universities”, Industry and Higher Education.  
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When universities embark on technology transfer to the private sector to reap the benefits of 
commercialisation, different mechanisms are available.  The most common ways are creating 
spin-off companies and licensing technologies. Several authors have assessed the determinants 
and outcomes of faculty involvement in technology commercialisation, such as the tendency 
of academics to patent and disclose inventions, co-author with industry scientists, and create 
companies (Siegel et al., 2007), while others have examined the characteristics of the 
knowledge transferred through licensing, evaluation of Technology Transfer Offices (TTOs) 
productivity and the role of incentives in licensing performance (Conti et al., 2007). However, 
only a few studies have focused on the factors underlying the choice researchers make, i.e. 
whether technology should be licensed or commercialised by creating a spin-off company.  
With the aid of case study methods, focusing on technology transfer activities at South Africa’s 
two oldest and premier research-led universities (University of Cape Town (UCT) and 
Stellenbosch University (SU)), the following questions were addressed in this section: 
1. What is the rationale for technology transfer at the two universities? 
2. What progress with regard to technology transfer has been made at these universities?  
3. What motivates researchers to license their inventions?  
4. Why would researchers in a position to create a spin-off, i.e. those who have a 
technology with commercial potential, choose not to do so? 
The answers to these questions will contribute valuable insights primarily for TTOs, university 
management, and policymakers in South Africa and similar developing countries. The purpose 
and scope of this section is therefore not aimed at settling debates in the context of technology 
transfer mechanisms.  
 
The remainder of this section is structured into seven sub-sections. Sub-section 2 gives a brief 
survey of the literature on technology transfer from universities to the public, while sub-section 
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3 deals with the role of technology transfer offices. Sub-section 4 contains the technology 
transfer activities at the two universities. In sub-section 5 the purpose and scope of the study is 
described and the data and methodology used are explained and then the results are presented. 
In sub-section 6 the main discussion is undertaken and the conclusions are highlighted in sub-
section 7. 
 
2.3.2. The Importance of Technology Transfer from Universities 
In this section, the research first examines the meaning of technology transfers (TTs); the 
research then considers the purpose of TTs and finally, explains the methods of technology 
transfers.  
 
There is no internationally accepted definition of technology transfer. Synder et al. (2003: 3) 
define technology transfer as “the application and sharing of scientific knowledge between 
researchers and research organisations (including laboratories, universities, industry, research 
institutes, local and state governments and third party intermediaries (e.g. venture capitalists 
and management companies)”. According to Dos Santos and Rebolledo (2008), technology 
transfer is made in different ways (e.g. oral communications, the physical transfer of a tangible 
research result or through the IP licensing). Supporting this point of view, Parker and 
Zilberman (1993, cited by Dos Santos and Rebolledo; 2008: 280) state that “technology 
transfer is any process by which basic understanding, information, and innovations transfer 
from a research institution (e.g. a university, an institute or a governmental laboratory) to 
individual or firms in the private and quasi-private sectors”.  Also taking into account TT as a 
process, Thursby and Thursby (2002) observe that technology transfer is a production process 
occurring in three stages: 
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(i) the first-stage of development is the invention disclosure which is filed by faculty 
members when they believe that their research results have commercial potential;  
(ii) the second-stage is patent applications by TTOs for those disclosures they believe can 
be patented and licensed; 
(iii)  the final-stage is obtaining licensing.  
Friedman and Silberman (2003:18) identify TT as "a process whereby invention or intellectual 
property from academic research is licensed or conveyed through use rights to a for-profit 
entity and finally commercialised". This process involves several steps as can be seen in figure 
2.2.  
 
According to Fernandez (2007) universities perform two main societal functions: educating 
students and conducting research26. Over time, a third function has been added that today 
generates much interest: since the enactment of the Bayh-Dole Act27 in the United States of 
America (US) in 1980, the promotion and commercialisation of universities’ research results 
has been a focus of attention. In other words, transfer of technologies arising from university 
research, to industry, through patenting, licensing and creating companies, has come to be seen 
as a third function. 
 
The most common ways of transferring technologies are through the licensing of technologies 
and the creation of spin-off companies. The research first considers the definition of licensing 
from the literature.  
 
                                                 
26 In developing countries such as South Africa, community engagement is considered another contribution that 
universities make. 
27 The Bayh-Dole Act of 1980, which helped to set up the field of technology transfer in the United States, made 
commercialisation easier by clearing the way for universities to claim legal rights to innovations developed by 
their faculties using federal funding. 
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 Figure 2.2: The process of university technology transfer 
 
Source: adapted from Friedman and Silberman (2003) 
 
Lee and Win (2004: 435) define licensing as “the transfer of less-than-ownership rights in 
intellectual property to a third party, to permit the third party to use intellectual property”. It 
can be exclusive or non-exclusive and is mostly preferred by small business. Bercovitz and 
Feldman (2006: 178) describe a university licensing which provides the right for companies 
and others to use intellectual property in the codified form of either patents or trademarks. 
According to them, “contractual licensing agreements involve selling a company the rights to 
use a university’s inventions in return for revenue, in the form of upfront fees” and the regular 
payments of royalties.  
 
Secondly, the research assesses the existing definitions of spin-offs in the literature to provide 
a contextual framework as there is no single definition of university spin-offs in the literature. 
Bercovitz and Feldman (2006: 179) point to various possible definitions for “university 
spinoffs” (USOs): "firms formed by the university, faculty or staff; firms formed around a 
university license of intellectual property; startup firms that have joint research projects with 
the university; and firms started by students or post-doctorate students around research 
conducted at the university". Pirnay et al.’s (2003: 356) definition of USOs is “new firms 
created to exploit commercially some knowledge, technology or research results developed 
within a university”. Landry et al. (2005: 3) see a university spin-off as a new firm that is 
Research  
Expenditures 
Invention 
Disclosures 
Patent 
Applications 
Technology 
Licenses 
Executed 
Technology 
Licenses 
Yielding 
Income 
Jobs 
Wealth 
License 
Income 
Start-up 
Companies 
81 
 
formed to transfer commercially available scientific and technological knowledge from a 
parent organisation to the market. University spin-off activity is seen as a means to transform 
local economies and a mechanism which provides a way to capture the benefits of proximity 
to research universities (Bercovitz and Feldman, 2006). Summarising the essence of these 
definitions, the research can say that a spin-off involves; a technology, knowledge or research 
result developed within the university and then transferred into a new venture. Furthermore, 
the founder(s) either stay at or transfer from the university to the new venture as well.  
 
Recognising the importance of technology transfer, many countries, including South Africa 
have introduced legislation to facilitate this process, including the creation of institutional 
mechanisms to drive technology transfer. One such mechanism is the technology transfer 
office, the role of which the research discusses next. 
 
2.3.3. The Role of Technology Transfer Offices 
Technology transfer offices (TTOs) are expected to play an active role between the universities, 
faculty members and industry. Siegel et al. (2007:641) see TTOs as ‘intermediaries’ between 
suppliers of innovations (university researchers) and those who can potentially assist to 
commercialise them, i.e. firms, entrepreneurs, and venture capitalists. Dos Santos and 
Rebolledo (2008: 279) in similar vein define TTOs as ‘institutional mechanisms created with 
the aim of promoting universities’ interaction with industry and government. TTOs perform a 
systematic survey of existing research and knowledge within the universities while 
encouraging researchers/students to commercialise their technological opportunities in their 
research and disclose their discoveries to the TTO. The latter promotes the technologies they 
identify as having market value to potential users (Cartaxo and Godinho, 2011). Young (2005) 
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lists four primary reasons for establishing university TTOs as identified by the Association of 
University Technology Managers (AUTM): 
 facilitating the commercialisation of research results for the public good 
 rewarding, retaining, and recruiting high-quality researchers 
 developing closer ties with industry 
 generating income for further research and education, and, thus, promoting economic 
growth. 
 
The TTOs are established not only to improve the effectiveness of university performance, but 
also to augment the university income through the transfer of research results through different 
mechanisms (e.g. setting up a company, licensing technologies). The activities of TTOs have 
important economic and policy implications, since technology licensing and spin-offs can 
result in additional revenue for the university, employment opportunities for university-based 
researchers and graduate students, and local economic and technological spill-over through the 
stimulation of additional Research and Development (R&D) investment and job creation 
(Siegel et al., 2007: 641). The benefits from university technology transfer can be quite 
significant. For instance, in the USA, annual licensing revenue generated by US universities 
and research institutions rose from about $160 million in 1991 to $1.4 billion in 2005. By 2011, 
this figure had grown to $2.5 billion (AUTM Licensing Survey, 201228).  In 2011 alone, 671 
start-up companies were started; while a total of 3927 start-up companies were still operating 
at the end of the financial year  2011 (AUTM Licensing Survey, 2012).   
 
                                                 
28 The 2011 survey was sent to 305 U.S. institutions (234 universities and colleges, 65 hospitals and research 
institutions, two national laboratories, and four third-party technology investment firms). Of these 305 U.S. 
institutions, 186 responded to the survey. The respondents included 157 universities, 28 hospitals and research 
institutes, and one third-party technology investment firm. 
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Almost all research universities in the US have established TTOs to commercialise their IP. 
The success of US technology transfer has attracted interest from universities and research 
institutes all around the world. TTOs have been set up in many countries other than the US: 
developed countries such as Germany, the United Kingdom, and developing countries such as 
the Republic of China, South Africa, and many others have changed their laws and policies, 
modelling them after US practices, the Bayh-Dole Act, to allow universities and faculty 
members to manage and transfer intellectual property (IP) to the market (Nelsen 2007).  
However, TTOs are relatively new at South African universities and research institutions, and 
are not yet found in all universities and research institutions. Some efforts were made to 
promote TT activities as early as the 1980s; but TTOs were established at a few institutions 
only during the late 1990s (Wolson, 2007). The South African Government introduced the 
Intellectual Property Rights from Publicly Financed Research and Development Act 51 of 2008 
(“the Act”) to promote the patenting of publicly funded research (So et al., 2008). The 
objectives of “the Act” are inter alia to encourage commercialisations of IP created in public 
institutions through the creation of Technology Transfer Offices; to create the National 
Intellectual Property Management Office (NIPMO) and an Intellectual Property Fund (IPF) 
(Government Gazette, 2008). Some higher education institutions have recently set up offices 
and other institutions without TTOs are in the process of setting them up. Currently 18 
universities and Public Research Organisations (PROs) have established TTOs. Adding to this, 
one regional Technology Transfer Office was also set up in the Eastern Cape Province to assist 
universities to manage their commercialisations29. The Act also aims to:  
                                                 
29 The Eastern Cape Regional Technology Transfer Office (ECR-TTO) was formed by all four Eastern Cape 
universities (University of Fort Hare, Rhodes University, University of Walter Sisulu and Nelson Mandela 
Metropolitan University (NMMU)) under a Memorandum of Agreement.  The ECR-TTO assists institutions to 
manage and commercialize their Intellectual Property, particularly as Universities of Fort Hare, Rhodes and 
Walter Sisulu do not have fully-fledged Technology Transfer Offices.   The NMMU's TTO is the Department of 
Innovation Support & Technology Transfer. The ECR-TTO is funded by the National Intellectual Property 
Management Office. 
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a. identify  commercialisation opportunities; 
b. encourage and reward human ingenuity and creativity; 
c. assist, grow and develop the private sector, particularly Small and Medium Enterprises 
and Broad-Based Black Economic Empowered (BBBEE) enterprises30; 
d. provide for protection of IP prior to publication of research findings; and 
e. provide for State “walk-in” rights - where necessary (the State may use the results of 
publicly financed research and development, in circumstances where IP is required for 
the country’s health, security and emergency interests). 
 
As can be seen from the aims, there are many similarities to the US Bayh-Dole Act. However, 
there are conditions in the South African IP Act of 2008 that are unique, such as the preference 
for licensing to BBBEE companies. 
 
2.3.4. Technology Transfer at Two South African Universities 
South African higher education institutions and research organisations are growing to 
appreciate the value of intellectual property (IP), which is evident in the establishment the 
TTOs, but the capacity to manage IP varies considerably across institutions; with the Council 
for Scientific and Industrial Research, Medical Research Council, Universities of Cape Town, 
Stellenbosch, Pretoria, Witwatersrand and North-West having relatively well-established and 
resourced TTOs while, some other institutions may have a single person who, in addition to 
other responsibilities, is expected to oversee the institution’s entire IP management portfolio 
and its transfer to the market (Gumbi, 2010). 
 
                                                 
30This stems from the legacy of inequitable access by the majority of the population to the economy under 
Apartheid, which has led to a provision for redress in almost all South African legislation. 
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Significant research output is a logical requirement for technology transfer to happen. Two 
universities that have a long record of experience of technology transfer activity are the 
research-oriented universities of Stellenbosch and Cape Town in the Western Cape, South 
Africa. In the next sections, the research elaborate on the progress that these two institutions 
have made regarding technology transfer with the aim of benefiting the university, industry, 
the inventors, and the broader society. 
 
2.3.4.1.University of Cape Town: Research Contracts and Intellectual Property Services 
The University of Cape Town (UCT) is the oldest university in South Africa, that places a 
strong emphasis on technology transfer activity. The University’s success in the area of 
innovation and technology transfer is confirmed by its performance, in the Most Innovative 
Higher Education Institution competition 2008, run by the Innovation Fund (an instrument of 
the Department of Science and Technology). UCT received a certificate of recognition for 
coming second overall, and won the Best Case Study category as well as the category for Best 
Improvement in Technology Transfer Capacity.  The latter is measured by assessing the overall 
improvement in capacity and effectiveness of the commercialisation office to facilitate the 
commercialisation process (www.innovus.co.za; Innovation at UCT, 2010). 
 
The technology transfer office of UCT has seen many incarnations. it started as the Office for 
Industry Liaison (OIL) in 1999; then in 2002 UCT Innovation was established and renamed 
Research Contracts and Intellectual Property Services (RCIPS) in 2007 
(www.sarimaconference.co.za). The Office’s role is to receive disclosures of inventions, 
evaluate their commercial merit, and protect the intellectual property and in collaboration with 
the inventors, market and license the technology, or create spin-off companies (Innovation at 
UCT, 2010).  It also supports UCT’s research activities by centrally managing, authorising and 
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negotiating research contracts entered into with a wide variety of funders. RCIPS seeks to 
stimulate the growth of the South African economy by fostering small business development 
and/or the creation of jobs through the commercialisation and implementation of UCT’s 
intellectual property, transforming society and leading to social and commercial benefit31.  
 
In Table 2.20 to Table 2.23 we present UCT’s commercial activities and performance with 
respect to patents, disclosures, licensing, revenues and spin-offs. The disclosures received, 
provisional patent applications filed and total number of patent applications since 2004 are 
presented in Table 2.20. One hundred and forty three (143) disclosures have been made to the 
Office over the period 2004 to 2010. 
 
There has been an increase in the number of disclosures received and patent applications filed. 
The number of patents granted has also increased.  Whereas two were granted in 2004, by 2010, 
it had grown to 36. This has been as a result of RCIPS moving from a passive service mode 
into a more proactive mode of exploration for new IP and raising awareness of patenting and 
IP in the different departments (Innovation at UCT, 2010).  
 
Table 2.20: Annual UCT Patent Portfolio Statistics 
 2004 2005 2006 2007 2008 2009 2010 
Disclosures 20 20 7 9 31 25 31 
Patent Applications Filed 26 26 23 50 64 46 57 
National Phase Patents Granted 2 9 6 3 10* 47* 36 
Application Details;  
Provisional 8 12 4 5 27 9 - 
PCT 3 5 9 3 3 20 - 
National (including Divisional, 
excluding Regional) 
10 7 6 36 28 10 - 
Regional 5 2 4 6 6 6 - 
* Includes country validations following European patent grant 
Source: UCT Innovation 2010 and RCIPS 2011 
 
                                                 
31  www.uct.ac.za 
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Fifty-one license and assignment agreements relating to UCT intellectual property have been 
entered into over the period of 2001 to 2010 (Table 2.21). 
 
Table 2.21: License Agreements Relating to UCT Intellectual Property 
Year Disclosures Number of License Agreements 
2001 - 1 
2002 - 1 
2003 - 8 
2004 20 9 
2005 20 4 
2006 7 3 
2007 9 3 
2008 31 8 
2009 25 6 
2010 31 8 
Total 143 51 
-: the research could not find the data for these years 
Source: UCT Innovation 2010 and RCIPS 2011 
 
UCT’s revenue and income derived from commercialisation of its IP is presented in Table 
2.2232.  
 
Table 2.22: IP Commercialisation Revenues (Rand) 
Year Licensing (R) Sale of IP (R) Profit UCT Companies (R) 
 
Total (R) 
 
2001 0 87,143 0 87,143 
2002 0 107,952 0 107,952 
2003 0 0 0 0 
2004 13,905 0 0 13,905 
2005 1,728 0 0 1,728 
2006 70,058 0 0 70,058 
2007 49,815 0 0 49,815 
2008 170,266 150,000 0 320,266 
2009 136,494 0 693,630a 830,124 
2010 3,500,000 0 400,000 3,900,000 
Total 3,942,266 345,095 1,093,630 5,380,991 
a This company is currently being incubated within UCT and is as a ‘ring-fenced’ operation. This is an unaudited 
figure. 
Source: UCT Innovation 2010 and RCIPS 2011 
                                                 
32 The value of equity held in companies has not been included in the table and many of these companies being 
early start-ups have yet to declare dividends. 
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A total of five spin-off companies have been formed, based on UCT IP (Table 2.23). According 
to Innovation at UCT (2010) three further companies would spin out in 2010 and another is 
being incubated within the university whilst it establishes itself in the market and proves its 
viability. UCT has also recently acquired shares in a medical device start-up which will work 
closely with the university in order to develop their IP further, due to strong synergies with the 
university. 
 
Table 2.23: Spin-Off Companies from UCT33 
Year Number of company set up 
2004 2 
2005 - 
2006 2 
2007 - 
2008 - 
2009 1 
Total 5 
Source: UCT Innovation 2010 
 
2.3.4.2.Stellenbosch University: ‘Innovus Tegnologie Oordrag’ (Pty) Ltd 
Stellenbosch University (SU) has a well-established structure for technology transfer activity. 
Stellenbosch University regards the commercialisation of its Intellectual Property and 
knowledge as part of its responsibility in the area of community interaction. The University 
mission shows it clearly; “The raison d’être of the Stellenbosch University is to create and 
sustain, in commitment to the academic ideal of excellent scholarly and scientific practice, an 
environment within which knowledge can be discovered, can be shared, and can be applied to 
the benefit of the community”34. The University’s success in the area of innovation and 
technology transfer is underscored by its performance in the Technology and Human Resources 
                                                 
33 Numbers provided by TTO only. 
34 www.sun.ac.za  
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for Industry Programme (THRIP).35 In 2005, Stellenbosch University won the Department of 
Science and Technology award as the Most Technologically Innovative Higher Education 
Institution (Reichelt, 2007) and in 2008, the University, received a certificate of recognition 
for coming third overall in the Most Innovative Higher Education Institution competition 
(www.innovus.co.za). The institution has developed administrative structures to support its 
commercialisation and technology transfer activities and has also created a favourable 
environment for researchers in terms of intellectual property rights (Reichelt, 2007). 
 
The University had two arms for the commercialisation of its research. First, the University 
had an intellectual property office (InnovUS) under the Executive Director: Finance and 
Operations. The “Office for Intellectual Property” was set up in 1999 as TTO of Stellenbosch 
University and renamed InnovUS in 2004 (Nel, 2009). InnovUS was responsible to facilitate 
the exploitation of intellectual property derived from faculty members and students.  InnovUS 
handled all of the normal technology transfer related duties one might expect: review of 
invention disclosures, intellectual property, mining, and review of intellectual property clauses 
in research contracts, technology marketing, and license negotiation and management 
(Garduno, 2004). Second, the university established a wholly-owned private company called 
Unistel Group Holding Ltd. (UGH) that functioned along with InnovUS in commercialisation 
of technology and IP from university research through start-up companies. 
In 2009 the structure of TTO was changed and the new company, InnovUS Tegnologie Oordrag 
(Pty) Ltd., replaced Unistel Group Holdings (Pty) Ltd and also encompasses the innovation 
and commercialisation infrastructure of the past. According to Nel (2009) the core 
responsibilities of InnovUS Tegnologie Oordrag (Pty) Ltd. are; 
                                                 
35 An incentive scheme of the department of Trade and Industry (www.dti.gov.za), which matches every R1 in 
research funding secured from industry to encourage innovation and skills development. 
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1. to apply  SU technology to the benefit of society, 
2. to serve faculties and to increase awareness of technology transfer among faculty, 
researchers and students,  
3. to maximise third stream income for SU through commercialising IP, 
4. to promote value creation within and growth of the SU portfolio of spin off companies, 
5. to raise the profile of SU as top performing university in order to attract top researchers. 
 
Successful university technology transfer offices must have clear policies regarding the 
protection and exploitation of intellectual property developed by university faculty members, 
staff and students (Reichelt, 2007). Stellenbosch University has a detailed policy regarding the 
exploitation of intellectual property. The policy36 includes detailed steps e.g. the IP ownership 
issues including staff, students, visiting lecturers and researchers (including post-docs), outside 
organizations, sponsors, funders and the government; exploitation of IP through licensing and 
new business formations (start-ups) and allocation of income derived from commercialisation 
of intellectual property. 
In Table 2.24, Table 2.25 and Table 2.26 the research present the performance of InnovUS with 
respect to patents, disclosures, licensing, royalty incomes and spin-off companies created. 
 
Table 2.24 shows that technology transfer activity in terms of disclosures has increased 
significantly since the beginning of the decade, to total 269 (2001-2011).  Invention disclosures 
increased from 12 in 2001 to 62 in 2009 and then decreased to 45 in 2010. The table also 
indicates that final patented technologies increased locally, in Europe, the USA and other parts 
of the world.  
 
                                                 
36  The policy can be downloaded from the website (www.innovus.co.za). 
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Table 2.24: Patent Status of Innovus Tegnologie Oordrag (Pty) Ltd 
Year Disclosure Provisional Patent PCT South Africa Europe USA Other 
2001 12 7 0 2 0 0 0 
2002 12 10 1 1 0 0 0 
2003 14 14 0 1 0 0 0 
2004 9 13 2 5 0 0 1 
2005 8 6 2 1 1 0 1 
2006 8 9 1 1 0 0 0 
2007 43 19 1 2 0 1 4 
2008 36 21 5 0 0 1 0 
2009 62 24 9 5 2 2 6 
2010 45 19 14 9 3 3 10 
2011 20 8 5 1 1 0 4 
Total 269 150 40 28 7 7 26 
Note: Other (New Zealand, India, Canada, China, Japan, Australia, Russia, Brazil and Singapore) 
Source: Innovus Tegnologie Oordrag (Pty) Ltd 
 
 
Table 2.25: Licensing-Related Performance Indicators of Innovus Tegnologie Oordrag (Pty) 
Ltd 
Year Disclosures Licence Agreements Royalty Income (Rand) 
2003 14 0 315,456.55 
2004 9 1 512,678.34 
2005 8 0 578,514.91 
2006 8 2 313,071.13 
2007 43 0 653,981.54 
2008 36 6* 1,378,305.04** 
2009 62 6* 896,800.92 
2010 45 2 5,085,065.74 
20111 20 1 4,862,219.01 
Total 245 18 14,596,093.18 
*5 Licences signed plus one Memorandum of Understanding (MoU), **R566 757 in Escrow (per agreement with 
licensee) until milestones achieved.  
1 Up to date.  
Source: Innovus Tegnologie Oordrag (Pty) Ltd 
 
Table 2.25 presents the commercial activity of InnovUS. Whereas 40 patents were generated 
between 2001 and 2011 (Table 2.24), 18 licenses were allocated between 2003 and 2011. 
Royalty income from licensing agreements increased from R315,456 in 2003 to R 4,862,219 
in 2011 and total income (2001 to 2011) totalled more than 14,5 million Rand (around 
US$2,085,174). 
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Table 2.26: Spin-Off Companies Created37 
Year Number of company set up 
1999 1 
2000 1 
2001 - 
2002 1 
2003 - 
2004 - 
2005 - 
2006 1 
2007 2 
2008 - 
2009 1 
Total 7 
Source: Innovus Tegnologie Oordrag (Pty) Ltd 
 
The TTOs records (presented in Table 2.26) indicate slow progress in the creation of spin-off 
companies. It is, however, important to note, that these are solely entities that were created 
under the auspices of the TTO. Independent spin-off activity is not recorded here. 
 
2.3.5. Case Study: Spinning-Off or Licensing? 
The TTO normally receives suggestions from scientists whether a project is marketable through 
licensing or spin-off creation. Later, the firms that are interested in such new projects consider 
the prospects, which could be a proof of concept or a complete prototype, or R&D still in 
embryonic stage that needs further development.  
 
In the context of this chain of decision-making, previous research, which examined academic 
entrepreneurial activities focusing on spin-off creation at Cape Town and Stellenbosch 
universities (Jafta and Uctu, 2009) resulted in interesting questions arising, such as why 
academic researchers who are in a position to create a spin-off choose not to do so and, what 
motivates researchers to license their technologies?  This section therefore aims to explore 
                                                 
37 Numbers provided by TTO only. 
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these questions.  
 
2.3.5.1.Methodology 
As a first step, the research had to establish whether technologies for licensing were available 
at the two universities in the study, and to identify the academics in possession of research 
results that could lead to technologies that can be licensed.  
 
Twenty-seven technologies ready for licensing from Stellenbosch and eight from UCT were 
identified in 201038. After follow-up visits and contacts with the TTOs, the research found that 
five technologies had been terminated, one technology had been assigned to a spin-off 
company and another one was used to establish a company. The research excluded these 
technologies from the research, so that the total technologies being investigated were 20 from 
Stellenbosch and eight from UCT.   
 
Following the investigation, a questionnaire was developed to be completed by the principal 
researchers who created the technologies. The research started e-mailing in mid-2010 for the 
first time, with a follow-up later in 2010. By the end of September 2010, eleven researchers 
had responded to the survey of which only eight were willing to participate in research. The 
participant number is therefore small. A TTO officer interviewed explained that this is not 
uncommon, since most researchers are reluctant to participate in questionnaire surveys. Due to 
the small number of technologies studied, no claim of generality to other populations of 
                                                 
38 Technologies were gathered from the Tektique’s web site (www.tektique.co.za) which is a collaboration of 
South Africa's leading universities, the Medical Research Council (MRC) and their technology transfer offices. 
Tektique is funded by the Department of Science and Technology through the Innovation Fund. This web platform 
was created to offer third party organisations and industry more insight into and access to the IP and patents 
available from South African universities and science councils, and thereby ensuring greater ability to 
commercialise technology and patents stemming from publicly financed research and development.   
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technologies or researchers can be made from the primary data and their analysis, but it is 
believed the insights gained here are valuable in constructing larger research projects in future 
The questionnaire included questions requesting information on the profile of the researchers, 
as well as the technologies. For the two crucial questions the research were exploring, namely 
the motivations to license and the factors influencing the decision to license rather than create 
a spin-off, the research used a five-point Likert scale where 5 was most important and 1 
unimportant. Technologies are coded from A to H. 
 
2.3.5.2.Limitations of the study 
Since the study is based on one province in South Africa, and since there is only a small number 
of respondents, no generalisations to academic technology transfers (spin-offs and/or licensing 
technologies) in the rest of the country can be made. This particular section can be considered 
to be an exploratory study, as prelude to a larger scale study of the rest of the country’s regions. 
At this stage, comparisons to academic technology transfers (spin-offs and/or licensing 
technologies) at other South African regions are therefore not yet possible. 
 
2.3.5.3.The Results of Case Studies 
Three of the technologies studied  originated from  the engineering faculty (technology B, C 
and D), two from science (technology A and G),  one from health science (technology H), one 
from agricultural science (technology F) and one technology from two faculties (technology 
E) (Engineering and Health Sciences jointly). It was revealed in the survey that three 
technologies fall in the biotechnology sector, four technologies in other sectors (Precision 
Engineering, Wood in Wine, Biomedical Engineering and Medical Devices) and one 
technology combined biotechnology, nanotechnology and green technology (Table 2.27). 
 
Table 2.27: Sectors  
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 Bio PE Nano GT WiW BE MD 
Technology A 
Technology B 
Technology C 
Technology D 
Technology E 
Technology F 
Technology G 
Technology H 
O 
- 
- 
- 
O 
- 
O 
O 
- 
- 
- 
O 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
O 
- 
- 
- 
- 
- 
- 
- 
O 
- 
- 
- 
- 
- 
- 
O 
- 
- 
- 
O 
- 
- 
- 
- 
- 
- 
- 
- 
O 
- 
- 
- 
- 
- 
Bio: Biotechnology, PE: Precision Engineering, Nano: Nanotechnology, GT: Green Technology WiW: Wood in 
Wine, BE: Biomedical Engineering, MD: Medical Devices 
Source: Authors survey 2010 
 
It was found that all the technologies were the product of collaboration.  Four technologies 
were created by two to three researchers (technologies B, D, F and G). Three technologies were 
created by four to five researchers (technologies A, E and H) and one technology had between 
six to ten researchers (technology C).  Patents indicate evidence of a country’s technological 
and inventive achievements (Pouris, 2005). Of the eight technologies, four had worldwide 
patents (technologies A, C, F and G), one was a South Africa-based patent (technology B) and 
three patents were provisional (technologies D, E and H). 
 
Respondents were asked to rate their motivations for licensing the technology on a Likert scale 
varying from 1 (not important) to 5 (most important). Results are presented in table 2.28. The 
analysis of the motivations behind the licensing of the technology shows that the major 
motivations are that the researcher(s) wished to apply their knowledge to practical applications, 
followed by wishing to fully utilize existing knowledge, and finally, the desire to pursue profit. 
Other motivations were that licensing is a common strategy within the industry sector; it is a 
niche technology and personal success. 
 
 
 
Table 2.28: Motivations 
Motivations Average score 
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Apply knowledge to practical applications 
Fully utilise existing knowledge 
Profit making 
Licensing is a common strategy within the industry sector 
It is a niche technology 
Personal success 
Final step to complete existing  project(s) 
The technology is near market and requires little further development and investment 
Building an industrial network 
The technology fits an existing company's IP/product portfolio 
A company is linked with the research either as a sponsor or interested observer 
Others factor(s) 
4.2 
3.8 
3.8 
3.7 
3.6 
3.6 
3.4 
3.3 
3.0 
2.8 
1.8 
- 
Likert scale: 5 = most important, 1= unimportant 
Source: Authors survey 2010 
 
Lastly, researchers were asked to rate the factors affecting their decision not to create a spin-
off company (Table 2.29). The most cited reason was funding, followed by commercialisation, 
distribution and estimation of market demand. In the discussion in section 6, the research places 
these results in context, both with respect to authors’ expectations and findings in similar 
studies in the literature. 
 
Table 2.29: Factors affecting the Decision not to set up a Company 
Factors1 Average score 
Funding 
Commercialisation 
Distribution (product and/or services) 
Estimation of the market demand 
Leaving the academic position 
Regulatory compliance 
Family commitment(s) 
Problems in human resources 
Technical problems in development and production 
Relationships with the parent university 
Problems among owner(s) of the technology 
Others factor(s)  
4.7 
4.2 
4.2 
3.7 
3.2 
3.1 
2.8 
2.7 
2.5 
1.8 
1.2 
- 
Likert scale: 5 = most important, 1= unimportant 
1 one participant did not complete this part of the questionnaire 
Source: Authors survey 2010 
 
 
2.3.6. Discussion  
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2.3.6.1.Motivations 
What would motivate a university scientist to license a technology, rather than simply making 
their research results available through publications, conference participation or exhibitions? 
The analysis of the motivations behind the licensing of the technology shows that the major 
motivation is that the researcher(s) wishes to apply knowledge to practical applications, 
followed by a desire to fully utilise existing knowledge, and to pursue profit. Other motivations 
were:  “licensing is a common strategy within the industry sector”; “it is a niche technology” 
and “personal success.”  One participant mentioned that his university does not have the 
knowledge and capability to create a successful spin-off company in a particular niche market. 
According to the participant, the easiest way to make a profit is through licensing.  
 
Of course, the motivations would differ depending on the stakeholders’ perspective. Siegel et 
al. (2003) present the motivation for technology transfer from university to industry from the 
perspectives of scientists, technology transfer offices and firms/entrepreneurs in five research 
universities in two regions of the US (Table 2.30). 
 
A primary motive of scientists is recognition within the scientific community (e.g. publications 
in journals and research grants). University scientists may also be motivated by personal 
financial gain and/or a desire to secure additional funding for graduate students and laboratory 
equipment. The primary motive of the TTO is to protect and market the university’s intellectual 
property. 
 
 
Table 2.30: Motivations & Actions of Stakeholders in TT 
Stakeholders Actions Primary motives Secondary motives Perspective 
University 
scientists 
Discover of new 
knowledge 
recognition within the 
scientific community 
e.g. publications, 
financial gain and a desire to 
secure additional research 
scientific 
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grants (especially if 
untenured) 
funding (mainly for graduate 
students and lab equipment) 
TTO works with faculty 
members and firms/ 
entrepreneurs to 
structure deals 
protect and market 
the university’s 
intellectual property 
facilitate technological 
diffusion and secure 
additional research funding 
bureaucratic 
Firm/ 
entrepreneur 
commercializes 
new technology 
financial gain maintain control of 
proprietary technologies 
entrepreneurial 
Source: Siegel et al., 2003 
 
Secondary motives include securing additional research funding for the university (through 
royalties and licensing fees, sponsored research agreements) (Siegel et al., 2003) and 
facilitating technology diffusion. Firms and entrepreneurs also express great concern about 
‘‘time to market,’’ since the ultimate benefits from product and process innovation depend on 
commercialising the product or perfecting the new production process before competitors do 
(Siegel et al., 2003). 
 
Zuniga and Guellec (2009) carried out a business survey on the licensing-out of patents in 
Europe and Japan. The aim was to investigate the intensity of licensing to affiliated and non-
affiliated companies, its evolution, and  the characteristics, motivations and obstacles met by 
companies already licensing or willing to license. The authors found that for both European 
and Japanese companies, the first motivation to license patents to third parties is “earning 
revenue”. This supports the notion that financial gain is a strong motivation for both private 
companies and academics. To sum up, especially from the perspective of scientists’ 
motivations, this section’s findings are similar to that cited from the literature.   
 
 
2.3.6.2.Factors Affecting the Decision Not To Set Up a Company 
One of the questions faced by technology transfer managers and inventors is whether to license 
a technology or to create a start-up firm to commercialise it. According to Cervantes (2003), 
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the answer to this question, depends on the nature of the technology to be transferred, the 
market for such a technology, the skills set of the staff, researchers involved in the invention, 
access to venture capital, and the institution's mission. Certain platform technologies with a 
wide range of applications may be commercialised via a start-up company for example, while 
others may be licensed to larger firms with the business capacity to develop the invention 
further and integrate it into its R&D and business strategy. 
 
Participants were asked in the survey the reasons why they chose not to create a spin-off. The 
biggest reason put forward was lack of funding, followed by commercialisation, distribution 
and estimation of market demand. Jafta and Uctu (2009) found support for the significant role 
played by funding in this decision in earlier research on spin-offs. In previous research, the 
authors examined the major problems that spin-off companies encountered at two South 
African universities and found that apart from funding, factors such as finding skilled people, 
lack of facilities, marketing of developed products, and time constraints all played a part in 
deterring the creation of spin-offs. Furthermore, Kamariah et al. (2011) and Nelsen (2007) 
argue that university-generated technologies are often still in embryonic stage and will require 
substantial investment in time, money and skills to develop something to take to market. The 
funding requirement for an academic researcher to start a spin-off may be daunting, whereas a 
license holds a promise of less risk and an income stream. 
 
The same question was asked to the TTO officers. According to one of the TTO officers there 
are two main reasons; first of all, most of the inventors/researchers are not entrepreneurs and 
are not willing to leave the academic world (according to the IP policy, if a university 
researcher sets up a company, they should leave the university’s employment). Further reasons 
given were that researchers enjoyed doing research and publishing their work.  Licensing, 
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moreover, afforded an opportunity to earn money from technologies. According to one TTO 
officer, on the other hand, new generations (younger researchers) are more passionate about 
creating companies than licensing the technologies. Secondly, funding is a problem. When one 
wishes to create a company, s/he, at least, must secure 5 years’ money to get back the result 
(start earning money). For these reasons most of the researchers come to the decision to license 
their technologies. 
 
As can be seen from the case studies and the universities’ technology transfer activities, 
researchers tend to license their technologies rather than creating companies. If the objective is 
to create more companies, both universities should change their incentive system. For example, 
K.U. Leuven Research and Development (a Belgian TTO) has generated over 90 companies 
since 1972, having a combined total turnover of over 400 million euro and employing more 
than 3,500 people (for more info, http://lrd.kuleuven.be/en/spinoff/creation). One of the main 
reasons for being successful is that TTO’s incentive system. In the case of spin-offs, individual 
researchers could receive up to 40% of the intellectual property shares; and can invest 
financially in the spin-off company created (Vendrell-Herrero, 2008). 
 
These findings and observations have implications for IP policy and practice at universities, 
especially in relation to incentive structures aimed at encouraging technology transfer and 
commercialisation. 
 
 
2.3.7. Concluding Remarks 
The technology transfer from universities to the market has historically been dominated by the 
practice of licensing, while other literature shows that in the UK in particular, successful 
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universities lean more towards the development of spin-off companies (Vendrell-Herrero, 
2008). In the last few years, therefore, deciding whether to license or create a spin-off has 
become a relevant question for researchers, scientists and TTO managers. 
 
When the TTO receives a profitable invention, one quandary is how to commercialise it, i.e., a 
license or spin-off. Some researchers argue (for example Shane and Stuart, 2002; Locket et al., 
2003) that spin-offs are a better solution to commercialise the invention where the patent 
system is less effective, therefore, the TTO’s experience and legal support are very important 
in such decision.  
 
In this section, the researcher was curious about the role of technology transfer at two Western 
Cape universities, and in particular, what would motivate academic researchers to license their 
technologies, as opposed to creating a spin-off company.  Furthermore, the researcher was 
interested in finding out the reasons for their decision. These questions were pursued in the 
context of the activities and rationale of university technology transfer offices, including an 
overview of the performance of these offices at the two universities. This overview allowed 
researcher to discern a pattern regarding the spin-off and licensing behaviour for the period, 
with licensing being favoured over spin-offs. Against this backdrop, the case studies provided 
useful further insights.  
 
This research is based on a very small sample and can therefore not be generalised. It is 
however, significant to note that findings with respect to the motivations for licensing and the 
factors influencing the decision to license rather than spin-off are not that different from the 
existing literature. 
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Funding (or the lack thereof) still plays a significant role in creating spin-offs (as if they do not 
have funds to create spin-off, licensing their technologies is a better option), and so does the 
desire to put knowledge to practical use. The latter motivation bodes well for a country sorely 
in need of innovations that will address socio-economic challenges and spur economic growth. 
 
Throughout the preceding sections, reference was made to the importance of skills, education 
and training in the context of academic entrepreneurship and technology transfer, and the 
particular expertise required to achieve success in biotechnology start-ups. The research now 
turns to an assessment of the pioneering efforts to address this need in the Western Cape RIS. 
 
 
 
 
 
 
 
 
 
 
 
 
PART III: STRENGTHENING CAPACITY FOR BIOTECHNOLOGY 
 
This part of the thesis is novel as it evaluates early efforts in South Africa to equip bio-
entrepreneurs with the skills necessary to build a bridge between the science of biotechnology 
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and the commercialisation of knowledge and ideas in this field in the form of bio-
entrepreneurship programmes which is presented as a section here.   
 
3. Building a bridge between science and business in a regional cluster: evaluating initial 
bio-entrepreneurship training efforts in South Africa39 
 
3.1.Introduction and background 
Biotechnology is seen as a major growth industry and a significant contributor to economic 
growth in many countries. Consequently, national governments across the globe take it 
seriously (Hine and Kapeleris, 2006) as evidenced by the fact that they have invested billions 
of dollars into strategies to enhance biotechnology research, development and 
commercialisation (Collet and Wyatt, 2005). 
 
In the development of regional biotechnology industries, small-to-medium size enterprises 
(SMEs) will be the driving force with start-up companies figuring predominantly in bringing 
biotechnology products and processes to the global marketplace. New ventures such as 
biotechnology start-up companies or projects in established SMEs require champions with a 
sound knowledge of the relevant science and a familiarity with the business principles relating 
to product innovation, market development and venture capital (Collet and Wyatt, 2005). One 
of the most important factors needed to develop a biotechnology industry in a region is the 
existence of an entrepreneurial culture. This refers to the fact that scientists should look not 
only at the scientific side of research, but also at the commercial exploitation of their results 
(Chiesa and Chiaroni, 2005). The commercialisation of research is essential to the development 
                                                 
39This section was published in a journal. Reference as follow; Uctu, R. and R. Jafta (2013), “Bio-entrepreneurship 
as bridge between science and business in a regional cluster: South Africa’s first attempts”, Science and Public 
Policy, July 2013, doi:10.1093/scipol/sct049, pp. 1-15. 
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of a local biotechnology industry and there is a critical need for graduates able to drive this 
process (Collet and Wyatt, 2005). Many countries operate bio-entrepreneurship training 
programmes to generate appropriately skilled people to grow the biotechnology industry 
(Meyers and Hurley, 2008), and thus to create “bio-entrepreneurs” in their countries. This is an 
emerging trend in the world and the bio-entrepreneurship training field is still in the fluid phase 
in which many players are in the process of developing programmes, and no dominant design 
or success story has yet emerged.  
  
Empirical literature on bio-entrepreneurship training in developing countries is still sparse. 
Studies on the entrepreneurial activities in biotechnology have focused mainly on the USA, 
UK and other developed countries. This section is novel in that it assesses the first structured 
attempts in South Africa to equip scientists with the skills necessary to build a bridge between 
the science of biotechnology and the commercialisation of knowledge and ideas in this field. 
The research present a case study on the bio-entrepreneurship training programme 
implemented at Cape Biotech, which was one of the Biotechnology Regional Innovation 
Centres40 and now part of the Technology Innovation Agency (the TIA)41. The bio-
entrepreneurship training programme is targeting scientists who have feasible business ideas 
(no business registered yet) and scientists who have already registered their start-up, but lack 
business skills. The main objective of the programme is to support and facilitate the 
                                                 
40The South African Department of Science and Technology (DST) introduced the National Biotechnology 
Strategy (NBS) in 2001 to modernize the government’s biotechnology institutions and to develop the 
biotechnology industry given a changing political and technical environment. An important product of the NBS 
was the formation of biotechnology regional innovation centres (BRICs) in 2002 to develop and commercialise 
the biotechnology industry. These are Cape Biotech Initiative in Western Cape, the East Coast Biotechnology 
Consortium (EcoBio, operating under the trade name of LIFElab) in Kwazulu Natal and Biotechnology 
Partnership for Africa’s Development (BioPAD) in Gauteng province. 
41The Department of Science and Technology (DST) has recently established a new public institution, the TIA, 
which is a single public agency that was formed from a merger of seven DST-funded organisations, namely, 
BRICs (Lifelab, Biopad and Cape Biotech), Plantbio, Tshumisano, Innovation fund and Amts (Advanced 
Manufacturing Technology Strategy). BRICs (Lifelab, Biopad, and Cape Biotech) no longer exist and are now a 
component of the Technology Innovation Agency (TIA). 
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development of business skills necessary for sustainable biotechnology ventures, as well as the 
development of bio-entrepreneurs and future business managers in South Africa. The 
programme is evaluated against its objectives from the perspectives of the participants. In 
addition, it gives a measure of the effectiveness of the programme in terms of the number of 
bio-enterprises created. This evaluation was done against the backdrop of the participants’ 
understanding of bio-entrepreneurship, their views on the prospects for South Africa’s 
biotechnology industry, and their assessment of the strengths and weaknesses of this industry 
in the Western Cape. 
 
The rest of the section is structured as follows: first there is a survey of literature on bioscience 
entrepreneurship followed by a detailed case study of the Cape Biotech bio-entrepreneurship 
programme. The last section concludes the section.     
 
3.2.Overview of the literature on Bio-entrepreneurship 
It is accepted that small entrepreneurial businesses in high-technology industries have 
contributed to job creation, technological innovation, knowledge, technology transfer and 
regional development (Muller et al., 2004). Particularly, in the context of biotechnology, 
Persidis (1996) in Hine and Kapeleris (2006) describes bio-entrepreneurship as wealth creation 
that comes from life science discoveries in the laboratory and that are applied in the commercial 
market. Meyers (2008) describes it as a process of creating value from life science innovations. 
For authors’ purposes, the research describes bio-entrepreneurship as the form of 
entrepreneurship in which a bio-entrepreneur identifies a business idea from the field of 
biotechnology and seeks to commercialise the idea by setting up a new business. In another 
words, it is simply the creation of biotech enterprises. Bio-entrepreneurs tend to have different 
characteristics than those needed in the traditional context as is shown in Table 3.1 below.  
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Table 3.1: Traditional Entrepreneurs and Bio-entrepreneurs 
 Traditional Entrepreneurs Bio-entrepreneurs 
Background Business Scientific 
Education MBA Life science (Masters, PhDs) and/or MBA 
Age Younger Relatively Older 
Objectives Involved only with development and 
marketing of the product 
In addition, also have an in depth knowledge of 
the product itself. 
Source: http://www.rishibiotech.com/bioentrepreneurship  
 
One of the greatest challenges for researchers is converting scientific discoveries and 
innovations into successful companies. The literature on biotechnology identifies three crucial 
elements, commonly called the “three pillars”, essential for the success of a biotechnology 
start-up company: (i) managerial skills, (ii) sufficient capital and (iii) access to new technology 
that leads to products. The "start-up" phase of biotechnology companies is essentially a "valley 
of death" that has to be crossed by bio-entrepreneurs who often lack the experience and 
expertise necessary to convert their ideas into commercial products suitable for public 
consumption. Most biotechnology companies face difficult managerial challenges in R&D 
because it is costly and often the most critical aspect of bringing a product to market. Even 
when biotechnology start-ups source R&D externally, particular skills are required to 
incorporate the R&D results and align it with company strategy and objectives. Biotechnology 
research is often more complex than traditional pharmaceuticals because researchers may not 
know for years what forms their products will take after they begin their research. It needs 
careful management and strategy. In addition to these significant obstacles, management at a 
biotech start-up company face additional challenges such finding the correct balance between 
cutting-edge scientific research and commercialisation opportunities. Resolving the economic 
and commercial challenges faced when developing a new product requires a different set of 
skills from conducting research on technology and its application. One of the important 
components is that the management team must ensure various means to encourage scientific 
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staff to work on the one or two products that will lead the company to its success. Often, a 
scientific team has a wide range of potential products; however, they often lack the resources 
to simultaneously exploit several products commercially.  In contrast, big pharmaceutical 
companies enjoy the luxury of having the means of experimenting with a wide range of 
technologies and products in order to find that one blockbuster, whereas the start-ups must be 
selective due to their circumstances. Management also faces the exciting but daunting task of 
bridging the gap between the scientific and business side of a company. In addition they also 
need to decide which direction would be most beneficial for the entire company (Malazgirt, 
2011). Biotechnology companies therefore require cross-disciplinary knowledge, skills and 
talents (including marketing, the basics of Intellectual Property Rights (IPR), early-stage 
technology finance, and knowledge of scientific, regulatory and ethical issues) (Schoemaker 
and Schoemaker, 1998; Meyers and Hurley, 2008; York et al., 2009; Malazgirt, 2011). In 
addition to these requirements, bio-entrepreneurs should have special communication, 
emotional and social intelligence skills, such as self-awareness, self-control, and social 
awareness (Meyers and Hurley, 2008). These authors also argue that the demand for talent is 
not only a problem in developing countries but an international problem. In the case of the 
Singapore cluster, the biggest problem has been identified as a continued shortage of 
entrepreneurial scientists and managers. It is in this area that the Singapore government meets 
its greatest challenge – it is difficult to inculcate creativity and the entrepreneurial spirit. These 
qualities are difficult to impose, even on a willing populace (Arroyo, 2005: 54). Volery et al. 
(2007) showed that Switzerland has several key challenges in management of young 
biotechnology companies, which include managing funding, planning strategies, marketing 
and sales, IP and administration. Nosella et al. (2006) cited Italy, where managerial skills at 
university start-ups are lacking in the scientific staff at universities. Rutherford and Fulop 
(2006) found a similar lack of expertise in Australian biotechnology start-ups. They observed 
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that business awareness of science is low and scientists lack the entrepreneurial skills to 
commercialise their research. To overcome these problems, Rutherford and Fulop (2006) and 
Nosella et al. (2006) suggested training and equipping scientists with the necessary 
commercialisation and managerial skills and to get assistance from TTOs for organisational 
and financial support. Nosella et al. (2006) for Italy suggested a joint scientific and managerial 
competency with founders comprising a team of academic scientists and industry managers. 
 
Chiesa and Chiaroni (2005) highlight the following practices that are used to help the diffusion 
of the bio-entrepreneurial culture among researchers in nations and specifically in regions: 
i)  Setting up managerial courses for science and technology graduates. Scientists often fail 
to evaluate the commercial possibilities of the research results correctly.  In addition, they lack 
the necessary managerial competences to define company strategy in the long term. Teaching 
managerial courses to life science graduates, even at a low level of specialisation, may make 
them ‘familiar’ with the managerial approach and may help them to understand and better 
evaluate external support by ‘professional’ managers; 
ii)  Offering MBA and related courses dedicated to biotechnology. The characteristics of 
business models of biotech companies are such as to require ‘tailored’ managerial solutions, 
that may also be made available to scientists; 
iii)  Encouraging entrepreneurial experiences among researchers. For instance, making it 
possible for academics to try the entrepreneurial adventure with the option, in case of failure, 
to go back to their previous academic position; 
iv)  Creating competition for research grants. Competition for research grants may be 
introduced at national and regional level, by ranking universities and public research centres 
by looking at their scientific outputs and also at their attitudes to the commercial exploitation 
of such outputs. This way of evaluating scientific activity, by adding the perspective of 
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commercial exploitation, achieves the twofold objective of rewarding leading centres and 
forcing them to improve their exploitation mechanisms. 
 
The research now moves from bio-entrepreneurship per se to bio-entrepreneurship education 
in developed and developing countries, with the latter focusing mostly on developments in the 
South African NIS. 
 
3.2.1. Bio-entrepreneurship Education in Developed countries 
University-trained biotechnology graduates may generally possess a solid knowledge-base but 
often lack real world business insight and are often not entrepreneurially inclined, preferring 
instead to pursue careers focused on science. As such, the average biotechnology science 
graduate is generally not suited to or capable of operating in the commercialisation 
environment between research and the market that is the focus of start-ups and established 
SMEs (Collet and Wyatt, 2005). Many universities have realised this problem. Hence, there 
has been growth in the number of bio-entrepreneurship programmes in the world that provide 
bio-business education. According to Meyers and Hurley (2008) bio-entrepreneurship 
programmes are designed to teach the knowledge, talents and attitudes required by 
entrepreneurs who are interested in biotechnology commercialisation. The USA, European 
Countries, Scandinavian countries, Canada and Australia are some of the countries that have 
created bio-entrepreneurship programmes in their higher institutions. All of these new 
entrepreneurial programmes are reshaping the graduate education of scientists and engineers 
and creating new entrepreneurs in biotechnology. Table 3.2 indicates some selected dual-
degree graduate programmes in biotech and business for illustration purposes. 
 
Table 3.2: Selected dual-degree master's programmes in business and biotech 
University Location Degree Year  Started 
110 
 
Johns Hopkins Baltimore, Maryland, the USA MS/MBA 2000 
University of 
Pennsylvania 
Philadelphia, the USA MB/MBA 2003 
Macquarie University New South Wales, Australia MB/Master of Commerce in 
Business 
2004 
University of Calgary Alberta, Canada MBT/MBA 2004 
University of Florida Gainesville, the USA MS/MBA 1993 
RMIT University Melbourne, Australia MBB (Masters of 
Biotech/Business) 
2001 
Source: Waltz (2005), iMB, MBT, Master of Biotechnology 
 
3.2.2. Bio-entrepreneurship Education in South Africa   
Most of the bio-entrepreneurship programmes and activities have been established in 
developed countries, whereas little is known about bio-entrepreneurship education 
programmes offered in developing countries, with a few exceptions, such as the exploratory 
study on bio-entrepreneurship in Kenya by McEnrue (2011). McEnrue (2011:4) confirms the 
paucity of data and research on bio-entrepreneurship in developing countries, especially in Sub-
Saharan African countries. The concept of “bio-entrepreneurship” is still comparatively new 
in these countries. In South Africa only a few institutions and private companies have recently 
created bio-entrepreneurship programmes. In Gauteng and the Western Cape these 
programmes are mainly run by public institutions.  
 
Table 3.3 below shows these programmes, in chronological order. 
 
 
 
 
Table 3.3: Bio-entrepreneurship course and programme created in Western Cape and Gauteng 
regions  
 
Name Location Year Brief Description 
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Biotechnology in the 
Workplace- FABI, 
University of Pretoria 
Gauteng 
region 
2006 The BSc-Honours in Biotechnology which is an inter-
departmental programme between Biochemistry, Genetics, 
Microbiology, Plant Pathology and Plant Science 
departments. They developed a new course called 
Biotechnology in the Workplace (BTW) has been introduced 
for students in their fourth year (i.e the first post-
baccalaureate year). The course was established with the 
help of the Case Western Reserve University and was taught 
as part of the Molecular and Cell Biology module. The 
course helps students to understand the basic concepts of 
bio-entrepreneurship in South Africa and introduces some 
managerial and business skills that are needed by bio-
entrepreneurs including entrepreneurship, intellectual 
property, marketing, financial aspects and start-up ventures 
for the biotechnology industry. 
The Certificate in Bio-
entrepreneurship- 
University of Pretoria 
Gauteng 
region 
2008 After the creation of the TIA, the Certificate in Bio-
entrepreneurship at University of Pretoria, joined the 
Certificate in Bio-entrepreneurship, the first level, presented 
by the Technology Innovation Agency. 
The Cape Biotech Bio-
entrepreneurship 
programme 
Western 
Cape 
region 
2008 This programme was the first bio-entrepreneurship 
programme in the Western Cape region. After the creation 
of the TIA, the Cape Biotech Bio-entrepreneurship 
programme joined the Certificate in Bio-entrepreneurship, 
the first level, presented by the Technology Innovation 
Agency. 
The E-learning 
Certificate Programme 
Country 
wide 
2010 It’s in a choice of three specialised Bio-Entrepreneurship 
Courses   administered by Xcell Bioconsulting, a private 
company, and presented in association with the Graduate 
School of Business, the University of Cape Town, is 
accessible country wide. Successful candidates may 
participate in the Advanced Certificate in Bio-
entrepreneurship of TIA presented by the University of 
Basel and, if selected, may proceed to a week-long Bio-
entrepreneurship Summer School, held in Switzerland. 
The Certificate in Bio-
entrepreneurship 
presented by the 
Technology Innovation 
Agency42 
Gauteng 
and 
Western 
Cape 
region 
2010 This is a three level programme of which the first level is 
the Certificate in Bio-entrepreneurship presented by the 
University of Pretoria in Pretoria and Cape Town. The 
second level is the Advanced Certificate in Bio-
entrepreneurship presented by the University of Basel and 
the third level sees selected candidates proceed to a week-
long Summer School held in Switzerland. 
Bio-entrepreneurship 
programme 
Western 
Cape 
region 
2012 This initiative is administered jointly by three Western Cape 
universities namely the University of Western Cape, 
University of Cape Town and Cape Peninsula University of 
Technology. Graduates of this programme are  accepted as 
participants to the first level Entrepreneurship programme 
presented by TIA and they may participate in the Advanced 
Certificate in Bio-entrepreneurship presented by the 
University of Basel and, if selected, may proceed to a week-
long Bio-entrepreneurship Summer School, held in 
                                                 
42 Programme changed to a 3 tier programme co-sponsored by Swiss 
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Switzerland43. 
The Gauteng 
Accelerator Programme- 
Biosciences (GAP - 
Biosciences) 
Gauteng 
region 
2012 Programme started in collaboration with Emory University 
in Atlanta, Georgia. GAP Biosciences is a comprehensive, 
nine-month programme that includes educational 
programmes and a business plan competition, designed to 
accelerate the establishment of biosciences-based 
companies that will be both profitable and contribute to 
Gauteng’s socio-economic development. 
Source: Authors own construction, 2013 
 
 
Since the University of Pretoria in the Gauteng Province played a pioneering role in setting up 
bio-entrepreneurship programmes, it seems appropriate to expound in more detail on their 
efforts, before proceeding to the pioneering work in the Western Cape RIS, the focus of this 
research. Kunert et al. (2008) mention the BSc-Honours in Biotechnology which is an inter-
departmental programme between Biochemistry, Genetics, Microbiology, Plant Pathology and 
Plant Science departments. They developed a new course called Biotechnology in the 
Workplace which helps students to understand the basic concepts of bio-entrepreneurship in 
South Africa. The course was established with the help of the Case Western Reserve University 
and was taught as part of the Molecular and Cell Biology module. The course introduces some 
managerial and business skills that are needed by bio-entrepreneurs including 
entrepreneurship, intellectual property, marketing, financial aspects and start-up ventures for 
the biotechnology industry. Pepper (2009) mentions another bio-entrepreneurship course 
(Certificate in Bio-entrepreneurship) which was set up and presented by the Institute for the 
Cellular and Molecular Medicine (ICMM) at the University of Pretoria44. The course covers 
scientific and managerial skills ranging from biotechnology overview to marketing. Other 
modules are health biotech (Drug development and clinical trials, TB diagnostic, Stem cells), 
GMOs and biosafety, biotech business  management and biotech from a Department of Science 
                                                 
43 A personal interview with the manager at Cape Biotech, 07 November 2012 
44 Information gathered from a workshop. PhD candidate attended Human Capacity Development for 
Biotechnology Workshop at Innovation Hub, Pretoria, South Africa (supported by Cape Biotech), 30 November 
2009 
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and Technology perspective (incl. Technology Innovation Agency), business incubation, 
intellectual property, licensing (incl. NIPMO-the National Intellectual Property Management 
Office, the biotech funding environment, biotech business models (and business plan), 
leadership, bioethics and bio-law and an idea-to-product module.  
Learning outcomes of this course are45; 
1 to understand the nature of biotechnology with a focus on red (health) and green 
(agricultural) biotechnology, 
2 to understand the funding policy environments as they relate to biotech 
3 to explore different biotech business models and to acquire the fundamentals of biotech 
business management, 
4 to understand the requirements of a biotech business plan in particular from the 
perspective of prospective funders 
5 to be able to manage issues in intellectual property and licensing as they pertain to 
biotech 
6 to understand the nature of business incubation and its place in the biotech value chain 
7 to develop fundamental notions with regard to marketing in the biotech space and  
8 to understand the complexity of the interface between stakeholders 
9 to be able to take an idea to market. 
 
The research now turns to the bio-entrepreneurship programme in the Western Cape RIS.   
 
 
3.3.Bio-entrepreneurship education: an empirical study of the first steps in the Western 
Cape RIS 
                                                 
45 information gathered from www.up.ac.za 
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3.3.1. Description of the Bio-entrepreneurship programme and its origins 
Biotechnology is accepted as a driving force for South African economic growth in the field of 
health care, life sciences and agriculture. In 2001, South Africa introduced a key policy 
document, the National Biotechnology Strategy (NBS), to build a biotech hub. The South 
African government allocated R450 million (around US$58 million) in public funding for 
biotech development (Al-Bader et al., 2009; Louet, 2006) between 2004 and 2007. The aim of 
this strategy was to stimulate the development of biotechnology skills, capacities and tools in 
South Africa (Gastrow; 2008). The NBS drew some important conclusions from a review of 
the management of biotechnology activities of other countries: 
 A dedicated agency was needed to champion biotech and manage relevant activities to 
ensure coherence between programmes 
 Strong Science & Technology capabilities must be build, targeting human resource 
development  
 Investment must focus on the commercial products and processes locally and 
internationally (Wolson, 2005).  
Government attempted to close the gap between research activities and commercialisation by 
encouraging Public-Private Partnerships (PPPs) between local and international actors and 
creating the Biotechnology Regional Innovation Centres (BRICs) (Cloete et al., 2006). 
 
BRICs served as vehicles for facilitating and supporting biotechnology innovation and 
commercialisation. Three biotechnology innovation centres were created, namely, Cape 
Biotech Initiative (CBI) in Western Cape, the East Coast Biotechnology Consortium (EcoBio, 
operating under the trade name of LIFElab) in Kwazulu Natal and Biotechnology Partnership 
for Africa’s Development (BioPAD) in Gauteng province (Table 3.4). The BRICs have 
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different focus areas: Cape Biotech and LIFElab focus on human health biotechnology research 
and development while BioPAD concentrates on several areas, including biotechnology 
research and development in agriculture, mining, and environmental applications.  
 
Table 3.4: Biotechnology Regional Innovation Centres (BRICs) in South Africa 
BRICs Location Aims 
Cape Biotech Black River Business Park, Cape 
Town 
Industry stimulation and capacity creation, and 
disseminating and managing government funds by 
investment in promising projects in human health 
LIFElab East Coast region The two primary program areas are human health and 
bio-processing 
BioPAD The Innovation Hub Science 
Park, Pretoria 
The application of biotech to industrial growth through 
process and product development, mining 
competitiveness and environmental rehabilitation or 
prevention of adverse environmental effects 
Source: Akermann and Kermanni, 2006a 
 
Cape Biotech is one of several trusts created to boost this initiative. Cape Biotech Initiative 
was incorporated as a Section-21 Company in 2002 (Pouris, 2008) with a vision to facilitate 
and invest in the development of a biotech economy, by focusing on five selected areas. These 
included point of care diagnostics, nutraceuticals from biotechnology processes, combination 
and conjugate vaccines, drug delivery and high throughput bio-prospecting (DST, 2006). The 
Initiative won the tender to establish a R150 million (approximately USA$ 20 million) 
incubator in terms of the National Biotechnology Strategy (www.capegateway.gov.za). 
Through regionally focused projects, the Cape Biotech acts as a centre for the development of 
a range of businesses and new product offerings, as well as having the capacity to support these. 
With an interest in capacity creation, portfolio and knowledge management, Cape Biotech is 
therefore a cluster development initiative in addition to a funding body 
(www.blueprintbiotechlab.co.za). Cape Biotech in essence, has three major roles: industry 
stimulation through capacity creation; management of government funds by investing in 
promising projects; and co-ordination of business support networks. Its functions include 
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investment, networking, bio-economy intelligence, marketing and capacity development 
(www.fdimagazine.com). 
 
To exploit the potential of the biotechnology industry in South Africa, there is a need for 
entrepreneurial scientists who should have both research and management skills and also an 
understanding of scientific, regulatory and ethical issues. Entrepreneurs able to develop the 
industry and build bridges between the science of biotechnology and the commercialisation 
thereof are needed.  By developing new competencies through education, biotechnology 
entrepreneurship can promote new biotechnology creations (Kunert et al., 2008; Kunert et al., 
2012).  
 
Kunert et al. (2008, 2012) found that there are three major restrictions to the development of 
an active and competitive bio-entrepreneurship environment in South Africa. 
1.  First, the small number of researchers involved in biotechnology who may have 
potential as a bio-entrepreneur. There are fewer researchers in South Africa compared 
to developed countries which negatively impacts the availability of sufficient and 
adequate technical expertise and skills required for biotechnology start-up companies. 
This skill shortage continues even though South Africa has several excellent 
biotechnology research groups and centres, where research is driven by well-trained 
and experienced staff. This shortage also shows up in the relatively low number of 
patent and scientific publications in the biotechnology field. An encouraging element 
is that these publications demonstrate the potential capacity to develop a local 
biotechnology industry in South Africa. 
2. Secondly, new graduates in biotechnology lack the skills to stimulate the industry. 
Reason is quite clear; graduate students receive sufficient research training in 
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preparation for a future academic career, but few educational programs provide training 
in entrepreneurial skills for these students. Graduates have little knowledge about 
biotechnology entrepreneurship and innovation when they graduate. Further, they often 
have not received extensive training in collection of information required to solve 
problems, critical review of information, and techniques to search for new solutions. 
This creates a major problem for companies interested in finding new ideas with 
potential for commercial success. This lack of skills is also due to both the existing 
shortage of well-trained faculty in biotechnology in academic institutions and also the 
disinterest of many faculties in bio-entrepreneurship and commercialisation. Since 
graduates frequently receive a very narrow specialised training in these institutions, 
they are further poorly equipped to adapt to rapid changes in technology, which is a 
necessity for biotechnology. Adding to this, as a result, in South Africa up to 75% of 
PhD graduates remain in higher education institutions, government research 
organisations or public service. Thus, relatively few post-graduate students consider 
industry as a future career. 
3. Because of limited local opportunities in industrial positions and the less than 
favourable environment for start-ups, South Africa loses many well-trained students to 
other countries. Unfortunately, the current climate for the development of a 
biotechnology industry and bio-entrepreneurship in particular is also not very 
favourable. A rather complicated funding system, which is less favourable for start-ups, 
limits the prospects of even the most innovative individuals. 
To set up a successful biotechnology industry and support bio-entrepreneurship in South 
Africa, biotechnology graduates should be encouraged to obtain interdisciplinary training. 
Therefore, one of the aims of the Cape Biotech is to develop bio-entrepreneurial skills and 
promote the growth of a bio-entrepreneurial culture within existing companies and research 
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institutions. For this purpose, Cape Biotech created business skills development programmes, 
namely the Bio-entrepreneur programme, Bio-mentor programme and Higher Education 
Institutions Entrepreneurial Programme. The details are below.  
 
Bio-entrepreneur programme: The main objective of this programme is to support and 
facilitate the development of business skills necessary for sustainable biotechnology ventures 
in the Western Cape. CBI aims to involve participants such as CEOs and/or GMs of biotech 
start-ups, second-line management, and aspiring biotech entrepreneurs. The objectives of this 
programme are; 
 to build and augment the business skills of participants in the context of their own 
business ventures through: 
 Delivery of business theory and concepts 
 Transfer of tacit knowledge and experience between course conveners and the 
participants 
 Application of the learning to real business situations 
 to equip participants with the skills to improve the robustness of their business ventures 
 to support the development of bio-entrepreneurs and future business managers 
 
In 2008 and 2009 the programmes were run by four venture capitalists. Their backgrounds are 
respectively Chartered Accountant (CA), Geologist, IT expert and one had a medical 
background (physiotherapy), but all four were entrepreneurs. The programme was outsourced 
and the same type of programme has been running for more than five years now, in a part of 
ICT cluster in Cape Town. The content of the Bio-entrepreneur programme is:  
 14 practical hands-on group lecture sessions over 28 weeks covering various business 
and financial topics. Business modules are value proposition, market and customer 
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segmentation, business model, practical operations strategy, pricing, marketing, sales, 
negotiation, people management and preparing a business plan. In the financial 
module; analysis and interpretation of financial statements, budget, forecast and 
performance measurement, growth, working capital and cash flow management and 
valuations and exits have been taught. 
 Assignments for practical application of the theory 
 Monthly mentorship sessions with individual mentors. 
Selection criteria for the Bio-entrepreneur programmes differed from the first one (2008) to 
the second one (2009)46. For the first programme, a few people from Cape Biotech were 
admitted and the companies in which money had been invested were asked to each send one 
member of their personnel. The idea was simply to fill the venues. When the programme proved 
successful and positive feedback was received, people became interested in attending the 
programme, and companies began to approach the manager at Cape Biotech. Apart from the 
different selection criteria, changes were also made to the modules offered before the second 
programme. The manager at Cape Biotech also pointed out that after receiving feedback from 
the people, a 3rd programme would start in April 2010 and by November 2009 four applications 
had already been received47.  
 
Bio-mentor programme: The participants in this programme are the graduates of the bio-
entrepreneur programme, biotechnology business managers and bio-entrepreneurs. The main 
aim of this programme is to provide a forum for identifying and addressing issues that affect 
biotechnology companies and to support networking and cluster development. Other objectives 
of the programme are: 
                                                 
46 A personal interview with the manager at Cape Biotech, 18 November 2009. 
47 This was the time when the field work was done, 15 February 2010. 
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 To up-skill bio-entrepreneurs through interaction with experienced business leaders 
 To provide a forum for networking between biotechnology business managers & 
technology developers 
 To provide a forum for leveraging synergies for win-win business collaborations and 
clustering. 
 
HEI Entrepreneurial programme: The main purpose of this programme is to raise awareness 
of the technology commercialisation process required to develop and take an innovative idea 
to market and of the crucial inter-disciplinary nature of the process. Other objectives of these 
programmes are: 
 To understand the key concepts and options in commercialising hi-tech technologies in 
the biotechnology sector 
 To understand how to assess technologies for their commercial potential 
 To understand the steps that technologies go through in the journey from the laboratory 
to the marketplace. 
 To have a working knowledge of the business plan process 
 To explore the roles that intellectual property protection and licensing play in the 
commercialisation process. 
Cape Biotech aimed to reach graduate students, post-graduate students, and post-doctoral 
fellows interested in innovation - taking their inventive research outcomes to the marketplace 
and/or those interested in a career in biotechnology business development or in joining a start-
up company. The Manager of Human Capital Development of Cape Biotech stated48 that 
activities were started at the University of Cape Town for the first time in 2009, but there were 
no formal courses at other universities.  
                                                 
48 A personal interview with the manager at Cape Biotech, 18 November 2009. 
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This study focuses on the bio-entrepreneur programme, in particular. 
 
3.3.2. Research Purpose and Methodology 
Given that this training programme represents the first structured attempt at enhancing the 
entrepreneurship skills of scientists, this research: 
1. evaluates the programme against its own objectives from the perspectives of the 
programme graduates primarily to give feedback to Cape Biotech and other relevant 
agencies to fulfil an expressed need to improve and expand the programme;  
specifically, the objectives are 
o to build and augment the business skills of participants in the context of their 
own business ventures through: 
o Delivery of business theory and concepts 
o Transfer of tacit knowledge and experience between course conveners and 
the participants 
o Application of the learning to real business situations 
o to equip participants with the skills to improve the robustness of their business 
ventures 
o to support the development of bio-entrepreneurs and future business managers 
2. deriving from these objectives, we discern a measure of the effectiveness of the 
programme in terms of the number of enterprises that have been created by participants, 
but cannot yet say something about the growth and longevity of the enterprises. 
 
The study procedures included conducting a literature survey via internet and library research, 
and conducting interviews with the Cape Biotech bio-entrepreneurship programme graduates. 
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A case study was undertaken in order to understand the bio-entrepreneurship education context 
and details in South Africa. In the paper two consecutive Cape Biotech bio-entrepreneurship 
programmes are analysed. In 2008 the programme was operated successfully and seven 
students graduated, followed by sixteen graduates in 2009.  
 
A total of 28 graduates and a manager at Cape Biotech were included in this research. 
Interviews were conducted based on a questionnaire, aimed at evaluating the programmes and 
gaining useful feedback to inform further efforts at bio-entrepreneurship training. Twelve 
questions were prepared for the manager at Cape Biotech and ten for the graduates. Interviews 
were semi-structured and took 15 to 40 minutes. All interviews were recorded and transcribed. 
We received responses from three of the twelve 2008 graduates (25%) and twelve of the sixteen 
2009 graduates (75%). If we include the manager this means that there were 16 responses 
overall (57.1%). 
 
3.3.3. Research Results 
 
3.3.3.1. Historical context of the bio-entrepreneur programme 
The programmes that are the subject of this study were preceded by an earlier attempt in 2007. 
During this first bio-entrepreneur programme, Cape Biotech entered into a partnership with a 
British-based company. The aim of this programme was to transfer essential bio-business skills 
to university scientists, promising entrepreneurs and early-stage companies in an industrial 
environment. The two-year programme was intended to consist of industrial seminars, 
workshops, MBA courses and electives and business skill courses. The programme was 
intended to be taught by leading academics, industrialists and entrepreneurs from the Cape, 
Cambridge, Munich, Boston, San Diego and San Francisco biotech clusters. The hope was that 
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the course would lead to at least ten students graduating from this programme every year 
(Akermann and Kermani; 2006a). The Bio-entrepreneurship Programme, 2007 was launched 
at Cape Biotech, but was unfortunately not a success. We asked the manager at Cape Biotech 
the reasons for being unsuccessful and she responded “I was not in Cape Biotech then but what 
I know is that the programme 2007 was replaced with another programme called “The Hellfire 
programme” and the people who were involved in this programme were very young and went 
back to the corporate sector. This programme is not an entrepreneurship programme, it is 
mostly about intrapreneurship.” The Hellfire internship programme is explained in their 
website49 as a first of its kind in the South African life sciences sector, and is aimed at 
addressing skills development, job creation, increase entrepreneurship and life-science 
innovation and technology which can be transferred from a research basis to the marketplace. 
Hellfire is sponsored by Acorn Technologies50 and the Godisa Trust (now SEDA Technology 
Programme - STP). Since the first programme did not take off, and its replacement is not an 
entrepreneurship programme, we will henceforth consider the 2008 bio-entrepreneurship 
programme the first programme and the 2009 programme the second programme. The first 
programme started in November 2008 and was completed in April 2009. The second 
programme started after this and graduation took place in November 2009. The duration of the 
Bio-entrepreneurship Programmes was 28 weeks. The 2008 bio-entrepreneurship programme 
produced 19 graduates in different categories. There were seven attendance certificates (those 
whom did not complete all the modules), seven graduates and five graduation certificates with 
special recognition (top graduates). In this section the focus will be on the graduates and 
graduation certificates with special recognition only and interviews with them will be reported. 
The 2009 bio-entrepreneurship programme produced 16 graduates. The manager at Cape 
                                                 
49 www.hellfire.org.za  
50 Acorn Technologies had merged with Cape Biotech (Al-Bader et al., 2009). 
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Biotech believed that these programmes were successful because they were presented by 
people who were already in the industry and because it is not a theoretical course. The people 
who presented the programme are actually venture capitalists and they know the ins and outs 
of the business plan and industry. One of the outcomes of the 2009 programme is that a new 
company will be created by one of the graduates. In the next section the profiles of the 
participants are presented. 
 
3.3.3.2. Profiles of participants 
Table 3.5 below presents the general profile of participants including their gender, age, degree 
obtained, field, university and their current positions. 
Meyers and Hurley (2008) discuss in their research that some trends are reshaping the future 
graduate-level education in bio-entrepreneurship programmes and one of them is the low 
participation of women and minorities in science, technology, engineering and maths (STEM). 
 
Littlehales (2006) points out that many specialised academic training, seminar and mentoring 
programmes in the USA are slowly beginning to focus on equipping female bio-entrepreneurs.  
This is not only a problem in developing countries but also developed countries. Littlehales 
also explains that especially in the biotechnology industry there are only a handful of successful 
women bio-entrepreneurs.  
 
Table 3.5:  Profile of participants in the bio-entrepreneurship programmes 
Year 2008 2009 
Number of graduates from programme 12 16 
Number of participants in this study 3 12 
Gender Female 2 6 
Male 1 6 
Total 3 12 
Age1 20-30 - 5 
31-40 2 5 
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41-50 1 1 
Total 3 11 
Education BSc in Plant Biotechnology - 1 
BSc in Biotechnology - 1 
BSc (Honours) in Biochemistry 1 - 
BSc (Honours) in Pharmacology - 1 
BSc (Honours) in Immunology - 1 
MSc in Bio-medical Engineering 1 1 
MSc in Bioinformatics - 1 
MSc in Immunology - 1 
PhD in Medical Bio-chemistry - 1 
PhD in Microbiology 1 - 
PhD in Plant Biotechnology - 1 
PhD in Neuroscience   - 1 
PhD in Molecular Biology - 1 
MB ChB in Medicine - 1 
Total 3 12 
University2 Stellenbosch University (SU) 1 3 
University of Cape Town (UCT) 1 6 
University of Pretoria (UP) - 2 
University of Edinburgh - 1 
Total 2 12 
Position Honours student - 1 
Post-doc fellow - 1 
Director of a company - 2 
CEO of a company - 1 
Project manager of a company - 2 
Business Unit manager of a company - 1 
Technical Assistant at a company - 1 
Intern at a Public Research Organisation - 1 
Self-employed - 1 
Serial Entrepreneur - 1 
Manager of Medical Devices at one of the BRICs 1 - 
Head of Quality Control at an Institute (PPP) 1 - 
Researcher at one of HEIs 1 - 
Total 3 12 
1,2One participant did not answer this question. 
Source: Authors construction based on data obtained through interviews, 2010 
 
That is why universities and some institutions now run special entrepreneurship programmes 
for females to increase the number of scientists with special managerial skills. In the case of 
the study, of the 15 participants, eight (53.3%) were female and seven were male graduates. 
The results of Pepper’s research (2009) support the trend of increased female participation. He 
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indicates that in the bio-entrepreneurship course organised by ICMM at the University of 
Pretoria 10 female, and 18 male participants responded. 
 
The age of the participants is also shown in Table 3.5. Most of them are in the young age group. 
The average age is 33.64. Out of 14 participants, 12 are between 20 and 40 years of age, with 
five of them under 30 and seven in the 30 to 40 age group. Only two participants were over 40. 
Pepper (2009) found that the average age of participants in the UP bio-entrepreneurship course 
was 33.85. This seems to indicate that the majority of participants in bio-entrepreneurship 
courses offered in South Africa are fairly young.  
 
The minimum degree obtained by any participant was a BSc (two people). Three people had 
obtained BSc Honours, four MSc, five PhD and one MBChB. As was mentioned at the 
beginning of the section many entrepreneurs in the biotechnology field have doctor’s degrees. 
As can be seen from the table, 35.7% of the participants had achieved a PhD in the 
biotechnology field. 
 
Following the emergence of genetic engineering and cell fusion, biotechnology applications 
have become diverse, with a range of biotechnology companies becoming involved in the 
businesses of biopharmaceuticals, biochips, bioinformatics, cell culture, medical diagnostics, 
medical devices, food and agricultural and environmental products (Poon and Liyanage, 2004). 
Some programmes are designed for narrow market niches like biologics while others focus on 
attracting a wider audience with more diverse backgrounds (Meyers and Hurley, 2008). 
Participants in this study had degrees in various disciplines, such as Plant Biotechnology, 
Biochemistry, Pharmacology, Immunology, Bio-medical Engineering, Bioinformatics, 
Medical Bio-chemistry, Microbiology, Neuroscience and Molecular Biology. Having different 
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backgrounds brings different perspectives to the classroom and advantage can be taken of these 
talents in networking sessions.  
 
The results show that most of the participants received their degrees from UCT (50%) followed 
by Stellenbosch (28.5%) and the University of Pretoria (14.2%), and one participant had a 
degree from the University of Edinburgh. The research also shows that most graduates already 
filled positions in different institutions. That is what Cape Biotech aimed at when they set the 
programme up. Targeted audiences were CEOs and/or GMs of biotech start-ups, second-line 
management, and aspiring biotech entrepreneurs. 
 
3.3.3.3. Understanding of bio-entrepreneurship 
In this section, the participants were asked to define the concept bio-entrepreneur. A bio-
entrepreneur is one who looks for commercial value in the technologies that he/she applies in 
conducting research in the field of biotechnology. Most participants define a bio-entrepreneur 
as “a person who has a scientific/medical background and finds a way to convert a 
biotechnology application from an academic idea to a commercially viable product or service 
by finding a suitable market and who is passionate about becoming an entrepreneur with 
starting his/her own business and making money”. In addition to this, some participants also 
believe that an entrepreneur can also be interested in expanding companies. A keyword analysis 
of the respondents’ definitions produced three recurring elements of the definition: 
 Personality traits or personal attributes (‘go-getter’s mentality’, ‘having guts’, not for 
the faint-hearted’, people with ‘lots of ideas and energy’) 
 Features distinguishing bio-entrepreneurship from other entrepreneurship; 
 Obstacles such as scale of start-up costs and the length of commitment to the venture 
before significant returns are generated. 
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3.3.3.4. Views on biotechnology prospects 
 
3.3.3.4.1. Global competitiveness 
Since biotechnology is viewed as a global source of future growth, the respondents were 
prompted on their views regarding South Africa’s biotechnology prospects. According to the 
participants South Africa is still far behind the EU and the USA in biotechnology. Sixty per 
cent of the participants agreed that South African biotech is still very small and in the infancy 
stage. The participants advanced various reasons for this assessment: that South Africa is 
situated at the foot of Africa and not close to Europe; the mind-set here is different. People 
often think that South African products are simply not good enough, not of high quality and 
also that it is very expensive to export them and to work around the foreign regulations like EU 
regulations. Back (2009) points out that international marketing is complicated and that there 
are differences in the regulatory environments in the USA and other countries. In the context 
of global markets, the manager at Cape Biotech emphasises that bio-entrepreneurs in South 
Africa need to be familiar with these regulations. Therefore, international bio-entrepreneurship 
has to be taught by experts.  
 
Participants came to the conclusion that South Africa still has some problems that need to be 
solved in order to be in the global league, namely: 
1. People need to work in a team but in South Africa people work in solo conditions, 
where people hold on to their ‘own little IP and struggle to create a value chain from 
the lab to the market’.  
2. More funds are needed. ‘If you do not have the finances you can hardly compete with 
the amount of venture capital in biotechnology in the US. People rather put their money 
129 
 
in the bank to gain higher return on the investments at the moment rather than later in 
biotech. As far as the growth rate of companies is concerned, you will get your 
investment’s return eventually. The lead time in biotechnology matters, obviously 
because in takes 10 years to actually get your products commercialised. People require 
a quick turnaround time in terms of how they want their money back. If people can just 
get into the high growth phase so that there is a market’. 
3. Marketing is important. 
4. There is a need to attract some overseas investors to invest in South Africa. 
5. There is a need to look at India and Brazil as our competitors and to learn from them. 
6. South Africa has the potential to capitalise on our indigenous heritage. The main 
concern is that South Africans are ‘oblivious to capitalising on IP’.  
7. Venture capital, which really does not exist in SA. ‘SA VC likes to make safe bets 
which are a contradiction in terms’. 
8. It was also pointed out that in the South African context, government has recognized 
the biotechnology industry and has put money into it. Yet, it is believed that South 
Africa is at the moment very diversified (‘all over the place’) in terms of biotechnology. 
If South Africa focused on unique products and field, it will not be so hard to find a 
place in international market. Two participants suggest that SA Biotech needs to have 
a clearer and constructive investment approach and more focused field’.  
 
The participants, however, also identified opportunities; even though the biotech sector is very 
small, they believe South Africa has a lot of opportunity and scope to participate globally. The 
opportunities that were identified by the participants include: 
1. Exploration and application of the available ‘indigenous plants and indigenous ideas’.  
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2. South Africa has specific needs; being a leader in Africa. There is a big need for food 
in Africa, and South Africa is in the position to address that need. This is a great 
opportunity for South Africans.   
3. South Africa has many unique problems to deal with that can possibly only be solved 
from the South African angle. South Africa has a ‘competitive advantage in terms of 
the prevalence of diseases like HIV and TB and overseas biotechnology companies can 
test their diagnostic kits and their drugs here’. 
4. South Africa has a comparative advantage due to its immense biodiversity’. 
 
3.3.3.4.2. Strengths and weaknesses of the Western Cape biotechnology industry 
In the table below (Table 3.6) the strength and weaknesses of the Western Cape biotechnology 
are shown. Knowing the participants’ views on the strengths and weaknesses helps to identify 
elements in the bio-entrepreneurship programmes that address these weaknesses (and to reveal 
gaps). The important strengths as identified by the participants include; having Cape Biotech 
in the Western Cape; a strong network; people are open to innovation; the location of Cape 
Town, the well-known and friendly city, research universities like UCT and Stellenbosch and 
the prevalence of diseases like HIV and TB. 
They identify lack of funding as one of the main weaknesses, followed by lack of data; less 
bio-business; lack of collaboration; being far away from other centres, lack of academic mind-
set; lack of bio-incubators and bio-science parks, lack of coordination and a lack of trained, 
skilled people. 
 
Table 3.6: Strengths and Weaknesses of the Western Cape Biotech Industry 
Strengths of the 
Western Cape 
Biotechnology 
Industry 
1. Having Cape Biotech is important. The government shows a lot of commitment, 
towards bio-technology, especially for the BRICs, 
2. The Western Cape has a good network and a relatively strong community compared 
to the rest of the regions in the country. People create networks through structures like 
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Cape Biotech and the activities they organise or through personal contact with former 
classmates and colleagues. Because the industry is so small, people know each other, 
3. People are open to innovation, 
4. Location. Certainly the allure of Cape Town as a destination both for South Africans 
and foreigners is great. Everyone knows where Cape Town is and this adds credibility 
to companies based in Cape Town,   
5. The Western Cape is in an ideal situation to become a hub, 
6. Many overseas people explore and invest in the Western Cape (i.e. Kapa Biosystem), 
7. Friendly-life environment, 
8. International airport/harbour, 
9. Biodiversity, 
10. Good science departments at the universities,  
11. Having many people suffering from TB and HIV so that tests can be done. 
 
Weaknesses of the 
Western Cape 
Biotechnology 
Industry 
1. There is never enough money, lack of funding, 
2. Not commercial enough like in Johannesburg and Pretoria, 
3. A lack of data bases   
4. Lack of collaboration amongst the institutions, 
5. Far away from international Biotech hubs such as Boston (USA) and Europe etc where 
money is available, 
6. Scientists do not know how to run businesses, 
7. The unsuitable mind-set of the local academics, 
8. The lack of science parks and incubators specifically focused on biotechnology.  
9. Little coordination. There are few bridges between the universities and the industries 
and between the companies themselves,  
10. Lack of trained and skilled people. Lack of education is also a weakness (especially 
skills) not only in the WC but also in SA as a whole, 
11. Young industry, with limited infrastructure/facilities to support aspiring Biotech 
entrepreneurs, 
12. There are limited multi-mentorship programmes and also sharing the success stories, 
13. Difficult to get information, advice and access to the necessary skills locally. 
 
Source: Authors survey 2010 
 
3.3.3.5. Bio-entrepreneurship programme 
 
3.3.3.5.1. Expectations and perceptions of the programme 
 
3.3.3.5.1.1. Before enrolment 
The research asked graduates what their expectations were before enrolment, in order to see 
whether these were met, and whether their perceptions of the programme had changed upon 
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completion. Three participants did not have any expectations before the enrolment. Others 
participants’ expectations were; 
 to find out more about the various aspects of business environment (e.g., marketing 
and all the related terminology and various aspects of finance and all the different levels 
in business start-up and set up), entrepreneurship in biotech space and the growth of 
South African biotech, 
 to know more about how to write a business plan 
 to be able to launch a business with a better understanding of what is required to launch 
a successful biotech company 
 to receive more training in the financial side of running a business 
 to look at science from a business point of view, to bury “the doctor approach “ a little 
bit and take a business approach, 
 to participate in networking. 
One participant especially stated that s/he was very confused about whether s/he wanted to 
follow an academic career or to look more closely at the biotech industry. S/he attended the 
course to better her/his understanding of entrepreneurship and business. As a result s/he does 
not want to be in business but s/he said that if an opportunity presented itself in future s/he 
would be equipped to take advantage of it.  
 
Another participant said s/he would be taught valuable skills and lessons during the 
programme, and then be teaching others, transferring this knowledge to others that can benefit 
from her/his attending the programme. 
 
When one looks at what bio-entrepreneurship requires, it is an extensive repertoire of 
knowledge, skills and attitudes which are listed by Meyers and Hurley (2008) such as 
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knowledge of the legal environment (like understanding basic IP and licensing terms, and being 
able to interpret a term sheet), marketing, international bio-entrepreneurship (e.g. understand 
the regulatory environment in international markets), new product development (e.g. 
understanding how to manage an R&D portfolio), business development and planning (e.g. 
being able to write an innovative business development plan), manufacturing, finance, leading 
bioscience ventures (e.g. being able to demonstrate managerial skills and leadership ability like 
team building, project management, budgeting, negotiation and inspiring the employees), 
clinical trials and validation, communication skills, technology development, management and 
commercialisation (e.g. understanding the basic technology transfer setting between industry, 
academia and government and different technology transfer mechanisms like in and out 
licensing, spin-out etc), emotional and social intelligence skills (such as self-control and  social 
awareness). It is insightful to note that most of the participants’ expectations were about 
understanding the various aspects of the business environment (marketing and the financial 
side of the business). We assumed that this is because most of the participants are already in 
business; they are CEOs, directors or second line managers. 
 
3.3.3.5.1.2. After completion 
Participants’ articulation of expectations was different after completing the programme. One 
participant compared the programme with European bio-entrepreneurship programmes that she 
had attended before and found that the bio-entrepreneurship programme that was offered in 
South Africa lacked scientific contents and was more focused on entrepreneurship and that 
presenters did not have a bio-science background. That is a crucial point when one looks at the 
programme offered here. Because of the time limit, presenters are not able to teach all subjects 
in depth. Programmes mostly covered the business and financial modules. Business modules 
include: value proposition, market and customer segmentation, business models, practical 
134 
 
operations strategy, pricing, marketing, sales, negotiation, people management and preparing 
a business plan. The financial modules include: analysis and interpretation of financial 
statements, budget, forecast and performance measurement, growth, working capital and cash 
flow management and valuations and exits. The modules did not cover the other knowledge, 
skills and attitudes as listed by Meyers and Hurley (2008) in their paper and mentioned in an 
earlier section of this section.   
 
Some participants pointed out that they have learned more about the biotechnology 
environment and bio-entrepreneurial activities in Western Cape and also the role government 
played in creating a favourable environment. As a scientist it was also valuable to know the 
business side (marketing, finance etc...) and being able to create a business plan. It was also 
helpful to know what investors look at when they invest in bio-business. 
Two participants’ expectations were to be independent in terms of being able to start businesses 
and having the correct tools to go about it.  
 
Some others were interested in networking and seeing what kind of channels there are and how 
to go about running a company. For an entrepreneur to run a company, it is necessary to 
understand what needs to be done. And the programme taught it. 
 
3.3.3.5.2 Motivation for choice of bio-entrepreneurship programme 
Closely linked to the expectations of the programme, are the reasons why a participant would 
choose this programme over other options. We asked the interviewees what motivated them to 
enrol in this programme rather than studying for an MBA. Most of the participants indicated 
that the reason why they did not study for an MBA was that an MBA is expensive, a huge 
investment financially, a broad and intense course, that it requires lots of dedications and time 
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and lastly that an MBA teaches the typical structures and dogmas in corporate business, and 
does not focus on innovative and entrepreneurial teachings that challenge the status quo.  
 
The reasons why they participated in this course were that it was cheaper, a very good 
introductory course and relatively quick. A person running a business, did not have to be absent 
from his/her business for a long time. The course was practical, not an in-depth course, it was 
more focused and touched on a lot that the MBA course does. This course allowed a person to 
get a feel for the whole environment, the assignments required were helpful, networking was 
very good and participants could learn from one another. Because each person came from a 
different background of the biotechnology sector, one did not only learn from the presenters, 
but from the other participants as well51.  
 
In addition, some participants mentioned that the time frame was nice, and the hours were 
flexible. It was not an intensive course but at least it opened their eyes to many issues. There 
was no other programme available that focused on what was really a niche market. It seemed 
like a mini-MBA that was applied to the biotech industry. 
 
One of the participants was about to apply to do an MBA, another one was already doing MBA 
and two are planning to do it in the future. 
 
3.3.3.5.3. Strengths and weaknesses of programme 
Table 3.7 shows the strong and weak points of the programme according to the participants. 
Seven participants especially highlighted how lecturers were good and knowledgeable. Six 
                                                 
51 Some of the reasons given by participants in this paragraph could not have been known beforehand which could 
be served as motivation, and should be viewed as ex-post justifications. 
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participants also liked the mentorship programme and mentioned that this added value to the 
course. Other important strong points of the programme were networking and interaction with 
each other. Seven participants opined on this topic. They also mentioned that they found the 
topics and concepts useful.  
 
Five participants criticised the length of the programme and felt that more case studies could 
have been done. One participant, unlike the others, feels that presenters do not take the 
scientists perspective and says “Presenters are in IT technology and that type of industry, they 
have businesses but they do not have knowledge of biotechnology. If you do a bio-
entrepreneurship course you need to relate with it”. Another weak point of the programme was 
touched on by two participants, namely that every participant were not at the same level: “The 
weak point, not everyone attending the course is on the same page. Not all of them have the 
same business experience; some are just setting up, some are at the idea phase, and some are 
already running a successful business. It makes it harder to extract value for everybody at the 
same lecture.  You can set up levels: beginner, intermediate, experienced levels or otherwise 
start-up phase, already running phase and already successful business phase. That would be 
beneficial.” 
 
“No way of determining skill level / quality of attendee. It would help if there were some sort 
of grading for the programme that is recognised. It helps when approaching investors etc, they 
can find out if you were proficient in the programme or were just a spectator. You had some 
people who were already in business for a long time and people who have not been into 
business so there could be two different classes for experienced and inexperienced students.” 
One participant touched on an important point, saying; “Practically I think only a handful of 
people were really going to become bio-entrepreneurs and start their own businesses. The rest 
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of us were just trying to learn more about what to do if any opportunity came around”. Three 
participants did not identify any specific weak points. 
 
3.3.3.5.4.  Explicit benefits 
According to the interviewees the bio-entrepreneurship programme was highly beneficial for 
almost every participant. Crispeels et al. (2009) argue that in the biotechnology industry one 
individual cannot set up and run a biotech company. There is a need for “an entrepreneurial 
team” to grow a successful company. One participant also thinks that it is more beneficial and 
productive when people work as a team. At the end of the programme two participants found 
it very beneficial but decided not to go into business rather to work in a team and in academia. 
But they stated that they now understand the bio-entrepreneurial environment and business 
much better.  
 
Others found it highly beneficial. Answers were also in broad sense in line with the nature of 
their work environment. Some participants think that it opened their eyes to see as a manager 
what to deal with in the future. Some believed it seemed beneficial, and that they will see the 
result when the business starts making money, whereas others found it beneficial and plan to 
use what they’ve learned in future. Networking and meeting other people was another stated 
benefit of the programme. One participant stated how important it was for her “our company 
is fairly well established unlike many of those where the other participants come from. As we 
have many separate departments where people are more specialised, a lot of the information 
was more theoretical and not directly related to what I do on a daily basis. However, in order 
to do the assignments I had to speak to people internally and now have a much better 
understanding of how the company operates”. 
 
Table 3.7: Praise and criticism of the course 
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Strong points 1. Content of the course: The course was well-balanced. All the topics were applicable, 
thought-provoking and at an appropriate level.  The introduction of financial topics 
was a good idea. 
2. The participants: It was good to mix with people from different backgrounds. 
Participants could learn from each other. 
3. The presenters: The presenters were good, passionate and knowledgeable.  Many of 
them were experienced businessmen. 
4. Mentors: It was helpful to have mentors.  
5. Assignments: The assignments were helpful. One participant says that writing the 
assignment forced him to interview workers in his own company and that he now has 
a much better idea of how his own company works. 
6. Involvement: The involvement of the government and the private sector was a good 
idea.  
7. Networking: The course created opportunities for networking 
 
Weak points 1. Contents of the course: Certain topics were not of interest to all the participants. It was 
argued that the course should be longer. 
2. The participants: The knowledge levels of participants differed. Participants should 
qualify to attend. The businesses of entrepreneurs were at different stages. There should 
be different courses for example for beginners or those at the start-up stage and for 
those more experienced. 
3. The presenters: Some presenters came from the IT sector. They had too little 
knowledge of biotechnology. Some lectures were very theoretical. There is a need for 
more practical help for example regarding administration. 
4. Mentors: There should be more time for mentors and participants to meet.  
5. Assignments: The financial budgeting assignment was too difficult. There was too little 
feedback on assignments. 
 
Source: Authors survey 2010 
 
3.3.3.5.5.  Relevance for current work environment 
The participants were asked whether they use the knowledge they gained from the programme. 
Fifty-three per cent of the participants said that they did, 20% said that they used some aspects 
and 26.6% said that that they did not use it at the moment, but would later.  
 
Participants who use their new knowledge use it for business plans, negotiations, reading 
balance sheets, working with people, budgeting and understanding statements. For instance 
one participant says that he applies the knowledge “more on the operations and finance side 
where it is very helpful. As I have no interaction with external customers, the modules on 
Marketing, Pricing, Sales, etc. were not directly applicable to what I do”. 
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The participants, who do not use the knowledge, do not do so because of the fact that the 
positions that they currently hold, do not require such knowledge.   
 
3.3.3.5.6.  Recommendation to others  
The participants were asked whether they would recommend this course to others. All 
participants agreed that they would recommend it to others. Some of them especially 
highlighted the reason why they would. It is; 
 A good course to take especially if a person is not sure if he/she would like to enter 
the business environment. 
 A good course from the networking point of view 
 A good course for people who are involved in setting up new ventures and who 
need a sense of direction and sound business advice 
In sum, it is fair to conclude that most of the participants’ expectations were met, with a few 
exceptions, as set out above. 
 
To complete this assessment, the research matches the objectives of the bio-entrepreneurship 
programme with the participants' observations about the programme. The programme had three 
broad objectives: 
 to build and augment the business skills of participants in the context of their own 
business ventures through: 
 Delivery of business theory and concepts 
 Transfer of tacit knowledge and experience between course conveners and the 
participants 
 Application of the learning to real business situations 
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Judging from the observations of the participants, the majority implied that this objective was 
largely met. Constructive criticism related to the duration of the programme, the backgrounds 
of the facilitators, and the diversity in terms of level of experience of the participants.  
 
Although these were minority views, they provided useful suggestions for improvement, which 
the research highlights again in the concluding section. 
 to equip participants with the skills to improve the robustness of their business ventures. 
The programme developers did not provide clarity on how success in achieving this objective 
is to be measured, and the results are likely to emerge only over time, following implementation 
of the new knowledge. Indications are, however, that the participants believed that they would 
reap the benefits in their businesses. 
 to support the development of bio-entrepreneurs and future business managers.  
Although the support was given, the reflections of the participants indicate that only a few of 
them really wanted to be bio-entrepreneurs, but that the course was useful in giving them the 
exposure to come to the conclusion that this was not the avenue they wanted to pursue. 
Although this result is to be expected in a new initiative, it sends a strong message about the 
selection criteria.  
 
Lastly, when considering the effectiveness of the programme in terms of the number of 
enterprises created, we do not see a rapid progression from 2008, where out of 12 graduates, 
two had existing companies, and four (33,3%) created new companies after graduation, to 
2009, where out of 16 participants, five had existing companies and four (25%) created new 
enterprises after graduation52. 
 
                                                 
52 TIA, personal communication, 9 April 2013 
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3.4.Conclusion and policy recommendations 
In the context of general policy measures aimed at improving economic growth and creating 
jobs, South African policy makers view new growth sectors, such as biotechnology as an 
important means of contributing to the achievement of these objectives. Like other countries 
pursuing the benefits of biotechnology as a growth industry, South Africa faces a shortage of 
entrepreneurial skills that would bridge the gap between science outputs and marketable bio-
products. To address this need, Cape Biotech, now a component of TIA, has implemented a 
bio-entrepreneurship programme which was one of the first structured attempts in South Africa, 
to specifically equip scientists with adequate knowledge and skills to build a bridge between 
the science of biotechnology and the commercialisation of knowledge and ideas in this 
particular field. This bio-entrepreneurship training programme has been constructed to expose 
participants to theoretical and practical learning on entrepreneurship and management skills 
that span science and commerce. The programme was an integrated cross-faculty programme, 
with multiple background participants, stimulating teamwork, networking and learning from 
each other throughout the courses to shape the individuals and teams. These aspects have been 
shown to determining factors for the future success of young innovative biotechnology 
companies. 
 
This study assessed the programme in terms of its objectives and against the expectations of 
the participants, as well as their views on the strengths and weaknesses of the programme and 
its implementation. The results allow us to draw out recommendations specifically pertaining 
to the programme, as well as general policy implications for agencies such as the TIA, as well 
as policy makers. 
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Although the participants viewed the programme as largely successful, certain key aspects 
emerged that, when addressed, could improve the effectiveness and efficiency of the initiative, 
and could also inform design of other initiatives: 
 Finding the balance between biotechnology and commercial expertise and experience 
in compiling the course content and selecting the facilitators; 
 Fine-tuning the time-allocation for the course content, so as to balance scope and depth 
of the learning materials; 
 Revisiting the selection criteria for participants. One respondent suggested devising 
beginners, intermediate, and advanced categories or levels for start-up phase, growth 
phase and already successful business participants, which seems like a workable idea. 
 Lastly, the participants expressed a need for the qualification to be graded specifically, 
so that it represents a signal to the market, e.g. potential investors, about the participant, 
e.g. active and committed participant, or spectator. This could be an important 
distinguishing factor in an environment where funds are scarce and investors risk 
averse. 
From the literature as well as our case study emerged a number of issues that policymakers and 
the relevant agencies and institutions should consider to determine the way forward for the 
development of the biotechnology sector and bio-entrepreneurship in particular: 
 A recurring theme is the question whether bio-entrepreneurship training should be 
incorporated in the undergraduate training of scientists, or added post-graduation; 
Related to the issue above, is the need to create awareness of biotechnology and the 
opportunities it holds for entrepreneurship at school, college and university level; Policy 
makers ought to consider whether in order to develop an awareness of biotechnology 
enterprise and biotechnology entrepreneurial spirit, such aspects should be incorporated 
into the school and college curriculum.  
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 Aspirant entrepreneurs are often faced with a lack of useful information and a scant 
network of resources, including skilled staff;  
The TIA could play a facilitating role in providing various informational services 
relating to promotion of entrepreneurship and acting as a network agency of the support 
system of academic institutions and Research & Development (R&D) organizations to 
foster entrepreneurship, and creating awareness among academics, government bodies 
and industry.  
 Although the National Biotechnology Strategy identified the need for a dedicated 
agency to champion the biotechnology sector, no such agencies exist; also not to 
promote bio-entrepreneurship. Aspects relevant to entrepreneurship policy can be found 
across a broad spectrum of ministries and agencies, ranging from education to trade and 
immigration (Audretsch, 2013). We recommend that the DST and TIA revisit the idea 
of a dedicated agency to champion biotech and manage the relevant activities to ensure 
coherence and efficiency in programmes designed to support the sector. 
The research conclude that the bio-entrepreneurship education ‘engineers’ at Cape Biotech had 
laid a solid foundation to build a bridge between science and business in the Western Cape, on 
which the rest of the structure can now be build.   
PART IV: EVOLUTION OF BIOTECHNOLOGY SPIN-OFFS-A MICRO VIEW 
 
This part of the thesis takes a micro view, tracking the evolution of biotechnology spin-offs 
from Western Cape universities, and highlighting the role that institutional changes played in 
the genesis, growth and, unfortunately, demise of some biotechnology spin-offs.  
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4. Where have all the university spin-offs gone? Turbulence in the biotechnology sub-
sector of the Western Cape RIS53 
 
4.1.Introduction 
Throughout this study, research has focused on the third role of universities in the RIS, i.e. their 
efforts to bridge the gap between science and market by means of technology transfer efforts. 
Over the course of the study, lasting several years, the research painstakingly put together a 
database of university spin-offs, and sought to understand the founders’ motivations for 
spinning off or licensing technologies, as well as the challenges faced by academic scientists 
venturing into the world of commerce. In this section the research is posing the question ‘what 
happened to the university spin-offs and start-ups since their inception?’, i.e. the research trace 
their trajectory from genesis to growth, or sadly, their demise. The research pursues this 
question with two broad notions in mind: 
a) The essential pillars that underpins growth in biotechnology spin-offs and start-ups 
(effective management, sufficient capital, and access to technology); 
b) The role of institutions and other actors in the RIS, aimed at supporting innovation. 
 
The research for this thesis was initially designed to complete the study with an investigation 
of the growth stories of the biotechnology spin-offs from the universities in the study. When it 
became evident that several of the firms targeted for this in-depth story, were no longer in 
existence, a more important question became ‘why did they fail?’. In the search for answers to 
this question, a tale of turbulence in the sector, and particularly in the environment in which 
they were to innovate and grow, emerged. Turbulence, in the literature on economics of 
                                                 
53 This section is submitted to a journal. Reference as follow; Jafta, R. and Uctu, R. (2014), “Turbulence in the 
biotechnology sub-sector of the Western Cape Regional Innovation System”, submitted to South African Journal 
of Science. 
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innovation, refers to entry and exit of firms in an industry or sector (Klepper, 1996; Malerba 
and Orsenigo, 1996; Bosma and Nieuwenhuijsen, 2000; Baptista and Karagoz, 2006). In 
general terms, turbulence also refers to discontinuities and changes that occur in the 
environment in which the firm operates, especially the institutions in the NIS or RIS that have 
or are supposed to have supportive linkages to the firms. We use the concept of turbulence here 
in both senses.  
  
The merit of this section lies in the fact that it draws together many of the useful insights from 
previous sections and the literature, and with the aid of the case studies, show how a complex 
series of internal (to the firms) and external factors (in the RIS) combined to lead to the failure 
of the biotechnology spin-offs. 
 
The rest of the section is structured as follows. After expanding on the three central 
requirements (the so-called ‘pillars’) for success in biotechnology commercialisation, the 
research proceed to the case studies, discussing the methodology and providing the broad 
information on the ten biotechnology firms that were initially targeted for in depth study, where 
after we present the case studies. The research derive lessons and policy implications in the 
discussion section and conclude in the last section. 
 
4.2.The Three Pillars of Successful Biotechnology Commercialisation  
According to the literature, there are three structural elements which are called the “three 
pillars” that are essential to gain success for a biotechnology start-up company: (i) effective 
management, (ii) sufficient capital and (iii) access to new technology that leads to products 
(Schoemaker and Schoemaker, 1998; Meyers and Hurley, 2008; Malazgirt, 2011). Effective 
management is not always a strong point for dedicated scientists who produce technologies. 
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Effectively bringing in the necessary know-how is essential to succeed. A start-up further needs 
access to good technology and associated patents in order to produce revenue. Finally, finding 
adequate capital is often a challenge for scientists who do not have a financial background 
(Malazgirt, 2011). This section describes how South African start-up companies (un)managed 
the three pillars. The following section gives brief information about each pillar. 
 
4.2.1. Effective Management 
Managerial talents are one of the most fundamental challenges and the weakest pillar in most 
biotechnology companies. R&D poses difficult managerial challenges because it is the most 
critical aspect of bringing a product to market and it is costly. Hence, biotechnology firms need 
a complex range of knowledge, skills and talents (Schoemaker and Schoemaker, 1998; Durai 
et al., 2006; Volery et al., 2007; Meyers and Hurley, 2008; Malazgirt, 2011). York et al. (2009) 
state that such a bio-entrepreneur should have cross-disciplinary knowledge and talents 
including marketing, the basics of Intellectual Property Rights (IPR), early-stage technology 
finance, and knowledge of scientific, regulatory and ethical issues. In addition to these 
requirements, bio-entrepreneurs should have special communication, emotional and social 
intelligence skills like self-awareness, self-control, and social awareness (Meyers and Hurley, 
2008). This feature, having technical and commercial skills, is mostly found in biotechnology 
companies where the biotechnology start-up companies have a dual decision team, with an 
executive manager (CEO) and a scientific manager (CSO) (Bureth et al., 2010). 
 
Researching the economic and commercial challenges in the development of a new product 
requires an entirely different set of skills from conducting research on technology and its 
applications. A successful management team must find a way to ensure that the scientific staffs 
are working on the one or two products that will ensure company success. Often, a scientific 
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group has a large set of potential products, but lacks the resources to exploit more than one or 
two commercially at any given time. Big pharmaceutical companies have the luxury of 
experimenting with many technologies and products to find that one blockbuster whereas the 
start-ups must be selective. Management is faced with the exciting, but difficult, task of being 
the bridge between the scientific and business sides of a company, and to decide which 
direction the entire company should take (Malazgirt, 2011). 
 
Finding appropriate talent is an international problem. A recent report describing the Singapore 
cluster, for example, noted that their biggest problem is its continued shortage of 
entrepreneurial scientists and managers (Meyers and Hurley, 2008). Volery et al. (2007) 
revealed in their research that Switzerland has several key challenges in management of young 
biotechnology companies, which include managing funding, planning strategies, marketing 
and sales, IP and administration. Nosella et al. (2006) gave another example from Italy. 
Managerial skills at university start-ups are mostly lacking in the scientific staff working at the 
university. Rutherford and Fulop (2006) found a similar lack of expertise in Australian 
biotechnology start-ups. The authors observed that business awareness of science is low and 
scientists lack the entrepreneurial skills to commercialise their research. To overcome these 
problems, Rutherford and Fulop (2006) and Nosella et al. (2006) suggested respectively to 
train and equip scientists with the necessary commercialisation and managerial skills and to 
get assistance from TTOs in terms of organisational and financial support. Nosella et al. (2006) 
suggested another solution that can solve the problem in Italy which is a joint scientific and 
managerial competency where the founders could be a team of both academic scientists and 
industry managers. 
 
4.2.2. Sufficient Capital  
148 
 
Capital forms the second pillar of any biotechnology company’s struggle, because the 
processes involved in developing a product in this field cannot be simply developed in an 
entrepreneur’s garage with a few friends, after hours. At the early stages, a biotechnology 
company can never have too much of this resource.  Biotechnology is capital intensive and in 
many cases requires huge amounts of funding for many years (Schoemaker and Schoemaker, 
1998; Durai et al., 2006; Volery et al., 2007; Malazgirt, 2011). According to some experts, it 
typically takes approximately US$1 billion, in addition to ten years of research and clinical 
trials, to release a drug to the international market. Over 200 new treatments and vaccines have 
run this gauntlet in recent years, including products to treat cancer, diabetes, AIDS, and other 
autoimmune disorders (Malazgirt, 2011). Therefore, bio-entrepreneurs must spend 
considerable energies on cultivating financial resources for their young companies 
(Schoemaker and Schoemaker, 1998). Konde (2012) echo this finding, stating that early stage 
biotechnology start-up investing is a resource-intensive business, where every entrepreneur 
needs to build partnerships with local and global investors, and with corporations and 
government entities, hoping to gain enough runway to validate their business model, create 
value and become cash flow positive, before they look for additional funding (Konde, 2012). 
 
This is a big problem in developing countries as well as developed countries. Byrd (2002) 
found that the major problem faced by Canadian biotechnology spin-off companies is access 
to the capital to develop the company. One of the biggest challenges faced by biotechnology 
start-ups in Singapore is getting sufficient funding to keep them going. In the high-risk early 
stage start-ups, companies mostly rely on angel investors (Thanabalasingam, 2012). This is 
also the case for India. The Indian biotech firms mainly rely on private equity (PE) and venture 
capital (VC) funds. In recent years, Indian start-up biotech companies have been left vulnerable 
by the decline in early stage funding, as private investors move to later-stage investment 
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strategies, due to the closed exit market and a lack of money to invest in new and risky projects 
(Konde, 2012). 
 
In both developed and developing countries, governments are the most important funders of 
the biotechnology sector. In South Africa, a developing country, government support is more 
important than private investments. Financing for biotechnology in South Africa is strongly 
government-led, with the BRICs (part of the TIA now) s instruments. However, compared to 
other countries, South Africa is still falling behind in this level of finance. The research returns 
to the South African situation in the case study analysis. 
 
4.2.3. Access to the Technology 
In the mid-1970s, the emergence of technologies based on recombinant DNA and monoclonal 
antibody breakthroughs, which evolved from the revolutionary work of scientific partnerships 
such as that of Cohen and Boyer, and Kohler and Milstein, established the foundations for the 
biotechnology industry. This is the third pillar upon which every company must be built. 
Today, most biotechnology companies still look first to university for sources of new 
technology. Universities provide a particularly fertile ground for harvesting such discoveries, 
the importance of which cannot be underestimated. The Bayh–Dole Act, and similar legislation 
that encourages academic institutions to license discoveries that emanate from federally 
(government) funded research, will most likely continue to fuel the biotechnology revolution 
(Schoemaker and Schoemaker, 1998). 
 
Every biotechnology company, from its inception, must have a well-defined and well-
articulated product focus. Whether directed toward a specific technology or toward a disease 
area, the company needs a clear vision of its basis for future revenues (Schoemaker and 
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Schoemaker, 1998). Biotechnology start-ups can only concentrate on one or two avenues of 
research, yet they are statistically no more successful than big pharmaceutical companies at 
developing a successful drug or other biotechnological process. According to current industry 
standards, approximately 8 out of 10 medicines will fail during clinical trials. For a 
biotechnology start-up, a 20% chance of success is a major hurdle. Larger companies can 
finance additional research with existing successful products, but it is difficult for a 
biotechnology start-up to stay afloat with other products (Malazgirt, 2011). The great challenge 
for any bio-entrepreneur in this time of ubiquitous opportunities is to maintain a rigorous focus 
on the chosen product and its underlying technology (Schoemaker and Schoemaker, 1998). 
 
Maintaining patents is another fundamental challenge for biotechnology start-up companies. 
The reason is that patents for a biotechnology process can be much more difficult to understand 
than patents in other fields (Malazgirt, 2011). 
 
Having explained the key requirements for successful biotechnology commercialisation, the 
research can now proceed to the empirical work, where the research will apply these insights 
in the South African cases. 
 
4.3.Case study: the evolution of biotechnology spin-offs and start-ups 
 
4.3.1. Methodology  
Following a literature survey and the initial survey on university spin-offs (Uctu and Jafta, 
2009), reported in Part II, the research ventured into the field to establish whether 
biotechnology spin-offs identified in the survey were still in existence, and whether new ones 
have been created since. This exploration resulted in ten biotechnology firms being identified, 
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two from the University of the Western Cape, four from the University of Cape Town and four 
from the University of Stellenbosch. 
 
For the purposes of these in-depth case studies, the research initially set the criteria that the 
companies should have been created after 2000 (to be comparable), must be active in 
biotechnology, and particularly in manufacturing, product development or research. The 
research therefore excluded service-type and consultancy firms (four) and one firm that was 
created in 1997 and closed down in 2007. Five companies fitted the criteria. However, when 
the research continued the investigation, the research found that more companies had gone 
under than survived. The more important question to pursue, became ‘why the failure?. Two 
of the companies that failed, were willing to participate in the in-depth interviews. One was 
from UCT and one from the University of Stellenbosch. To garner the perspective of the 
supporting agencies in the RIS, the research arranged and conducted interviews with senior 
staff at the universities’ technology transfer offices54 and the Technology Innovation Agency. 
The interviews yielded a considerable amount of information, which, as the research will show 
in our analysis, tell a tale of failure that hold important lessons for practitioners and policy 
makers. 
 
In the next section, the research elaborates on the company histories. The companies are coded 
Company A and B. 
 
4.3.2. Overview of biotechnology spin-off companies 
 
                                                 
54 Unfortunately, the TTO at UCT was only willing to confirm that Company B was no longer operational and 
the founder of the company refused to give any information beyond what is in the public domain. 
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4.3.2.1.Company A 
Company A, was a University of Stellenbosch spin-off company, which at the time of its 
establishment, represented and opportunity to realise the commercial potential by bringing to 
market the technologies developed, and capitalising on the research proficiency and extensive 
knowledge generated at the Institute of Wine Biotechnology(IWBT) at Stellenbosch University 
(Stellenbosch University, 2005, Rippenaar, 2006, Moore, 2008). This company was officially 
launched in 2005. It was a biotechnology-based start up with the aim of establishing a 
sustainable product and technology development process that would combine the research 
output and intellectual property generated by the IWBT with sound commercialisation and 
marketing practices (Stellenbosch University, 2005; Moore, 2008; Innovus, 2012; 
www.wynboer.co.za). 
 
To pursue this pioneering initiative, the IWBT appointed a team of five researchers to work 
solely on Company A projects, and a Project Manager to guide the commercialisation and 
business needs of the venture in 2005. The research staff members at the IWBT assisted the 
team, each contributing their expertise and knowledge to the Company A projects. There was 
a Project Leader who is a full Professor in a department at Stellenbosch University 
(Stellenbosch University, 2005).  
 
The company focused on the areas of genetic enhancement technologies, conventional 
development of unique yeast and bacterial strains, and development of quality control niche 
service offerings (chemical and microbiological) to the wine industry. Their projects were 
designed to generate a large number of hybrid and/or recombinant wine yeast strains. Research 
aimed, amongst others to develop yeast strains that are able to enrich wines with antioxidants 
and nutritional supplements. Company A also wanted make the fermentation process more 
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efficient through the production of yeast strains with enhanced levels of key fermentation 
enzymes, and reducing the reliance on sulphur dioxide during the fermentation process. 
(Stellenbosch University, 2005; Moore, 2008, Innovus, 2012; www.wynboer.co.za), these 
research and technology developments were believed to hold an important strategic advantage 
for the South African wine industry in the global market. Company A sought to actively 
commercialise the novel technologies at the IWBT, thus contributing towards the global 
competitiveness of the South African wine industry (Moore, 2008).  
 
To initiate the company, funding was obtained from Cape Biotech Initiative (CBI). The CBI 
was tasked with funding, promoting and supporting biotechnology activities in the Western 
Cape. The venture was in a three year project development phase after which it is envisaged 
that a private company will be incorporated, representing the commercialisation arm of the 
Institute for Wine Biotechnology (Stellenbosch University, 2005; Moore, 2008; 
www.agri.snowball.co.za, accessed in 2 November 2012; Innovus, 2012; 
www.wynboer.co.za). The details of the projects that Company A were working on, illustrate 
the potential they believed they could develop to bring to market: 
1. Wine Yeast Strains - Yeast plays a critical role in the production of wine, and determines 
many of the specific characteristics of the product. It not only conducts the fermentation 
process, turning grape sugars into alcohol and carbon dioxide, but also produces many 
aroma and flavour active metabolites. Company A planned to use both recombinant 
DNA technology and breeding and selection procedures to produce novel commercial 
yeast strains with clearly identifiable, marketable advantages. Many of the modified 
yeasts have already reached the proof of concept stage, which means that most scientific 
questions have been answered, but further development was necessary for the projects 
to become commercially viable. 
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2. Health and Wine - A change in consumer lifestyles has resulted in a renewed growth 
phase in the health and wellness product market world-wide. Consumers are demanding 
healthy, good tasting, convenient food and drink that is less processed, less preserved 
and more natural, to keep up with their fast-paced, 21st century lifestyles. With projects 
geared toward the low alcohol producing, and nutraceutical producing wine yeasts, 
Company A sought to cater for the unique needs of the discerning modern consumer. 
A regular glass of red wine is often suggested as part of a balanced, healthy eating plan. 
Antioxidants add to the health benefits of red wine and one of the compounds identified 
as contributing to this is resveratrol, found naturally in grape skins. Studies suggest that 
resveratrol reduces both the risk of heart disease and cancer. Company A intended 
producing yeast strains that increased levels of resveratrol, thus providing additional 
health benefits to the wine consumer. Another project at Company A was to develop 
yeasts that produce carnitine, a nutraceutical found mainly in meat and dairy products 
that help the body produce energy. The production of carnitine in wine would reduce 
the need for nutritional supplements, thereby allowing consumers to maintain a healthy 
diet, and enjoy a glass of good wine at the same time. 
3. Enzymes in Yeast - Enzymes important for winemaking either originate from the grape, 
the yeast, or are added during the fermentation process. Company A was attempting to 
improve the efficiency of this process, by manipulating wine yeasts to produce 
enhanced levels of certain enzymes that play an important role during fermentation. 
Ideally, this will translate into reduced input costs for the winemaker, with better control 
of the fermentation process, and ultimately an end product of higher quality. 
4. Wine Spoilage Organisms - The control of spoilage micro-organisms during wine 
fermentation is currently achieved with the use of chemical preservatives, such as 
sulphur dioxide (SO2). However, the excessive use of these chemical preservatives is 
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detrimental to the quality of the wine. Additionally, the wine industry is being 
confronted by mounting consumer resistance to the use of chemical preservatives such 
as SO2. This is reflected in the recent regulations introduced for wine exported to the 
European Union, which states that if the finished wine contains more than 10 
milligrams per litre of sulphur dioxide and sulphites expressed as SO2, it will have to 
carry a label stipulating this. In response to these trends, there has been interest in safe, 
food-grade preservatives of biological origin. Company A’s Bacteriocin Project aimed 
to target bacteriocins produced by lactic acid bacteria (LAB), for control of spoilage. 
This presents an alternative to the use of sulphur dioxide as an antibacterial ingredient, 
and the opportunity to reduce the reliance on SO2 during the fermentation process 
(www.wynboer.co.za). 
 
There was much hope that this company would be a successful example for future biotech spin-
offs. Scott (2007) reported that a California-based businesswoman noted that biotechnology 
start-ups could provide a critical kick-start to South Africa's economic growth as well as fight 
poverty. The example she gave referred to the fledgling Stellenbosch University company, 
Company A, which was one of fifteen Western Cape "baby biotechs" financially supported by 
the Cape Biotech Trust and designed to commercialise and utilise academic discoveries. 
Unfortunately, Company A was terminated in 2010. Some of its projects reverted to the IWBT 
and are pursued there.  
 
4.3.2.2.Company B 
Company B was created in 2006 by a PhD student who developed the technology at University 
of Cape Town. It was a start-up biotechnology company developing a 
production process for the manufacture and marketing of natural products derived from 
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microalgae. The objective of its project was to produce natural astaxanthin from microalgae 
for the local and international markets using closed system cultivation technology for better 
process control (www.fao.org). The astaxanthin project used technology developed at the 
University of Cape Town by the founder, who also received assistance the Professor who 
supervised his of the PhD research and heads the Centre for Bioprocess Engineering Research 
(CeBER) in the Department of Chemical Engineering at UCT. The research group at the 
university provided Company B with inocula (starter algal cultures), maintaining the algal 
culture to mitigate the risk of contamination at the Upington site, as well as providing routine 
analytical support (UCT Innovation, 2010). 
 
Astaxanthin is a valuable carotenoid pigment used in the aquaculture and animal feed industry 
and is gaining increasing status as a human nutritional supplement because of its antioxidant 
properties. The astaxanthin, which is produced by microalgae, is one of the most powerful 
antioxidants and is also found in certain fish and shell-fish species, giving them their distinctive 
pink colour. According to the report the algae are grown in small, shallow ponds for a short 
period. The algal strain has been derived from fresh water culture collections which has been 
adapted for commercial use. Once grown, the algae will be 'stressed' by changing the growth 
conditions which induces it to synthesize astaxanthin. Astaxanthin is produced by the cells as 
a secondary metabolite, which is only found in a specific cell state. The algal cells are then 
harvested and processed (www.fao.org, accessed 1 November 2012). 
 
The major market for astaxanthin is the aquaculture industry which provides feed for salmon 
(80%), trout (15%) and shrimp (3%). Other markets include the food and nutraceutical/ over 
the counter (OTC) market segments. Together these markets constitute about 2% of the global 
market value. Astaxanthin for the feed industry sells for between $2000-$3000 per kg, but is 
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considerably more costly for the OTC markets as this requires further processing of the crude 
product. Worldwide consumption of astaxanthin was about 170 tons per annum in 2008. Major 
consumers of astaxanthin include Europe (65%), Latin America (25%) and Asia (10). Natural 
astaxanthin for the OTC or nutraceutical market for human consumption is sold at a premium 
due to its associated health benefits (www.fao.org, accessed 1 November 2012). Ongoing 
research has proved that natural astaxanthin is effective against a number of health problems 
including age-related muscular degeneration, neurodegenerative diseases, cardiovascular 
diseases, cancer and blindness (www.fao.org, accessed 1 November 2012; www.biotech-
weblog.com, accessed 2 November 2012). 
 
Available funding for this project was used to further develop the technology and to establish 
a pilot production facility. Company B uses facilities in Upington for its manufacturing and 
piloting studies where the climatic conditions are favourable to algal growth. The location 
offers the best combination of maximal sunshine and light intensity coupled with minimal 
rainfall. The facility used both municipal and fresh river water in ponds cultivation system 
where nitrogen and carbon nutrients are added. The carbon source is carbon dioxide while the 
nitrogen source is nitrates. The waste water is recycled to recover nutrients and to reuse.  There 
was a plan for setting up an algal technologies platform at the pilot plant facilities in Upington 
where nascent algal companies can be accommodated. The market depends very much on the 
type of product e.g. astaxanthin market in South Africa is miniscule; hence most of the product 
was aimed at the export market. It was thought that Company B might act as primary algal 
products producers with onward distribution to established global formulation companies in 
Europe (www.fao.org, accessed 1 November 2012). 
 
Company B was incorporated in March 2006 after receiving funding of 3.8 million Rand 
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(~USD 600.000) from the Cape Biotech Trust, who funded the start-up operation, linking in 
with their other algal initiatives in Upington (UCT Innovation, 2010; www.fao.org, accessed 1 
November 2012). Company B was in a three year development phase from 2006 to 2009. After 
this phase a full scale plant capable of producing up to 2 tons of 100% astaxanthin were to be 
established. Company B was then in need of a second round of funding to progress to full scale 
production. (www.fao.org, accessed 1 November 2012). Not succeeding in acquiring the 
needed funds, the company was terminated in 2011. 
 
4.4.Anatomy of failure in biotechnology spin-offs: an internal and external environment 
perspective 
Using the insights from the literature discussed earlier in the section and the information 
garnered from the interviews, the research tabulate the factors linked to the failure by the 
interviewees in Tables 4.1 and 4.2. This allows to systematically identifying similarities and 
differences in the reasons for failure advanced from the different perspectives. 
 
Table 4.1: Reasons for termination from different perspectives 
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COMPANY A 
Firm perspective 
 Managerial skills Sufficient capital Technology Others 
Lack of knowledge and 
communication 
- - - O 
Funding - O - - 
New mandate in TIA - - - O 
TTO Perspective 
New mandate in TIA - - - O 
Technology was too far from the 
market   
- - O - 
Unclear market O - O - 
Timing O O - O 
Uncertainty in Company O - - - 
Having no leader O - - - 
Conservative market - - O - 
Expectations - - - O 
Freedom - - - O 
Not having a sustainable business 
plan 
O - - - 
TIA perspective 
Having no leader O - - - 
Having no commercial products - - O - 
Technology was too far from the 
market 
- - O - 
Unclear market O - O - 
Business model O - - - 
Expectations - - - O 
R&D driven O - - - 
COMPANY B 
TIA perspective 
No managerial and technical 
(engineering) skills 
O - - - 
Source: Authors’ own construction, 2012 
 
The research group the relevant factors for analytical purposes in terms of internal (firm-
specific) factors and external (relating to the environment in which they operated, and 
specifically to the relevant institutions or organizations in the NIS and RIS respectively). 
 
4.4.1. Firm specific factors 
 
4.4.1.1. Managerial skills and leadership 
Out of the three interviews conducted for Company A, only the TTO representative and the 
senior staff member at the TIA identified managerial factors as contributing to the demise of 
the company. According to the senior member of staff of the Company A the managers’ skills 
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were not such a big problem, because the early challenges were of a scientific and technological 
nature. She believes the need for business and financial skills would only become critical once 
the firm became a fully-fledged company. She stated that the company had created a pleasant 
and healthy working environment where the team, including the founders worked well 
together. The only hiccup was the fact that they had lost a project manager to another company 
and had difficulties finding another one. According to senior staff member at Innovus, the TTO 
at Stellenbosch University, the company did not have a CEO or a clear leader to take the 
projects further and this resulted in instability and uncertainty. That the company did not have 
feasible business plan and disagreed with the funder about it, also complicated matters (more 
on this below). According to the senior staff member interviewed at the TIA, the right person, 
with the right leadership and managerial skills, especially to drive the commercialisation and 
‘hunt money’, rather than research output, would have made all the difference. In the 
interviewee’s mind, the business model of chasing revenue from licensing, rather than further 
commercialisation was not the right one. The company already had something to 
commercialise, but the focus was too much on R & D, and not commercial products. 
 
The same interviewee also asserted that Company B failed because it had no managerial and 
technical (engineering) skills. 
 
4.4.1.2. Insufficient capital 
Both companies had funding from the Cape Biotech trust to fund start-up and development 
costs, but in both instances they were not able to muster enough funding to scale up operations 
to produce marketable products. From the firm’s perspectives, the trouble started when the TIA 
absorbed Cape Biotech in 2010, with resultant uncertainty and changes (staff turnover, loss of 
key contacts in Cape Biotech), new business plan investigations and viability studies. The end 
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result was that the TIA concluded that the Company did not fit their mission, and funding was 
terminated. The Innovus representative lamented the timing of this upheaval: “Company A 
needed about four more months of funding to get the desired results that would generate 
income, but the TIA decided to terminate the venture in November 2010. If they could just 
have continued for another season, they could have had wonderful results.” The TIA 
representative’s view was that there were expectations that the company should have 
commercialized some output from the project by year 3. The TIA position was clear: 
commercialise or the funding would be stopped. Commercialisation was not forthcoming, so 
the funding stopped. Company B had, according to the TIA representative ‘ a brilliant product, 
for which they had funding, but they could not take the project to the next level, i.e. scale it up, 
and therefore the TIA decided to terminate the company. 
 
4.4.1.3. Technology 
For both companies, the nature of the technologies they were trying to turn into marketable 
products, were such as to require a long lead time and many resources to bring the projects 
from production in pilot plants to production for large markets. According to the TTO 
representative as well as the TIA representative, the technology from Company A were still 
too far from being market ready, and for this reason, it was also unclear precisely which market 
to target to achieve the best pay-off. 
 
4.4.1.4. Market-related factors 
Both the TTO and TIA representatives identified market-related factors as problematic. Apart 
from emphasizing the fact that it was not yet possible to target a market for  products that are 
still too far from market-ready (discussed above), the Innovus interviewee also mentioned that 
the market that Company A chose (wine producers) are still fairly conservative and not likely 
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to adopt genetically modified products. In fact only America and Canada allow genetically 
modified wines to be sold. 
 
4.4.2. External (NIS, RIS) factors 
Most of the factors in this section have to do with the impact of changes in the institutions 
supporting the development of the biotechnology sector, and specifically the changes brought 
by the establishment of the Technology  Innovation Agency (a national body) in 2010 and the 
absorption of Cape Biotech (a regional body) into the TIA. 
 
4.4.2.1. Knowledge and communication gaps 
When the TIA took over, much uncertainty was created, with paralyzing effects. The company 
interviewee opined “the people appointed to the TIA did not know what was going on and their 
communication was terrible.” Almost a year elapsed before they were informed that their 
funding was terminated. 
 
4.4.2.2. Discontinuities: from Cape Biotech to TIA 
The TTO representative stated that the creation of the TIA resulted in a period of chaos, shifting 
the focus and mandate from a regional one under Cape Biotech to a national one under the TIA. 
Also, whereas Cape Biotech understood that biotechnology has a very long lead time before 
significant revenue is generated; the mind-set of the TIA was one that preferred funding 
companies with products and technologies close to market ready. This is an unfortunate 
development, in the face of the persistent refrain in the empirical literature and earlier research 
reported in section 2 and 3, about the long and costly development paths in biotechnology and 
the lack of venture capital markets in developing economies. On this latter point the research 
elaborate in the next section. 
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4.4.2.3. Funding sources in the innovation system 
The interviewees indicated that try as they might, the management teams at the biotech start-
ups under discussion here, could not garner the necessary funds to ensure their survival. Private 
financing for biotechnology remains severely limited in South Africa. The problem in South 
Africa is the lack of finance available for seed and start-up companies, the bulk of the capital 
going into replacement capital, such as management buy-outs and black economic 
empowerment transactions (Sherwin, 2007). Biotechnology companies usually run through 
multiple rounds of funding in order to achieve maturity. In the USA and European countries 
there can be as many as six rounds of venture capital funding before a company is self-
sustaining or lists on a stock exchange. In South Africa, several fledgling biotechnology 
companies have received two to three rounds of financing but are facing the 'valley of death' 
with no means of support (Sherwin, 2007; Al-Bader, 2009).  Government funds for the 
biotechnology industry are limited, and South Africa's investment community is immature in 
biotechnology, with having only one VC in biotechnology55. Without a change in this funding 
picture, the efforts that the government has made so far in stimulating biotechnology will be 
threatened (Al-Bader, 2009). In addition to the above explanations, Sherwin (2007) adds note 
that both the South African government and the private sector need to be realistic about the 
time frames and the amount of capital that required developing the biotechnology. According 
to her, this is not a three to a five year commitment, but a ten to a twenty year commitment at 
least. 
 
                                                 
55
 Only private biotechnology Venture Capital was dormant in 2010 due to investing in their whole portfolio 
(information received through interview with a manager at the TIA, 7 November 2012). The Biotech VC firm 
raised a size of R80 million funds in 2001. By the time in May 2010 company invested R76 million in to total 
number of 8 private equity/venture capital investments and current portfolio size was 3 
(www.accessmylibrary.com, accessed 09 November 2012).  
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4.4.2.4. Timing of interventions 
According to the interviewees at Company A and the TTO, the timing of the TIA interventions 
were very unfortunate. They believe that, if allowed to continue to work normally (absent the 
interruptions by TIA officials) and if they had funding for a few more months, they would have 
been able to deliver on commercialisation. 
 
Table 4.2: Firm-specific, NIS and RIS explanations for biotechnology spin-off failure 
 
COMPANY A 
 Firms RIS Institutions/Organisations 
Firm perspective 
Lack of knowledge and communication - O 
Funding - O 
New mandate in TIA - O 
TTO Perspective 
New mandate in TIA - O 
Technology was too far from the market   O - 
Unclear market O - 
Timing O O 
Uncertainty in Company O - 
Having no leader O - 
Conservative market O - 
Expectations - O 
Freedom - O 
Not having a sustainable business plan O - 
TIA perspective 
Having no leader O - 
Having no commercial products O - 
Technology was too far from the market O - 
Unclear market O - 
Business model O - 
Expectations - O 
R&D driven O - 
COMPANY B 
TIA perspective 
No managerial and technical (engineering) 
skills 
Limited scalability 
O 
 
O 
- 
 
- 
 Source: Authors’ own construction, 2012 
 
4.4.2.5. Expectations and business perspective of funder 
Insights from the TTO interviewee suggest that even before the discontinuity created by the 
takeover of Cape Biotech by the TIA, Company A and the former were at odds over the 
appropriate business plan for the company. She observes that Company A did not seem to have 
the freedom to choose their business model or the line of products that they wanted to pursue. 
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When the funder and the beneficiary are at odds, end goals are complicated and the desired 
outcomes are not clear. It may result in expectations not being met. 
 
In sum, these factors confirm the main obstacles that biotechnology start-ups face, as identified 
in the literature and our research for this thesis. The results further point to useful insights 
regarding the NIS and RIS. 
 
RIS structure in Figure 1 (see Part I earlier in this study; Cooke, 2002a) draws the main features 
and relationships of a functioning regional innovation system. But it only shows the linkages 
in a neutral way. To capture the variety of degrees of influence and decision-making authority, 
the presence or absence, or weaker and stronger relationships amongst the diverse possible 
kinds of application, exploitation, generation and diffusion elements of specific regions and 
their degrees of “systemness” (Cooke, 2002b: 137), one needs to investigate the interactions 
amongst the constituent parts of the system. Although the research have only focused here on 
biotechnology firms and certain institutions in the RIS, the research have learned plenty about 
the weak points and potential weak pints in the system. The research highlights the implications 
of these in the conclusion. 
 
 
 
4.5. Conclusion 
 In this last part of the study, the research wanted to trace the growth paths of the biotechnology 
companies that spun off from universities in the Western Cape RIS. The research efforts to find 
the spin-offs that were still active in the biotechnology sector, made it clear that a more relevant 
question to ask, would be ‘why do they fail?’ rather than ‘how did they succeed?’. 
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With the aid of the three pillars of successful biotechnology commercialisation from the 
literature, and the information on the case study companies, gathered from interviews with 
company, TTO and TIA representatives, the research constructed two sets of factors that led to 
the demise of these firms. These were the internal, or firm-specific factors, and external or 
NIS/RIS related factors. 
 
The research findings on the firm-specific factors underscore the importance a diverse set of 
managerial skills, discussed here, and in particular in the section on bio-entrepreneurship 
training. This is an important message for several players in the NIS and RIS, for example 
educational and training institutions, agencies such as the TIA that must play a supporting role, 
Technology Transfer Offices, some of which operate training programmes and incubators for 
biotechnology entrepreneurs. 
 
With respect to the factors related to the RIS and NIS, the following stand out: 
 The imperative to mindful of disruptive effects in the very sector or system that an 
institutional change is supposed to assist and support. In the case of Cape Biotech and 
the TIA, the change was clearly turbulent and competence and capacity destroying, 
rather than enhancing.  
 Funding for seed and start-up capital is consistently identified as an obstacle to growth 
in a promising sector of the economy. The nature of the technology and the longer-term 
investment horizon required makes the sector unattractive for investors with a shorter 
term perspective. It would now seem that the government agency tasked with promoting 
growth in the biotechnology sector has adopted the latter view. In addition, the venture 
capital market in South Africa is underdeveloped and resources scarce. Until this aspect 
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of the innovation system is addressed more effectively, firm formation and innovation 
in the sector may continue to remain under its potential level. 
  
5. CONCLUSION AND RECOMMENDATIONS 
The aim of this study was to apprehend how the regional innovation system in the Western 
Cape region was reconstructed, in order to allow for the evolution of the biotechnology sector 
in the region. Various institutions and organisations played a crucial role in affecting these 
changes. One of the most important changes involved legislation that altered the role that 
universities play in bridging the gap between research outputs and reaping commercial benefits 
from such outputs. Following the logic of the regional innovation system, the study focused on 
the institutional changes, the mechanisms employed to bridge this gap (from creating spin-off 
firms, and licensing technologies based on university research, to designing programmes that 
support the development of bio-entrepreneurs).  
 
When embarking on the reconstruction of the NIS or RIS, the initiators of the change 
presumably believe that the altered system will be better than the status quo. The NIS and RIS 
literature emphasize the importance of effective linkages amongst the actors in the system. 
Deviating from the standpoint that firms are the units that bring innovations to the market, 
alterations to the innovation system require an understanding of the  incentives and motives 
that lead to firm formation, the obstacles young firms encounter, and the factors that enhance 
or impede the growth of new firms. In South Africa several changes were enacted to support 
the development and growth of the biotechnology sector which is a relatively young, but 
promising sector in the economy. The most important changes observed were: 
 The National Biotechnology Strategy (2001) at NIS level; 
 The creation of the BRICS (2002) at RIS level; 
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 Intellectual Property from Publicly Financed Research and Development Act (2008), 
which altered the roles of universities, enabling universities and inventors to benefit 
from publicly funded research and creating technology transfer offices; [national level 
change; affecting regions] 
 The creation of the Technology Innovation Agency (2009/10), subsuming the BRICS. 
[National level]. 
 
This study focused on the outcome of these changes in a sub-sector of the Western Cape RIS, 
namely biotechnology. Six research questions (two main and four sub-questions) were 
presented, where all of them are relating to the aim of the thesis, namely:  
 What should be the alternative ways of developing a favourable environment for 
regional biotechnology concentration to emerge and develop in the knowledge-based 
economy? 
 What were the key mechanisms used to bring the output of scientists to market, 
i.e. spinning off or licensing technologies? 
 What motivated academics to create spin-offs or license their technologies and 
what were the main obstacles that they have encountered? 
 How effective was the first attempts at building a bridge between science and 
the market through bio-entrepreneurship training in the region? 
 What happened to the biotechnology spin-offs and start-ups over time, and what 
effect did the changes in the institutional and policy environment have on their 
growth or demise?  
 What are the strong and weak points to promote a biotechnology innovation system in 
Western Cape region? 
 
169 
 
Some conclusions with regards to each of these research questions mentioned are presented in 
the following sections. 
 
Since all the efforts to effect the changes to the RIS that would enhance the growth of a 
promising industry are relatively new, the study faced the usual problems associated with 
pioneering developments, such as small samples, a complete lack of databases, etc. For this 
reason, the questionnaire survey and case study methods were used throughout the study. A 
caveat is therefore sounded throughout, that because of the small samples, the results must be 
interpreted with care and generalisations cannot be made. The study, however, makes a 
significant contribution in the insights that it yields in a number of areas where the literature 
on spin-offs, biotechnology and bio-entrepreneurship training in developing countries is still 
sparse. The most important findings for the individual parts are summarised below and 
implications for policy makers and practitioners derived. 
 
6.1. The Contributions of this thesis and its findings 
In this section, an attempt is made to draw up the results of the thesis in order to gain the essence 
of the many lessons that have been learned during the duration of the study. In terms of the 
overall research design and the specific contribution that each of the five papers make, the 
limitations of this thesis have already been discussed. However, to what extent can more 
general conclusions be drawn from the thesis as a whole? What is the reach of these 
conclusions? As a matter of degree, the conclusions drawn in the following case study are those 
relating to the nature of innovation processes; 
 
Contributions 1: The study was confined to knowledge and technology transfers from the 
university to the market irrespective of whether they received university support or not. 
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Specifically, the thesis presented an understanding of the spin-off phenomena e.g. historical 
status, characteristics of spin-offs (including motivations behind certain creations, relationships 
with universities, obstacles they faced, etc.) from Western Cape universities in South Africa 
and identifying the biotechnology spin-offs from universities. From this contribution flow the 
following insights that are valuable to inform further research: 
 
Findings 1a: The research contributes to a practical definition of a spin-off company in the 
South African context as “A new firm created to exploit some knowledge, technology or 
research results conducted at the university by faculty members or students who receive (any 
kind) of support from the university (the TTO); a new firm created around a university license 
of intellectual property (founders may be or may not be from university); a firm created by the 
university itself (wholly university-owned)”. 
 
Findings 1b: Different interpretations of the definition of a spin-off firm exist in the minds of 
the founders themselves, as well as the people involved in the technology transfer process. This 
implies that researchers have to be very precise in how they define a spin-off and communicate 
this clearly to the respondents. 
 
Findings 1c: Universities keep records of spin-offs, but these records do not seem to be 
updated, i.e. the universities do not closely track the progress of their spin-offs (except in the 
cases where they have equity). After the field excursion, research revealed that some of the 
spin-offs do not exist anymore, and others were discovered that do not appear on the lists. 
 
Findings 1d: In this thesis one of the main findings was that progress is slow in the creation of 
spin-off companies at universities, specifically, in biotechnology industry as a tool to increase 
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the knowledge transfer from universities. It was therefore important to understand why 
scientists, who are in a position to spin off, opted not to. One of the main reasons for 
researchers’ decisions not to create a company, but to license their technologies, is the 
challenge of finding funding, which still plays a significant role in creating spin-offs. 
Furthermore, those, who did create spin-offs, were motivated by the desire to put knowledge 
to practical use. This motivation bodes well for a country sorely in need of innovations that 
will address socio-economic challenges and spur economic growth. 
 
Contributions 2: There is an increasing trend towards spin-off companies in Asia as well, 
although only a small number of studies have so far dealt with biotechnology spin-offs from 
universities in Hong Kong as latecomer in biotechnology. One of the merits of this study, 
however, lies in the fact that it focused on university spin-offs in biotechnology in order to 
understand the dynamics and influence of this phenomenon as knowledge transfer process in 
biotechnology in Hong Kong. The study analyzed the local activity as an important step 
towards understanding the emerging biotechnology industry in latecomers. This study yielded 
the following insights: 
 
Findings 2a: that there is an increasing awareness of academic entrepreneurship in the form 
of creating university spin-offs in Hong Kong, but not yet for the biotechnology sector, where 
spin-offs are relatively few. 
 
Findings 2b: this study also contributed to refining the definition of biotechnology spin-offs, 
where it was evident that some companies clearly fitted the textbook definition but some others 
were more complex and required an expanded definition.   
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Findings 2c: This study contributed to the understanding of the rationale for and the nature of 
biotechnology spin-offs from Hong Kong universities.  
 
Contributions 3: Empirical literature on bio-entrepreneurship training in developing countries 
is still sparse. Thus, this study is novel as it assessed the first structured attempts in South Africa 
to equip bio-entrepreneurs with the skills necessary to build a bridge between the science of 
biotechnology and the commercialisation of knowledge and ideas in this field.  Through this 
assessment, the following insights emerged: 
 
Findings 3a: Like other countries, South Africa also faces a shortage of entrepreneurial skills 
that would bridge the gap between science outputs and marketable bio-products. The 
effectiveness of the first programme in terms of the number of enterprises created following 
the training; do not show a rapid progression. However, a beam of light is the relative success 
achieved with the development and implementation of a bio-entrepreneurship training 
programme, when measured against its own objectives and the expectations of the participants. 
This positive outcome laid the foundation to build a more sustainable bridge between the 
science of biotechnology and the commercial world where the wealth creation opportunities 
reside. 
 
Contributions 4: One of the merits of this part of the study lies in the fact that it draws together 
many of the advantageous insights from previous papers and the literature, and with the aid of 
the case studies, it shows how a complex series of internal (to the firms) and external factors 
(in the national and regional innovation systems) combined to lead to the failure of the 
biotechnology spin-offs. 
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With the aid of the three pillars of successful biotechnology commercialisation from the 
literature, and the information on the case study companies, gathered from interviews with the 
company, TTO and TIA representatives, two sets of factors that led to the demise of these firms 
were identified. These were the internal, or firm-specific factors, and external or NIS/RIS 
related factors. 
 
Findings 4a: Findings on the firm-specific factors underscore the importance of a diverse set 
of managerial skills, discussed here. This is an important message for several players in the 
NIS and RIS, for example educational and training institutions, agencies such as the TIA that 
must play a supporting role, and Technology Transfer Offices, some of which operate training 
programmes and incubators for biotechnology entrepreneurs.  
 
Findings 4b: With respect to the factors related to the RIS and NIS, the following stand out: 
 The imperative to be mindful of disruptive effects in the very sector or system that an 
institutional change is supposed to assist and support. In the case of Cape Biotech and 
the TIA, the change was clearly turbulent and competence and capacity destroying, 
rather than enhancing.  
 Funding for seed and start-up capital is consistently identified as an obstacle to growth 
in a promising sector of the economy. The nature of the technology and the longer-term 
investment horizon required make the sector unattractive for investors with a shorter 
term perspective. It would now seem that the government agency tasked with promoting 
growth in the biotechnology sector has adopted the latter view. In addition, the venture 
capital market in South Africa is underdeveloped and resources scarce. Until this aspect 
of the innovation system is addressed more effectively, firm formation and innovation 
in the sector may continue to remain under its potential level. 
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6.2. Recommendations 
Recommendations 1: The literature has shown that university systems differ across countries. 
The primary goal of universities usually lies in conducting scientific research and educating 
students. Over time, a third function has been added that today generates much interest: since 
the enactment of the Bayh-Dole Act in the United States of America (US) in 1980, the 
promotion and commercialisation of universities’ research results has been a focus of attention. 
In other words, transfer of technologies arising from university research, to industry, through 
patenting, licensing and creating companies, has come to be seen as a third function. 
Intellectual Property from Publicly Financed Research and Development Act (2008) has been 
created which modified the roles of universities, enabling universities and inventors to benefit 
from publicly funded research and creating technology transfer offices. However, in this study, 
findings on spin-off creation suggest that policy-makers and university management should 
reconsider the resources in terms of capabilities (amongst university management, technology 
transfer staff and scientists) and funding that are necessary for successful technology transfer 
and sustainable venture creation through spin-offs.  
 
This implies that universities need to adopt a strategic approach regarding knowledge and 
technology transfer. While they make choices concerning institutional goals and priorities, 
resource allocation, technological emphasis, patent strategies and modes of technology 
transfer, they can choose a mixture of licensing, spin-offs creation, sponsored research and 
other mechanisms for knowledge and technology transfer. However, universities should bear 
in mind that a spin-off strategy requires different resources and capabilities from those required 
for licensing and sponsored research activities (Mustar et al., 2008). 
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Recommendations 3: In South Africa, the survival rate of the spin-offs from universities is 
very low. Thus, universities and policymakers should consider strategies to improve this 
outcome. The literature on university spin-offs suggests some interventions such as incubators 
in universities to support those early-stage companies. 
 
Recommendations 4: Universities should update records of spin-offs and track the progress of 
their spin-offs. Some of the spin-offs do not exist anymore, and others were discovered that do 
not appear on the lists. For future studies, the research recommend that they publish their 
history of spin-offs creation. But, more importantly, for their own effectiveness, TTOs need to 
document and update technology transfer activities, including spin-offs. 
 
Recommendations 5: Prior to raising commercial interest, universities need to be aware in 
developing effective IP and patent strategies.  In addition TTOs need to ensure that IP is clean, 
well-defined and protected.  Therefore, the IP and patent strategy should consider what 
technology is proprietary to the department, which is licensed on an exclusive base and which 
parts are licensed on a non-exclusive basis (Mustar et al., 2008). Uncertainty in this regard may 
act as deterrent to technology transfer activity on the part of successful scientists. 
 
Recommendations 6: If so desired, universities should introduce programmes to stimulate 
academics to start spin-offs; the structure through which most universities operate creates 
constraints since career progression typically still depends largely upon the evaluation of a 
scientist’s academic output. There is a great need for the adaptation of promotion and 
remuneration systems both at a systemic level and within universities, so that 
commercialisation activities are valued (Mustar et al., 2008). 
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If the universities are more flexible on academic’s position at university, more scientists might 
consider spin-offs. Some scientist who have output that could be commercialised may be 
hesitant to spin off, because it might force them to leave academia. A flexible hybrid position 
may enable the university to gain the best of both worlds, i.e. first-hand experience from the 
business world and the retention of good scientists.  
 
Recommendations 7: Government should assess existing policies and their effectiveness of 
bridging the financial and knowledge gaps. In order to achieve this concept, the support for 
academic spin-off firms may play a larger role regarding knowledge transfer policy, which its 
sole purpose is to develop the transfer of knowledge between universities, business, and the 
society that constitutes third-stream activities of universities. The aim of the policy in concern 
should be concentrated on filling both the financial and knowledge gaps based on the notion of 
addressing market failure (Mustar et al., 2008). 
 
Recommendations 8: Government need to create awareness of biotechnology and the 
opportunities it holds for entrepreneurship at school, college and university level. Policy-
makers should consider whether, in order to develop an awareness of biotechnology enterprise 
and biotechnology entrepreneurial spirit, such aspects should be incorporated into the school 
and college curricula. 
 
Recommendations 9: Although the National Biotechnology Strategy identified the need for a 
dedicated agency to champion the biotechnology sector, no such agencies exist. Neither is there 
one to promote bio-entrepreneurship. Aspects relevant to entrepreneurship policy can be found 
across a broad spectrum of ministries and agencies, ranging from education to trade and 
immigration (Audretsch 2013). The research recommends that the DST and TIA revisit the 
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idea of a dedicated agency to champion biotechnology and manage the relevant activities to 
ensure coherence and efficiency in programmes designed to support the sector. 
 
Recommendations 10: An institutional change is supposed to assist and support in national 
and/or regional level. In the case of Cape Biotech (regional level) and the TIA (national level), 
the change was clearly turbulent and competence and capacity destroying, rather than 
enhancing. The research strongly recommends that the DST should revisit the idea of changing 
support system and reorganise for the innovative sectors, e.g. biotechnology. 
 
From this study, bearing in mind the small scale and the danger of generalisations, it would 
seem as if the reconstruction of the RIS and related changes in the NIS did not generate the 
results that the strategy hoped for (at least in the Western Cape, the focus of this study). A beam 
of light is the relative success achieved with the development and implementation of a bio-
entrepreneurship training programme, which laid the foundation to build a more sustainable 
bridge between the science of biotechnology and the commercial world where the wealth 
creation opportunities reside. 
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APPENDIX 
 
Appendix A: Questionnaire for Technology Transfer Offices at Hong Kong Universities 
 
RESEARCH SURVEY: UNIVERSITY SPIN-OFF COMPANIES IN HONG KONG 
The aim of this study is to analyse the biotechnology university spin-off companies in Hong Kong. 
These questions are sent to Technology Transfer Offices at the Chinese University of Hong Kong, Hong 
Kong Polytechnic University, University of Hong Kong, Hong Kong University of Science and 
Technology and City University of Hong Kong. All information gathered by this survey will be held in 
the confidential. 
 
PLEASE MARK APPROPRIATE FIELDS WITH AN “X” 
 
LEAVE ALL NON APPLICABLE FIELDS BLANK 
 
PART A 
 
Technology Transfer Office Particulars 
 
 
A1 University name: 
                    
A2 Official TTO name: _______________________________________________________ 
 
A3 Year of TTO’s foundation: _________________________________________________ 
 
A4 Date of filling in: _________________________________________________________ 
 
A5 Director: ________________________________________________________________ 
 
A6 Contact person(s): ________________________________________________________ 
 
A7 Address: ________________________________________________________________ 
 
  ________________________________________________________________ 
 
  ________________________________________________________________    
 
CUHK  PolyU  HKU  HKUST  CityU  
206 
 
A8 Telephone/Fax: ___________________________________________________________         
 
A9 Website: ________________________________________________________________ 
 
A10 Email: _________________________________________________________________ 
A11 How many staff works in TTO? _____________________________________________ 
 
A12 How many of them are full time staffs? _______________________________________ 
 
Department 
 
 
   
No of staff     
 
A13 How many of them are part time staffs? _______________________________________ 
 
Department 
 
 
   
No of staff     
 
PART B 
 
Spin-Off History 
 
B1 Are there any spin-off companies/ joint ventures in your university?  
 
If YES continue, if NO please go to QB4 
 
 
B2 How many spin-offs/joint ventures (JV) are in the following sectors? 
 Spin-off JV 
 Biotechnology    
 Chinese Medicines   
 Information and Technology & Telecommunications   
 Precision Engineering   
 Electronics   
 Nanotechnology   
 Green Technology   
Yes  
No  
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 Professional Services   
 Others 
Please specify……………………………… 
  
TOTAL:    
 
If there are biotechnology spin-off companies/ joint ventures, please continue. Otherwise, 
please go to QB4 
 
B3 Biotechnology spin-off companies/ joint ventures details: 
Name of the company  
Nature of the company  
Contact person (s)  
Tel  
Email  
Web page  
Address 
 
 
 
Name of the company  
Nature of the company  
Contact person (s)  
Tel  
Email  
Web page  
Address 
 
 
 
 
 
 
Name of the company  
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B4 What 
is your 
TTO’s 
object? 
 ___________________________________________________________________________
___________________________________________________________________________
__________________________________________________________________ 
 
B5 To what extent do you think your office achieved the objectives? 
 ___________________________________________________________________________
___________________________________________________________________________
__________________________________________________________________ 
 
Thank you for your participation! 
 
Appendix B: Biotechnology Spinoffs Questionnaire for Hong Kong Universities 
 
RESEARCH SURVEY: BIOTECHNOLOGY SPIN-OFF COMPANIES 
The aim of this study is to analyse the biotechnology university spin-off companies in Hong Kong. 
These questions are sent to the companies that spun off from the Universities in Hong Kong. All 
information gathered by this survey will be held confidential. 
 
PLEASE MARK APPROPRIATE FIELDS WITH AN “X” 
 
LEAVE ALL NON APPLICABLE FIELDS BLANK 
       Date: _______________      
Fill in by: ________________ 
PART A 
 
Name of the company  
Nature of the company  
Contact person (s)  
Tel  
Email  
Web page  
Address 
 
 
Nature of the company  
Contact person (s)  
Tel  
Email  
Web page  
Address 
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Company Particulars 
 
A1 Spun-off from: 
                    
A2 Official company name:  
 
A3 Year of Start-up:  
 
A4 Year of foundation:  
 
A5 Director:  
 
A6 Address:  
 
A7 Telephone/Fax:  
 
A8   Email: 
 
A9   Website:  
 
A10   Company’s turnover (million HK$ in 2008): 
 
 
 
 
 
 
 
 
 
A11   Company’s classification by type of activity: 
 
 
 
A12   Which sector does the company belong to? 
 
CUHK  PolyU  HKU  HKUST  CityU  
<3  
4-10  
11-50  
51-100  
101-300  
301-500  
>501  
Manufacturing-type Company  
Service-type Company  
Consultancy-type Company  
Research-type Company  
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Biotechnology   
Chinese Medicine  
Information Technology & Telecommunications  
Precision Engineering  
Electronics  
Nanotechnology  
Green Technology  
Professional Services  
Others 
Please specify___________________________ 
 
 
 
A13    What is the nature of company’s business? 
 _________________________________________________________________ 
 
PART B 
 
Company’s History 
 
B1 Number of Founder(s): 
a.  1 
b.  2-3 
c.  4-5 
d.  6-10 
e.   >10                                                                    
 
B2 Founder(s)’ original affiliation (fill in number): 
 
a.  University    
b.  Government research centre 
c.  University and Government research centre 
d.  University and industry 
e.  Government research centre and Industry 
f.   Industry                                           
 
B3  Where is the company’s market at start-up? (You can choose more than one region) 
Product-development Company  
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a. Hong Kong         
b. China 
c. South East Asia 
d. Other(s)  
     Please specify: ________________________ 
 
       B4 How important are the following motivations at start-up? 
 
1: Not important 2: Slightly important 3:  Neutral   4: Important 5: Most important 
 
  1 2 3 4 5 
Identification of market opportunities      
Complete the projects      
Apply knowledge into practical applications      
Profit making      
Fully utilise existing knowledge      
Aversion for bureaucracy and low risk orientation of the research 
environment 
     
Personal success      
To be independent      
Other factors      
 
Current Situation 
 
C1  Where is the company’s current market ? (You can choose more then one region) 
 
a. Hong Kong        
b. China 
c. South East Asia 
d. Others (Please specify) 
 
Current number of 
C2  Senior scientists:                                                      
C3  Post-doctoral assistants: 
C4  Research students (masters/PhD students): 
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C5  Technicians:  
C6  Administrative personnel:  
C7  Marketing and sales’ staff: 
C8  Total staff: 
 
C9  Major areas of research in which the company is actively involved: 
 
a. ______________________________________________________________________ 
 
b. ______________________________________________________________________ 
 
c. ________________________________________________________________ 
 
C10  Publications of the company in international peer-reviewed journals (last 5 years): 
 
1. Article Title __________________________________________________________ 
 
Journal __________________________ Year _________ Volume ___ Number _______ 
 
2. Article Title __________________________________________________________ 
 
Journal __________________________ Year _________ Volume ___ Number _______ 
 
3. Article Title __________________________________________________________ 
 
Journal __________________________ Year _________ Volume ___ Number _______ 
 
4. Article Title __________________________________________________________ 
 
Journal __________________________ Year _________ Volume ___ Number _______ 
 
C11  Commercial products and services developed by the company: 
 
1. ______________________________________________________________________ 
 
             2. ______________________________________________________________________ 
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             3. ______________________________________________________________________ 
 
C12  Does the company collaborate with government organisation(s)?             
 
If yes, which government organisation?  
 
1. ______________________________________________________________________ 
 
2. ______________________________________________________________________ 
 
3. ______________________________________________________________________ 
 
C13  Does the company collaborate with research group(s) at universities and/or research 
institute(s)?                                                                                       
 
If yes, which research group(s)/ research institute(s)? 
 
1. ______________________________________________________________________ 
 
2. ______________________________________________________________________ 
 
3. ______________________________________________________________________ 
 
Where is/are this research group(s)/ research institute(s) located? 
 
 
C14   Does the company collaborate with other spin-off companies?    
 
If yes, please provide the company’s names: 
 
YES  NO  
YES  NO  
 
 
Universities Research groups 
Locally China 
 
SEA Other part of the 
world 
    
 
Research institutes 
    
YES  NO  
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1. ______________________________________________________________________ 
 
2. ______________________________________________________________________ 
 
3. ______________________________________________________________________ 
 
C15   Total annual Research & Development (R&D) budget of the company (thousand HK$): 
 
a. <150 
b. 151-300 
c. 301-500 
d. 501-1000 
e. 1001-5000 
f. >5000 
 
C16   Sources of funds for start-up (please specify sources and percentage of the total capital of 
the company at start up): 
 
Category Source Percentage of 
total capital at 
start-up 
Personal resources (include friends and relatives)   
Governments   
Bank Loans   
Venture Capital   
International research foundations   
Competitive grants   
Other(s) 
Please specify; _________________________ 
  
 
 
      C17a   Does the company own any patent or licence? 
                         
Detail(s) ________________________________________________________________ 
  
(Worldwide _____________________or local _________________________________)  
 
 
 
 
 
 
 
YES  NO  
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C17b  Does the company use any patent or licence?  
 
Detail(s) ________________________________________________________________ 
  
(Worldwide _____________________or local _________________________________)  
 
C18  What are the main driving forces behind the company? 
 
 __________________________________________________________________________ 
 
 __________________________________________________________________________ 
 
 __________________________________________________________________________ 
 
C19   How important are the following obstacles that hinder the company’s growth? 
 
1: Not important   2: Slightly important   3:  Neutral   4: Important   5: Most important 
 
 1 2 3 4 5 
Funding      
Commercialisation      
Estimation of the market demand      
Distribution      
Technical problems in development and production      
Problems in the management of human resources      
Problems among owners      
Contractual problems      
Relationships with the parent university      
Problems related with the position played in the parent university      
Patenting      
Regulatory Compliance      
Others factor(s)  
Please specify; __________________________________________  
     
 
C20 Which definition fits in the company? 
 
YES  NO  
216 
 
(a) The core technology and the founder(s) came from the parent university, and the 
founder(s) continue to work for the parent university.  
(b) The core technology of the company created in the parent university, while the 
founder(s) employed by or was/were research student(s) at the parent university. 
(c) The core technology of the company originated in the parent university, but the 
founder(s) was/were not from the parent university. 
(d) The core technology did not originate from the parent university, but the founder(s) 
was/were an employee of the parent university 
(e) The core technology did not originate from the parent university, nor the founder(s) 
employed by the parent university, but the spin- off company used certain resources 
from the parent university.  
(f) The spin-off company was created by the parent university (wholly university-owned 
spin-off company). 
(g) Others 
Please specify: _____________________________________________ 
 
Thank you for your support and cooperation! 
 
Please write a contact person for the further question(s); 
Contact person: 
Email: 
Phone number: 
 
 
Appendix C: Spinoffs Questionnaire for South African Universities 
 
RESEARCH SURVEY: UNIVERSITY SPIN-OFF COMPANIES 
The aim of this study is to analyse university spin-off companies in South Africa, particularly in the 
Western Cape. These questions are sent to the companies that spun off from the University of Cape 
Town and Stellenbosch University. All information gathered by this survey will be used for academic 
research only. 
 
PLEASE MARK APPROPRIATE FIELDS WITH AN “X” 
 
LEAVE ALL NON APPLICABLE FIELDS BLANK 
       Date: _______________      
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Fill in by: ________________ 
PART A 
 
Company Particulars 
 
A1 Spun-off from: 
                    
A2 Official company name:  
A3 Year of Start-up:  
A4 Year of foundation:  
A5 Director:  
A6 Address:  
A7 Telephone/Fax:   
A8 Email:  
A9 Website:  
 
A10   Company’s turnover (million Rand in 2008): 
 
 
 
 
 
 
 
 
 
A11   Company’s classification by type of activity: 
 
 
 
 
 
 
 
A12   Which sector does the company belong to? 
 
UCT  SUN  
<3  
4-10  
11-50  
51-100  
101-300  
301-500  
>501  
Manufacturing-type Company  
Service-type Company  
Consultancy-type Company  
Research-type Company  
Product-development Company  
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Biotechnology   
Information Technology & Telecommunications  
Precision Engineering  
Electronics  
Nanotechnology  
Green Technology  
Professional Services  
Others 
Please specify___________________________ 
 
 
 
A13    What is the nature of company’s business? 
_________________________________________________________________ 
 
PART B 
 
Company’s History 
 
B4 Number of Founder(s): 
a. 1 
b. 2-3 
c. 4-5 
d. 6-10 
e.   >10                                                                    
 
B5 Founder(s)’ original affiliation (fill in number): 
 
a. University    
b. Government research centre 
c. University and Government research centre 
d. University and industry 
e. Government research centre and Industry 
f.   Industry                                           
 
B6  Where is the company’s market at start-up? (You can choose more than one region) 
 
a. Provincial        
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b. National 
c. Other(s)  
     Please specify: ________________________ 
 
       B4 How important are the following motivations at start-up? 
 
1: Not important 2: Slightly important 3:  Neutral   4: Important 5: Most important 
 
  1 2 3 4 5 
Identification of market opportunities      
Complete the projects      
Apply knowledge into practical applications      
Profit making      
Fully utilise existing knowledge      
Aversion for bureaucracy and low risk orientation of the research 
environment 
     
Personal success      
To be independent      
Other factors      
 
Current Situation 
 
C1 Where is the company’s current market? (You can choose more then one region) 
 
a. Provincial      
b. National 
d. Others  
    Please specify: ________________________ 
 
Current number of 
C2 Senior scientists:                                                      
C3 Post-doctoral assistants: 
C4 Research students (masters/PhD students): 
C5 Technicians:  
C6 Administrative personnel:  
C7 Marketing and sales’ staff: 
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C8 Total staff: 
 
C9 Major areas of research in which the company is actively involved: 
 
a. ______________________________________________________________________ 
 
b. ______________________________________________________________________ 
 
c. ________________________________________________________________ 
 
C10 Publications of the company in international peer-reviewed journals (last 5 years): 
 
5. Article Title __________________________________________________________ 
 
Journal __________________________ Year _________ Volume ___ Number _______ 
 
6. Article Title __________________________________________________________ 
 
Journal __________________________ Year _________ Volume ___ Number _______ 
 
7. Article Title __________________________________________________________ 
 
Journal __________________________ Year _________ Volume ___ Number _______ 
 
8. Article Title __________________________________________________________ 
 
Journal __________________________ Year _________ Volume ___ Number _______ 
 
C11 Commercial products and services developed by the company: 
 
1. ______________________________________________________________________ 
 
             2. ______________________________________________________________________ 
 
             3. ______________________________________________________________________ 
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C12 Does the company collaborate with government organisation(s)?             
 
If yes, which government organisation?  
 
1. ______________________________________________________________________ 
 
2. ______________________________________________________________________ 
 
3. ______________________________________________________________________ 
 
C13 Does the company collaborate with research group(s) at universities and/or research 
institute(s)?                                                                                       
 
If yes, which research group(s)/ research institute(s)? 
 
1. ______________________________________________________________________ 
 
2. ______________________________________________________________________ 
 
3. ______________________________________________________________________ 
 
Where is/are this research group(s)/ research institute(s) located? 
 
 
C14   Does the company collaborate with other spin-off companies?    
 
If yes, please provide the company’s names: 
 
1. ______________________________________________________________________ 
 
2. ______________________________________________________________________ 
 
YES  NO  
YES  NO  
 
Universities Research 
groups 
Locally Other parts of South Africa 
 
Other part of the world 
   
Research institutes    
YES  NO  
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3. ______________________________________________________________________ 
 
 
 
C15   Total annual Research & Development (R&D) budget of the company (thousand Rand): 
 
A. <50 
B. 50-150 
C. 151-300 
D. 301-500 
E. 501-1000 
F. >1000 
 
C16   Sources of funds for start-up (please specify sources and percentage of the total capital of 
the company at start up): 
 
Category Source Percentage of 
total capital at 
start-up 
Personal resources (include friends and relatives)   
Governments   
Bank Loans   
Venture Capital   
International research foundations   
Competitive grants   
Other(s) 
Please specify; _________________________ 
  
 
 
      C17a   Does the company own any patent or licence? 
                         
Detail(s) ________________________________________________________________ 
  
(Worldwide _____________________or local _________________________________)  
 
C17b Does the company use any patent or licence?  
 
 
 
 
 
 
 
YES  NO  
YES  NO  
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Detail(s) ________________________________________________________________ 
  
(Worldwide _____________________or local _________________________________)  
 
C18 What are the main driving forces behind the company? 
 
 __________________________________________________________________________ 
 
 __________________________________________________________________________ 
 
 __________________________________________________________________________ 
 
C19   How important are the following obstacles that hinder the company’s growth? 
 
1: Not important   2: Slightly important   3:  Neutral   4: Important   5: Most important 
 
 1 2 3 4 5 
Funding      
Commercialisation      
Estimation of the market demand      
Distribution      
Technical problems in development and production      
Problems in the management of human resources      
Problems among owners      
Contractual problems      
Relationships with the parent university      
Problems related with the position played in the parent university      
Patenting      
Regulatory Compliance      
Others factor(s)  
Please specify; __________________________________________  
     
 
C20 Which definition fits in the company? 
 
(h) The core technology and the founder(s) came from the parent university, and the 
founder(s) continue to work for the parent university.  
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(i) The core technology of the company created in the parent university, while the 
founder(s) employed by or was/were research student(s) at the parent university. 
(j) The core technology of the company originated in the parent university, but the 
founder(s) was/were not from the parent university. 
(k) The core technology did not originate from the parent university, but the founder(s) 
was/were an employee of the parent university 
(l) The core technology did not originate from the parent university, nor the founder(s) 
employed by the parent university, but the spin- off company used certain resources 
from the parent university.  
(m) The spin-off company was created by the parent university (wholly university-owned 
spin-off company). 
(n) Others 
Please specify: _____________________________________________ 
 
Thank you for your support and cooperation! 
 
Please write a contact person for the further question(s); 
Contact person: 
Email: 
Phone number: 
 
Appendix D: Interview Questions for Bio-entrepreneurs 
 
RESEARCH SURVEY: BIO-ENTREPRENEURSHIP IN WESTERN CAPE 
 
       Date: _______________      
Interviewed with: _______________ 
 
Statement of purpose  
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The purpose of this study is to investigate the bio-entrepreneurship program and its impact on 
the growth of the biotechnology industry. Specifically, how it addresses the need to foster an 
entrepreneurial spirit and expertise in the biotechnology industry in the Western Cape.  
Before I start this tape, for the record, I would like to ask. Do I have your permission to tape 
this interview?  
I assure you that this interview is confidential and that the information gathered will be used 
for research purposes only.  
You can stop this interview at any time should you wish to do so.  
 
Background to case and general impression  
 
To begin with, can you tell me about the general details concerning your background and your 
involvement in the biotechnology industry? 
 
PERSONAL: 
Age:  
Gender: 
 
Degree obtained: 
 
Current position: 
 
 
INTERVIEW QUESTIONS: 
1. What do you think about the South African biotechnology prospects in global competition? 
2. What are the strengths and weaknesses of the Western Cape’s biotechnology industry? 
3. How do you define a bio-entrepreneur? 
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4. You were the one of the graduates from the bio-entrepreneurship program. What were your 
expectations about the programme before enrol and what did you expect to be able to do 
after complete the programme?  
5. Why did you choose to enrol for the bio-entrepreneurship program? Why not an MBA, for 
example? 
6. What are the strong and weak points of the program? 
7. How beneficial was it for you? 
8. Do you use the skills and knowledge gained from the programme in your work? 
9. Will you suggest it to other entrepreneurs? 
10. Anything that you like to add about South African biotech of bio-entrepreneurship 
program; 
 
Thank you for your support and cooperation! 
 
Please write a contact person for the further question(s); 
Contact person: 
Email: 
Phone number: 
 
Appendix E: Interview Questions for Bio-entrepreneurship Program Director  
 
RESEARCH INTERVIEW: BIO-ENTREPRENEURSHIP IN WESTERN CAPE 
 
       Date: _______________      
Interviewed with: ________________ 
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Statement of purpose  
 
The purpose of this study is to investigate the bio-entrepreneurship program and its impact on 
the growth of biotechnology industry. Specifically, how it addresses the need to foster an 
entrepreneurial spirit and expertise in the biotechnology industry in the Western Cape.  
Before I start this tape, for the record, I would like to ask. Do I have your permission to tape 
this interview?  
I assure you that this interview is confidential and that the information gathered will be used 
for research purposes only.  
You can stop this interview at any time should you wish to do so.  
 
Background to case and general impression  
 
To begin with, can you tell me about the general details concerning your background and your 
involvement in the biotechnology industry? 
 
Interview questions  
 
1- What do you think about the South African biotechnology industry prospects in global 
competition? 
2- What is bio-entrepreneurship? How do you define it?  
3- How do you see the “bio-entrepreneurship” progress in South Africa and particularly in 
Western Cape? 
1: Not important   2: Slightly important 3:  Neutral   4: Important 5: Most important 
  1 2 3 4 5 
228 
 
      
      
      
      
      
      
      
      
      
 
4- In 2005, there was an initiative to offer a collaborative bio-entrepreneurship programme 
with a British Company, which was supposed to initiate in 2007. This did not go well, l 
believe. What were the lessons you learned? 
5- What did the bio-entrepreneurship program in 2008 entail? Can you give brief information 
about the program? 
6- What modules have been taught in the program? 
7- How did you establish the program? Have you benchmarked against international programs 
(Done this with national or regional biotech objectives in mind)? 
8- How many staff members have you had for teaching at the program? Who were the staff 
members’ origins/backgrounds? 
9- How did you select the students for the program? 
10-  Do you keep track of the graduates? Collaborations with them? 
11- Measured against objectives and outcomes 
 How did the program do? 
 Changes? What were they? 
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12- Plans to start new one? 
 
Thank you for your support and cooperation! 
 
Please write a contact person for the further question(s); 
Contact person: 
Email: 
Phone number: 
 
Appendix F: South African Universities’ licensing survey 
 
RESEARCH SURVEY: UNIVERSITY LICENSING OF TECHNOLOGIES VERSUS SPIN-
OFFS 
 
The researchers are conducting a project which is entitled "Delineating the concept of university spin-
off companies in the South African context:   an   exploratory   study   of     spin-offs   at   the   Universities   
of   Cape   Town   and Stellenbosch" and garnered information about the history and innovative status 
of spin-off companies in the Western Cape in order to understand the nature of this phenomenon in 
South Africa. During the research an interesting question arose: why would academics that are in a 
position to create a spin-off, choose NOT do so? Hence the focus of this questionnaire is to explore this 
question with a set of academics at Western Cape universities. These questions are sent to the principle 
researchers who have licensed technologies while at the Western Cape Universities. All information 
gathered by this survey will be used for academic research only.  
 
PLEASE MARK APPROPRIATE FIELDS WITH AN “X” 
 
LEAVE ALL NON APPLICABLE FIELDS BLANK 
 
       Date: _______________      
Fill in by: ________________ 
 
PART A 
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A1  Licensing  at: 
          
A2  Title of the technology:  
 
A3 Number of Researcher (s): 
a. 1 
b. 2-3 
c. 4-5 
d. 6-10 
e.   >10                                                                    
 
 
A4 Principle researchers (please identify with the title): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A5 Which sector does the technology belong to? 
 
Biotechnology   
Information Technology & Telecommunications  
Precision Engineering  
Electronics  
Nanotechnology  
Green Technology  
Professional Services  
Others 
Please specify___________________________ 
 
 
UCT  SUN  UWC  CPUT  
 
1  
2  
3  
4  
5  
6  
7  
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A6 Which faculty does/do the researcher(s) come(s) from? (Please specify the department (s)) 
 
Faculty of Agri-Sciences 
 
Department of____________________________________ 
 
 
Faculty of Engineering  
 
Department of____________________________________ 
 
 
Faculty of Science: 
 
Department of____________________________________ 
 
 
Faculty of Health Sciences: 
 
Department of____________________________________ 
 
 
 
 
      A7 Is a patent linked to the technology? 
                         
Detail(s) ________________________________________________________________ 
  
(Worldwide _____________________or local _________________________________)  
 
A8 How important are the following motivations for licensing your technology? 
 
1: Not important   2: Slightly important   3:  Neutral   4: Important   5: Most important 
 
Motivations 1 2 3 4 5 
It is a niche technology      
The technology is near market and requires little further development and 
investment 
     
A company is linked with the research either as a sponsor or interested 
observer 
     
The technology fits an existing company's IP/product portfolio      
Licensing is a common strategy within the industry sector      
Building an industrial network      
Fully utilize existing knowledge      
YES  NO  
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Final step to complete existing  project(s)      
Profit making      
Personal success      
Apply knowledge into practical applications      
Others factor(s)  
Please specify; __________________________________________  
     
 
A9 How important are the following obstacles in reaping the benefits when the technology is 
licensed? 
 
1: Not important   2: Slightly important   3:  Neutral   4: Important   5: Most important 
 
Obstacles 1 2 3 4 5 
Further investment is required in the technology and associated infrastructure 
in order to reach the market 
     
Estimation of the market demand      
Distribution of revenue streams      
Relationships with the parent organisation(s)      
Ownership and/or rights to develop technology      
Regulatory compliance      
Protection of the technology (e.g. patenting)      
The formation of partnerships      
Others factor(s)  
Please specify; __________________________________________  
     
 
A10 How important are the following factors in your decision NOT to create a spin-off company? 
 
1: Not important   2: Slightly important   3:  Neutral   4: Important   5: Most important 
 
Factors 1 2 3 4 5 
Leaving the academic position      
Funding      
Commercialisation      
Estimation of the market demand      
Distribution (product and/or services)      
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Technical problems in development and production      
Problems in human resources      
Problems among owner(s) of the technology      
Relationships with the parent university      
Regulatory compliance      
Family commitment(s)      
Others factor(s)  
Please specify; __________________________________________  
     
 
Thank you for your support and cooperation! 
 
Please write a contact person for further question(s) or feedback of results; 
Contact person: 
Email: 
Phone number: 
 
 
 
